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Breast cancer (BC) is the most frequently diagnosed malignancy and the first 
cause of death from cancer in women. Tamoxifen, an estrogen receptor (ER) 
antagonist, is the most common drug used in patients with ER-positive BC, which 
represents around 70% of BC tumors. However, approximately 30% of cases develop 
resistance to endocrine therapy, leading to tumor relapse. Our laboratory has 
demonstrated that tamoxifen resistant cells are enriched for cancer stem cells (CSCs) 
and express high levels of the stem cell marker Sox2. In this thesis, we examine the 
potential inhibitory effect of different polyoxometalate (POM) derivatives on Sox2 
activity in tamoxifen-resistant BC cells. First, we demonstrate that different POMs 
specifically block DNA binding activity of full-length Sox2 in vitro. K6[P2W18O62] (PW) 
derivative is the most effective POM driving cell growth inhibition via cell cycle arrest 
and induction of apoptosis of tamoxifen resistant cells. In addition, we show that PW 
specifically blocks Sox2 regulation of the epithelial to mesenchymal transition (EMT) 
marker SNAI2, inhibiting migration and invasion capacities of tamoxifen resistant cells. 
Furthermore, in vivo assays on chick embryo chorioallantoic membrane (CAM) 
confirm that PW-mediated inhibition of Sox2 reduces the content of CSC populations 
and restores tamoxifen sensitivity in vivo. Mechanistically, the inverse correlation 
between Sox2 and ER expression levels is reverted after PW treatment of Sox2-
expressing cells. Direct binding of Sox2 to target sequences on the promoter of the 
ESR1 gene is impaired by PW treatment leading to partial reactivation of ER signaling 
pathway and restoration of tamoxifen sensitivity. Therefore, the observed Sox2 
targeting in CSCs by PW highlights the potential therapeutic use of this inhibitor for 









El cáncer de mama es la neoplasia maligna diagnosticada con más frecuencia 
en mujeres y la primera causa de muerte por cáncer. El tamoxifeno, un antagonista 
del receptor de estrógeno (ER), es el fármaco más utilizado en pacientes con cáncer 
de mama ER positivo, que representan alrededor del 70% de los tumores. Sin 
embargo, aproximadamente el 30% de los casos desarrollan resistencia a la terapia 
endocrina, lo que conduce a la recidiva del tumor. Nuestro laboratorio ha demostrado 
que las células resistentes al tamoxifeno están enriquecidas en células madre 
cancerosas (CSC) que expresan niveles elevados del marcador de células madre Sox2. 
En esta tesis, examinamos el potencial efecto inhibidor de diferentes derivados de 
polioxometalatos (POMs) sobre Sox2 en células resistentes al tamoxifeno. En primer 
lugar, demostramos que diferentes POMs bloquean específicamente la actividad de 
unión al ADN del TF Sox2 in vitro. El derivado K6[P2W18O62] (PW) inhibe el crecimiento 
celular induciendo una parada de ciclo celular y la muerte programada por apoptosis 
en las células resistentes al tamoxifeno. Además, mostramos que PW bloquea 
específicamente la regulación del marcador de la transición epitelio-mesénquima 
(EMT) SNAI2 mediada por Sox2, inhibiendo las capacidades de migración e invasión de 
células resistentes al tamoxifeno. Además, los ensayos in vivo en la membrana 
corioalantoidea de embriones de pollo confirman que la inhibición de Sox2 mediada 
por PW reduce el contenido de la población de CSCs y restaura la sensibilidad al 
tamoxifeno. Molecularmente, la correlación inversa entre los niveles de expresión de 
Sox2 y ER se revierte con el tratamiento de PW en células resistentes al tamoxifeno. 
La unión directa de Sox2 a las secuencias diana en el promotor del gen ESR1 se ve 
afectada por el tratamiento con PW, lo que conduce a la reactivación parcial de la vía 
de señalización del ER y la restauración de la sensibilidad al tamoxifeno. Por tanto, 
dada la relevancia de atacar a las CSCs dependientes de Sox2 destaca el potencial uso 
terapéutico del derivado K6[P2W18O62] (PW) como inhibidor de Sox2 para tratar un 
















1. The human breast 
1.1 Structure and function 
The human breast is an exocrine gland whose main function is the production 
of enough milk for nursing young offspring (Inman et al., 2015). The apparition of this 
organ during evolution gives rise to the generation of the class Mammalia in taxonomy. 
The word mamma was taken from the Latin literally meaning “breast”.  
The mammary gland organization is complex, composed of two tissue 
compartments: the ectodermally derived epithelium (luminal and myoepithelial cells) 
and the mesodermally derived stroma. The breast epithelium consists of a 
tubuloalveolar organization of branching secretory ducts terminating in alveolar or 
acinar structures (Ali and Coombes, 2002) (Figure I 1). The parenchymal bilayered 
epithelium forms a structured network of 11-58 ducts, luminal cells forming the inner 
layer of the ducts and lobules surrounded by contractile myoepithelial cells. This 
structure, which radiates out from the nipple, ends in terminal ductal lobular units 
(TDLUs) (Russo and Russo, 2004). 
Figure I 1. Human mammary gland anatomy and histology. (A) The illustration shows the anatomy of 
the human mammary gland. Each breast contains 15-20 lobes with a series of branched ducts that 
drain into the nipple. (B) Histological sections of human breast immunostained for estrogen receptor 


























 Surrounding stroma provides support for the epithelial structure and stores an 
important lipid source to be turned into milk. The space between lobules is divided into 
interlobular or intralobular stroma, depending on its location in relation to the 
epithelium. Although adipose tissue is predominantly filling this space, breast stroma 
is a complex connective tissue composed not only of a variety of cell types including 
fibroblasts, adipocytes, immune cells, endothelial cells and nerve cells but extracellular 
matrix (ECM) components as collagens, proteoglycans and glycoproteins. The 
interlobular stroma surrounding the lobules is mainly ECM enriched in collagen, while 
the intralobular stroma surrounds the acini within TDLUs and contains fibroblasts, 
blood vessels, lymphocytes and plasma cells (Macias and Hinck 2012). Interactions 
between epithelial cells and stroma are essential for the correct development of the 
human breast. Particularly, it has been reported that fibroblasts have an important role 
in supporting mammary gland cells during development (Parmar and Cunha 2004).  
1.2 Development of the human breast 
The human mammary gland development begins very early at stages of 
embryonic development but is not completely mature until puberty. Mammary gland 
development starts at embryonic developmental day (EDD) 35 with the proliferation of 
a paired area of epidermal epithelial cells localized in the thoracic region called 
mammary ridges or milk streaks. After the generation of the milk production line, cells 
start to invaginate and proliferate in the surrounding mesenchyme to form bulb-shaped 
mammary buds. In the later stages of embryonic development, when the bud is fully 
formed the mesenchyme cells surround epithelial cells and start progressive elongation 
and branching leading to the formation of a rudimentary ductal tree (Inman et al., 
2015). Although hormone receptors are not expressed until puberty, mice experiments 
demonstrated that estrogen receptor alpha (ERα) or beta (ERβ), progesterone receptor 
(PR) and prolactin receptor (PRLR) deficiency, among others, have no effects on 
embryonic development of the mammary gland, showing the hormone independence 
at initial stages of development (Sternlicht et al., 2006).  
The mammary gland undergoes several stages of development, pubertal 
growth, pregnancy, lactation and involution after birth. Embryonic mammary gland 
development occurs equally in male and female embryos (Howard and Gusterson, 
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 2000). Differences appear in both epithelium and stroma of the female breast during 
puberty, once the ovulatory cycles have started. First, the complexity of the ductal tree 
increases through the proliferation of terminal end buds (TEB) allowing the elongation 
and branching of the TDLUs (Paine and Lewis, 2017). On the other hand, the stroma 
also undergoes changes, the amount of fibrous extracellular matrix and surrounding 
adipose tissue increase in adult non-lactating women. Pregnancy is the period when 
the most dramatic changes occur in the mature mammary gland followed by lactation 
and postlactational involution phases (Howard and Gusterson, 2000). During 
preparation for lactation, progesterone and prolactin enhance alveologenesis 
maturation by increasing the proliferation rate of luminal cells, which leads to an 
increase in secondary and tertiary ductal branching at TDLUs. Progesterone regulates 
mammary side branching while prolactin promotes the acini cell differentiation 
through JAK2/STAT5 signaling to synthesize milk and create a competent lactation 
gland (Brisken and O’Malley, 2010). Thus, luminal cells are responsible for milk 
production while myoepithelial cells play a key role in milk ejection. 
Post-lactational involution of the breast tissue starts with the weaning of the 
infant. The involution process takes place in two different phases. The first stage is 
reversible and it is characterized by an increase in apoptosis to remove milk-producing 
epithelial cells. The irreversible second stage starts with the collapse of the secretory 
alveoli. Tissue remodeling proteases are activated to breakdown ECM allowing the 
removal of the secretory epithelium in order to restore the architecture of the tissue 
back to the pre-pregnant state. Post-lactational involution is a highly regulated process, 
mainly controlled by signal transducer and activator of transcription (STAT) family 
members and matrix metallopeptidases (MMPs), as well as cytokines and several types 
of immune cells (Macias and Hinck, 2012). Finally, after menopause, mammary gland 
tissue undergoes another involution process in which ductal epithelium complexity is 
reduced. While intralobular connective tissue is substituted by collagen in the early 
menopause, ultimately stroma regresses and is replaced by adipose tissue (Watson and 
Kreuzaler, 2011). 
1.3 Endocrine system: estrogen receptor (ER) signaling 
Ovarian hormones, estrogen and progesterone, play an important role in 
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 normal breast development and cancer (Stingl, 2011). The three major naturally 
occurring estrogens in women are estrone, estradiol and estriol, which are synthesized 
from C19 androgenic steroids derived from cholesterol. The estrogens synthesis 
process is highly regulated by the action of several hormones. Pituitary gonadotropins, 
known as luteinizing hormone and follicle-stimulating hormone are stimulated by the 
hypothalamus in order to induce estrogens production in the ovaries of premenopausal 
women. In addition, there are secondary sources of estrogen production in 
considerably lower levels, such as the brain, bones, adipose tissue, vascular 
endothelium and aortic smooth muscle (Labrie, 2015). Estradiol (E2) is the most 
relevant steroid hormone involved in several physiological functions as mammary gland 
development, maintenance of reproductive organs, cardiovascular system regulation 
and homeostasis of immune, skeletal muscle and nervous system. Although most 
estrogen actions are beneficial in healthy women, it has been reported that most breast 
cancers are dependent on estrogens for tumor development (Yaşar et al., 2017).  
The actions of estrogens are mediated by the ERs. ERs are members of a large 
superfamily of different types of receptors. Glucocorticoid receptors, mineralocorticoid 
receptors, androgen receptors, estrogen receptors, and progestogen receptors form 
the steroid hormone receptors superfamily. Nevertheless, although not every steroid 
receptor, ERs are also included in the nuclear receptors superfamily formed by thyroid 
hormone receptors (TRs), retinoic acid receptors (RARs), vitamin D  receptors  (VDRs)  
and peroxisome proliferator-activated receptors (PPARs) as well as different orphan 
receptors (Aranda and Pascual, 2001). Estrogens bind to ERs and alter their structure 
so that, after recognizing the specific palindromic DNA sequence ((A/G)GG(T/C)CA) 
named Estrogen-Responsive Elements (ERE) within promoter sequences, modulate the 
expression of target genes (Carroll et al., 2006).  There are many ERs target genes 
described, for example pS2 gene (Jakowlew et al., 1984), GREB1 gene (Sun et al., 2007), 
CCND1 gene (Altucci et al., 1996) and MYC gene (Dubik and Shiu, 1988).  
Two different isoforms of ER have been described: ERα encoded by the ESR1 
gene (Green et al., 1986) and ERβ by ESR2 gene (Kuiper et al., 1996). ERα is a 64 kDa 
protein composed of 595 amino acids while ERβ (59 KDa) is formed by 530 amino acids, 
both divided into six different functional domains. The amino-terminal A/B region 
contains the ligand-independent and activating function-1 (AF-1) (Lees et al., 1989), 
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 which shares less identity between the ERs (17%). The central C domain contains the 
well-conserved DNA binding domain (DBD) formed by two zing fingers that bind EREs, 
shares 97% amino acid identity (Kumar et al., 1987). Region D (36% amino acid identity) 
also called the hinge domain, which contains the nuclear localization signal (NLS), acts 
as a connection between the DBD and the ligand-binding domain (LBD), the 
multifunctional E region.  The E domain (56% identity) called LBD is involved in ligand 
binding, dimerization and the interaction of the ERs with coregulatory proteins through 
the ligand-dependent activating function-2 (AF-2). E2 binding to the LBD induces 
structural rearrangements for dimerization or interaction with coregulators that 
converts inactive ER to a functionally active form (Yaşar et al., 2017). Finally, the F 
region (18% identity) is located in the C-terminal part of the receptor. F domain could 
affect the agonist/antagonist activity of selective ER modulators (SERMs), ER 
dimerization and ER-coregulatory interactions (Nilsson and Gustafsson, 2011) (Figure I 
2). 
 
Around 10-20% of luminal epithelial cells express ERα, hereinafter ER (Clarke et 
al., 1997). It has been reported by immunohistochemical staining that epithelial cells 
found in ducts and lobules express ER, while stromal and myoepithelial cells are ER-
Figure I 2. Schematic representation of amino acid sequence ERα and ERβ structural regions. (A) 
Amino acid sequence identity between ERα and ERβ. The numbers at the bottom of the bars indicate 
the last C-terminal amino acid of each region while percentages indicate the ERα amino acid sequence 
identity with respect to ERβ sequence. (B) ERs dimer cartoons showing estrogen binding and 
conformational changes. The figure is modified from Yaşar et al., 2017. 
ERα
180 263 302 553 5951
ERβ
144 227 255 500 5301





 negative (Clarke et al., 1997). These findings indicate that the ER-positive cell 
population controls the proliferation of the ER-negative cells through the induction of 
the paracrine factors, such as amphiregulin (AREG), that stimulates cell proliferation, 
terminal end bud formation and ductal elongation (Ciarloni et al., 2007). 
ER undergoes conformational changes after ligand binding to the LBD. The most 
important one is helix 12 (H12) of the ligand-binding pocket, allowing ER dimerization. 
This conformational change two exposes the two activating function (AF) sites: AF-1 
and AF-2 for the nuclear receptor co-activators (NCoAs) or co-repressors (NCoRs) 
binding. ER and coregulators, such as steroid receptor coactivator 1 (SRC1), GRIP1 and 
AIB1, and histone acetylases CBP, p300 and the p300/CBP associated factor (pCAF) 
form the transcriptional complexes which regulate the transcription of estrogen-
dependent target genes (Shang et al., 2000).  
Tamoxifen (Tam), an estrogen antagonist steroid hormone, selectively 
modulates ER activity blocking the estrogen-dependent ER signaling pathway. Initially, 
it was described that Tam acted as a competitive inhibitor of estrogen by binding to the 
ER and impairing estrogen access to the LBD (McDonnell et al., 1995). However, 
crystallization studies of the LBD with estrogen and SERMs like tamoxifen revealed that 
antiestrogenic ligands disrupt the interaction of ER with coregulators and basic 
transcription machinery. Structurally, Tam causes a conformational shift of H12 over 
the coactivator site preventing the binding with its coactivators (Shiau et al., 1998). In 
addition, studies performed with the SERM raloxifene, similar to Tam in terms of 3D 
chemical structure, have shown that SERMs have a side chain that extends from the 
binding pocket of the LBD and interferes with the exposure of the AF sites, preventing 
the binding of ER coregulators (Levenson and Jordan, 1998). Although Tam can recruit 
co-repressors to ER transcriptional complex and induce antiestrogenic response 
programs in breast cells, it can also recruit the co-activator SRC1 in endometrial cells 
performing the opposite effect (Shang and Brown, 2002). This is the mechanism by 
which the incidence of endometrial cancer increased after the first breast cancer 





 Cancer is the name given to a collection of related diseases involving abnormal 
cell growth with the potential to spread and invade surrounding or distal tissues. This 
uncontrolled proliferation gives rise to the apparition of an abnormal mass of cells 
named tumor. The word cancer was taken from the Greek word carcinoma which 
literally means crab, referring to the similarity of the pattern exhibited by tumors when 
spread into the body to crab‘s legs.  
In 2000, Hanahan and Weinberg published a review article enunciating the 
hallmarks of cancer. These were proposed to provide a logical understanding of tumor 
development. The authors claimed that the majority of cancer cell genotypes are a 
manifestation of six essential alterations in cell physiology that dictate malignant 
growth: self-sufficiency in growth signals, insensitivity to growth-inhibitory 
(antigrowth) signals, evasion of programmed cell death (apoptosis), limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis (Hanahan and 
Weinberg, 2000). Even though the authors anticipated that cancer research would 
clarify and simplify the complexity of tumor development, some years later other 
emerging hallmarks were added: reprogramming of energy metabolism and evading 
the immune response, genomic instability and mutation, as well as tumor-promoting 
inflammation were incorporated as enabling traits to this substantial complex 
perspective (Hanahan and Weinberg, 2011) (Figure I 3). 
However, what defines a cancer hallmark has become a big question. Lazebnik 
argued that cancer hallmarks should refer only to distinguishable features that 
characterize malignant tumors. To this extent, five of the six initial hallmarks would be 
shared by both benign and malignant tumors, except tissue invasion and metastasis, 
and become thus rather indistinctive of cancer over non-malignant conditions 
(Lazebnik, 2010). Moreover, tumor microenvironment forms another layer of 
complexity that is crucial for cancer development, progression and drug resistance 





3. Breast Cancer 
3.1 Epidemiology and etiology 
Breast cancer (BC) is the most frequently diagnosed malignancy in developed 
regions and the first cause of death from cancer in women. Around 2,1 million women 
worldwide were diagnosed with BC and 626.679 women were estimated to die in 2018 
(Bray et al., 2018). In 2020, there will be approximately 48.530 women diagnosed with 
BC in the United States of America and 42.170 estimated deaths, representing the 
second cause of death from cancer in women following deaths from lung cancer (Siegel 
et al., 2020). In Europe, over 355.000 women are estimated to be diagnosed with breast 
cancer in 2020, reaching 13,3% of all cancer diagnoses in both sexes. BC is the most 
commonly diagnosed female cancer representing 28,7% of the estimated new cases. 
However, BC remains the first cause of death from cancer among European females, 
estimating to be around 16,5% of deaths in 2020 followed by lung cancer deaths 
Figure I 3. The Hallmarks of Cancer. Diagram showing the six hallmarks originally proposed in 2000 
and the emerging hallmarks and enabling characteristics included in 2011, which define the acquired 


























 (15,6%) (ECIS - European Cancer Information System) (Figure I 4A).   
The incidence of BC has been rising with annual increases from 641.000 cases in 
1980 and increasing to over 2 million new cases in 2018. However, incidence rates vary 
from higher incidence (92/100.000 in North America) in high-income regions than in 
developing regions (27/100.000 in middle Africa and Asia) (Harbeck et al., 2019). This 
is attributed to the availability and utility of early detection techniques, which lead to 
early-stage BC detection and a good prognosis of patients from developed regions. 
However, in low-income regions, patients are diagnosed with later stages of the disease 
often associated with a poorer prognosis, a fact that is reflected in the mortality rates 
(Globocan 2018) (Figure I 4B). BC mortality is higher in low-income countries, such as 
sub-Saharan Africa and developing Asian countries due to delayed diagnosis and limited 
treatments. In addition, the biology of the tumors also varies by ethnicity, for example, 
Asian women develop BC earlier than women from western countries (Wong et al., 
2018) or African and African- American women had the highest rates of triple-negative 
breast cancer (TNBC) (Kohler et al., 2015). Mortality pattern is multifactorial and 
involves genetic predisposition, lifestyle and other environmental risk factors.  
Several risk factors have been associated with BC. As cancer is a disease 
associated with aging, age is one of the major risk factors, and of course, being a female 
dramatically increases the possibility of developing BC. Ovarian hormones are 
considered another risk factor since early menarche and late-onset menopause have 
been linked to BC risk due to the increased exposure to proliferative effects of ovarian 
hormone cycles. Consistent with this, it has been reported that adjuvant endocrine 
therapy (tamoxifen treatment), which is an integral component of care for hormone-
dependent breast cancer, induces ovarian function and hyperestrogenism in 
premenopausal women and has been considered as BC risk factor in young women. 
Exogenous hormone intake as oral contraceptives and hormone replacement therapy 
(HRT) has been associated with BC risk (Kim and Shin, 2020). In addition, reproductive 
factors should be also considered; an advanced maternal age for a first pregnancy and 
the lack of breastfeeding increases the risk of BC (Harbeck et al., 2019). Genetic 
predisposition causes approximately 10% of BC cases. Individuals with a first-degree 
relative who had breast cancer show a higher relative risk of early-onset BC. BC 
predisposition is mainly driven by autosomal-dominant inheritance of mutations in any 
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 of the two high-penetrance tumor suppressor genes, BRCA1 and BRCA2, whose 
proteins participate in homologous DNA repair. Mutations in these genes are 
associated with a higher risk of developing breast cancer, 72% for BRCA1 and 69% for 
BRCA2 mutations. Moreover, the frequency of BRCA1 and BRCA2 mutations in sporadic 
BC increases from 5-10% to 15-20% in familial BC (Brewer et al., 2017) (Figure I 4C). 
 
On the other hand, BC risk also increases by what are considered preventable 
risk factors, such as alcohol and tobacco consumption, the lack of physical activity and 
Figure I 4. Breast cancer epidemiology. (A) Estimated new cases and deaths from breast cancer in 
women in Europe for 2020 year. Adapted from ECIS - European Cancer Information System. (B) Breast 
cancer incidence (blue) and mortality (red) worldwide, taken from Globocan. (C) Most relevant risk 
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 obesity, particularly in postmenopausal women (Renehan et al., 2015). Indeed, Qureshi 
and colleagues have recently reported that the major pre- and postmenopausal 
estrogens play opposing roles in obesity-driven mammary inflammation and breast 
cancer development. The project in which I participated during my short internship in 
Dr. Slingerland lab at Braman Family Breast Cancer Institute, Sylvester Comprehensive 
Cancer Center in Miami, demonstrates that after menopause, ovarian estradiol 
production falls and estrone dominates. The postmenopausal high estrone:estradiol 
ratio that increases with obesity, drives inflammation and stimulates hormone-
sensitive breast cancer initiation and tumor growth (Qureshi et al., 2020). 
3.2 Histological variants of breast cancer 
 Although most of the breast tumors are adenocarcinomas (95%), the invasive 
ductal carcinoma (IDC) is the most common form of invasive BC (55%). Breast tumors 
have been histologically divided into four main different subtypes according to their 
ductal or lobular localization, being 80% of the cases diagnosed as ductal carcinomas 
worldwide (Makki, 2015): 
a) Ductal carcinoma in situ (DCIS): the neoplastic proliferation of epithelial cells 
limited to the ducts of the mammary gland tissue characterized by nuclear 
and cellular atypia coming from the early stage of atypical ductal hyperplasia 
(ADH). Historically, DCIS is divided into five subtypes according to the tissue 
architecture: the comedo, solid, cribriform, papillary and micropapillary. 
DCIS is considered a potential precursor of invasive breast cancer, but not 
obligate, suggesting that these two subtypes may be genetically different. 
b) Lobular carcinoma in situ (LCIS) is an intralobular proliferation of small cells 
originated in the TDLUs. This BC subtype is characterized by the absence of 
the immunohistological markers E-cadherin and β-catenin, whereas DCIS 
presents these markers. 
c) Invasive ductal carcinoma (IDC) is a heterogeneous group classified based 
on the malignant ductal proliferation through the surrounding stroma and 
according to the cell architectural features. Thus, it is subclassified into 
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 apocrine, mucinous, papillary, tubular, micropapillary and neuroendocrine 
invasive carcinomas. However, the majority of IDCs (75%) fail to exhibit clear 
features in order to be classified as a specific subtype. 
d) Invasive lobular carcinoma (ILC) is the second most common invasive breast 
cancer reporting around 15% of invasive cases. ILC tumor cells are typically 
round, small and non-cohesive and have a characteristic growth pattern 
with single-file infiltration of the stroma. Unlike what happens with IDC 
diagnosis, ILC cannot be directly diagnosed as invasive because it should be 
firstly associated with an LCIS. Thus, ILC tumors are subclassified into classic, 
pleomorphic lobular, histiocytoid, signet ring and tubule-lobular 
carcinomas. 
3.3 Breast cancer initiation and progression 
Breast cancer initiation and progression is a multistep developmental process 
that includes several abnormal stages. Ductal carcinomas initiate with ductal 
hyperplasia (DH) that usually progress to atypical ductal hyperplasia (ADH) and later to 
ductal carcinoma in situ (DCIS) that culminates in the potentially lethal stage of invasive 
ductal carcinoma (IDC) (Tharmapalan et al., 2019) (Figure I 5). Importantly, DH lesions 
are distinguishable from ADH, which is considered the premalignant state of in situ 
carcinoma. Then, the IDC stage is characterized by the invasion of the surrounding 
tissues and disruption of the basal membrane potentially leading to the invasion and 
colonization of distal organs. On the other hand, the progression of lobular subtype 
recognizes atypical lobular hyperplasia (ALH) and lobular carcinoma in situ (LCIS) as 
precursor lesions to invasive lobular carcinoma (ILC) (Beckmann et al., 1997). 
The mechanism by which breast cancer is initiated is not clear. At the cell of 
origin level, there are two models by which breast cancer initiation has been explained; 
1) the clonal evolution model, in which mutations and epigenetic changes accumulation 
occur in tumor cells driving the survival of the most capable ones and 2) the cancer 
stem cell (CSC) model (further explained in section 4.2). Nevertheless, a combination 
of both is mostly accepted due to the fact that CSCs may also undergo clonal evolution 
(Visvader and Lindeman, 2012). Morphologically, immunohistological as well as 
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 genomic and transcriptomic studies, support the hypothesis that DH, ADH and low-
grade DCIS represent an evolutionary process that culminates into IDC. At the 
molecular level, early molecular studies of the genomic alterations showed that there 
are two divergent molecular pathways of breast cancer progression, mainly related to 
ER expression and tumor grade and proliferation. These molecular studies on IDC 
tumors have demonstrated that low-grade IDCs display fewer chromosomal 
aberrations than high-grade IDCs. Particularly, low-grade IDCs present consistent allelic 
loss of 16q and gains of 1q, 16p and 8q. On the contrary, high-grade tumors exhibit 
recurrent losses of 8p, 11q, 13q, 1p and 18q; recurrent gains of 8q, 17q, 20q and 16p 
and high-level amplification of 17q12 and 11q13; reflecting the reduction or loss-of-
function of tumor suppressor genes and amplification of oncogenes (Bombonati and 
Sgroi, 2011). 
3.4 Molecular classification 
Strong efforts have been made to understand breast cancer heterogeneity in 
order to stratify patients into groups with similar pathological features and clinical 
outcome. Molecular studies done by Perou and colleagues shed light on this matter, by 
stratifying the 21 different histological subtypes into four main molecular clusters 
(Perou et al., 2000), which differ in response to treatments and overall survival rates 
(Sørlie et al., 2001). These subtypes are traditionally classified based on the expression 
of the hormone receptors ER and PR and the expression levels of human epidermal 
growth factor receptor-type2 (HER2) (Harbeck et al., 2019): 
a) Luminal A (ER+, PR+, HER2-) is the most common breast cancer (71%). It 
correlates with tubular cribriform and classic lobular histology. It is 
characterized by ER and PR expression and absence of HER2 activating GATA3, 
FOXA1, XBP1 target genes; low-grade and proliferation rate; low Ki67 index; less 
aggressive than other subtypes and the most favorable prognosis. 
b) Luminal B (ER+/-, PR+/-, HER2+): This cancer subtype is less abundant (12%). It 
is characterized by lower expression of ER and PR than Luminal A but also a high 
expression of HER2. 40% of tumors show PI3KCA mutations as well as 30-40% 
ESR1 mutations. Luminal B tumors correlate with micropapillary and atypical 
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 lobular histology; show a high Ki67 index associated with high proliferation rates 
and high-grade tumors that respond to targeted therapy. Intermediate 
prognosis. 
c) HER2-enriched (ER-, PR-, HER2+) subtype is the least abundant (5%), 
characterized by HER2 amplification, GRB7 amplification, PI3KCA mutations 
and/or TOPO2 and MYC amplification that lead to high Ki67 index associated 
with high-grade tumors. HER2 subtype correlates with pleomorphic lobular and 
micropapillary histology. 
d) Basal or triple-negative breast cancer (TNBC) (ER-, PR-, HER2-) (12%): This 
corresponds to the poorly differentiated histological grades that show the worst 
prognosis since there are no targeted therapies available. It is characterized by 
TP53 mutations, genetic instability and BRCA mutations associated with high-
grade tumors and high Ki67 index. 
 
However, the elucidation of BC subgroups and their molecular drivers requires 
genomic and transcriptomic analysis of representative numbers of patients. In this 
regard, Curtis and colleagues studied the somatically acquired copy number 
aberrations (CNAs) and the germline copy number variant (CNVs) of 2000 breast 
tumors and revealed novel molecular subgroups with distinct clinical outcomes. Here, 
the authors generated a map of CNAs, CNVs and single nucleotide polymorphisms 
(SNPs) in the BC genome to examine the impact of cis- or trans-acting variants on the 
expression landscape. Cis- or trans-acting variants are defined as genomic variants at a 
locus affecting its own gene expression or the expression of genes at other sites in the 
genome, respectively (Curtis et al., 2012). This integrative clustering analysis revealed 
several novel subgroups, firstly formed by the high-risk ER-positive subgroup composed 
of 11q13/14 cis-acting luminal tumors. Second, two subgroups with a lack of copy 
number and cis-acting alterations were described. One characterized by luminal A 
tumors with low genomic instability and the other included both ER-positive and ER-
negative cases with flat copy number landscape. Both subgroups presented good 
prognosis. Two luminal A subgroups with similar CNA profiles and favorable outcomes 
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 were also noted, as well as the basal-like tumors cluster defined by its high-genomic 
instability. 
Consistent with this, molecular heterogeneity complicates patient stratification 
and treatment. Next-generation sequencing techniques used for molecular screening 
of the genome have highlighted the spatial and temporal heterogeneity of breast 
tumors during progression and treatment (Appierto et al., 2017). Indeed, this 
heterogeneity has been reported among patients (intertumor heterogeneity) and in 
each individual tumor (intratumor heterogeneity) (Januškevičienė et al., 2019). An 
approach based on multiregional sampling and sequencing of a series of breast cancers 
has allowed identifying subclonal structure of the primary lesions and demonstrated 
that subclonal diversification may affect relevant genes for breast cancer (PIK3CA, 
TP53, PTEN, BRCA2, and MYC) and varied among cases without evidence of specific 
temporal order (Ellsworth et al., 2017). 
Nevertheless, metastatic BC is the main cause of death for patients with BC, so 
a better molecular characterization to predict the metastatic disease will allow earlier 
and better selection of patients who would benefit from new therapeutic approaches. 
Single-cell sequencing studies of breast tumors revealed that genomic rearrangements 
occurred early in breast tumor evolution remaining stable, while point mutations 
evolved gradually as the disease progresses. For example, triple-negative tumor cells 
showed around 13,3X increased mutation rate compared to ER-positive tumor cells 
(Wang et al., 2014). Therefore, the genomic characterization of early breast cancers is 
not representative of the metastatic tumors. Thus, it has been published a genomic 
characterization study analyzing metastatic breast cancer tumors demonstrated that 
mutations in nine driver genes (TP53, ESR1, GATA3, KMT2C, NCOR1, AKT1, NF1, RIC8A 
and RB1) were more frequent in HR-positive, HER2-negative metastatic breast cancers 
and associated with poor prognosis (Bertucci et al., 2019). Interestingly, in TNBC the 
most frequent genomic alterations in metastatic tumors were somatic biallelic loss-of-
function mutations in genes related to homologous recombination DNA repair (HRD) 
(Bertucci et al., 2019). Recently this year, the whole-exome sequencing analysis of 
metaplastic BC, aggressive breast tumors characterized by a mixture of 
adenocarcinoma and mesenchymal areas, revealed recurrent genetic alterations 
affecting TP53, PIK3CA and PTEN genes, similar patterns of gene copy number 
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 alterations, and enrichment in alterations affecting several signaling pathways such as 
Wnt and Notch. Additionally, bi-allelic alterations affecting HRD-related genes were 
also described (Moukarzel et al., 2020). Despite some differences in terms of specific 
genetic alterations between the genomic analysis in different BC subtypes, the 
pathways targeted by these alterations are remarkably similar in advanced BC tumors.  
Although molecular classification facilitates the design of effective treatment 
for each type of primary breast tumor, such findings question whether an optimal 
assessment of disease progression should be based on molecular features of primary 
or recurrent tumors, since tumor heterogeneity represents a crucial element for failure 
or success of personalized medicine. In this regard, the progressive Intensive Trial of 
Omics in Cancer (ITOMIC) enrolled patients with TNBC with bone metastasis for a 
comprehensive analysis of multiple biopsies collected over time for each patient. This 
study revealed that tumor samples acquired genomic aberrations in response to each 
treatment cycle but also shared mutations, indicating the presence of recurrent tumor 
cell populations that might be responsible for the outgrowth of tumor cells in response 
to therapy (Blau et al., 2016). Failure of specific targeted treatments is a consequence 
of intra-tumor and temporal heterogeneity. Therefore, an optimal therapeutic strategy 
should include molecular analysis of multiple biopsies as well as genomic profiling of 
primary and metastatic tumor samples. 
3.5 Breast cancer treatment 
Breast tumors are treated by a combination of therapies that may include 
surgery, radiation therapy, chemotherapy or endocrine therapy. The selection of the 
therapy has been classically based on tumor-node-metastasis (TNM) staging as well as 
ER and PR status, HER-2 overexpression and proliferative capacity of the tumor cells. In 
addition, age and menopausal status of the patient are also important factors (Harbeck 
et al., 2019). In the case of in situ carcinomas, surgery followed by radiotherapy is the 
main option. However, neoadjuvant chemotherapy prior to surgery might be 
considered in order to downsize the tumor burden in some cases. Patients with early-
stage invasive BC are treated with adjuvant chemotherapy in addition to surgery and 
radiation therapy.  
In HER2-positive BC tumors, neoadjuvant chemotherapy in addition to anti-
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 HER2 therapy is the standard of care. Dual HER2-blockade with trastuzumab and 
pertuzumab monoclonal antibodies, together with either an anthracycline-taxane or 
docetaxel and carboplatin combination chemotherapy improves the patient outcome 
(Gianni et al., 2016). Chemotherapy using anthracyclines or taxanes as well as docetaxel 
and cyclophosphamide is the standard treatment for TNBC tumors (Nitz et al., 2019). 
Some patients with luminal BC also receive chemotherapy based on the 
proliferation rate marked by Ki67 expression and the gene expression signature (GES) 
profile. The use of gene expression profiling assays, such as Oncotype DX® or 
MammaPrint®, is useful for chemotherapy decisions in ER-positive, HER2-negative 
breast cancer. However, luminal tumors are susceptible to be treated with endocrine 
therapy. ER/PR-positive tumors should receive hormone therapy, which consists of 
ovarian function suppression usually obtained by blocking the estrogen-dependent 
signaling.  
Tamoxifen (Tam), a selective ER modulator (SERM) is still the most extensively 
used drug to treat ER-positive BC tumors. Tamoxifen plays a key role in the treatment 
of early-stage ER-positive BC as adjuvant treatment for 5 years, delaying local and 
distant relapses and increasing overall survival (Lumachi, 2015). Tam selectively blocks 
ER signaling (as previously explained in section 1.3) inhibiting the proliferation of ductal 
cells in the breast. Tam was shown to prevent estrogen-dependent tumor growth a 
long time ago (Jordan, 1976), supporting the use of Tam for BC prevention. The first 
clinical trial analyzing the chemo-preventive effects of Tam started in 1986 at the Royal 
Marsden Hospital, UK. The results revealed that patients treated with Tam presented a 
significant reduction in the early incidence of breast cancer in both pre- and post-
menopausal women as well as lower serum cholesterol levels, which could reduce the 
subsequent risk of atherosclerosis and cardiovascular disease. However, some side 
effects were also reported such as an increase in the incidence of endometrial cancer, 
stroke, thrombosis and cataracts (Powles et al., 1989). Gail and colleagues developed a 
study estimating individualized probabilities of developing BC, which finally led to the 
approval of Tam for reducing BC risk in healthy women by the Food and Drug 
Administration of the USA in 1999 (Gail et al., 1989). These chemoprevention trials set 
the basis for the ideal SERM characteristics, ability to reduce the risk of BC, 
osteoporosis, cardiovascular disease, vasomotor symptoms, uterine prolapse, urinary 
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 incontinence, loss of cognitive function and possibly Alzheimer’s disease, without 
increasing the risk of thromboembolism or other types of carcinogenesis (Powles 2002). 
Nevertheless, treating healthy individuals for many years to prevent the occurrence of 
a few cancers that would occur years later is controversial. 
Aromatase inhibitors (AIs), which block estrogen synthesis, arose as an 
alternative approach for endocrine therapy. There are two types of AIs, the permanent 
steroidal inhibitors of aromatase and the reversible nonsteroidal inhibitors (Johnston 
et al., 2003). AIs, anastrozole, exemestane and letrozole, were successfully developed 
for the treatment of advanced BC. They have been shown to be more effective than 
Tam for the treatment of metastatic BC and after surgery of operable ER-positive 
tumors (Mouridsen et al., 2001; Lumachi 2015). However, the side effects provoked by 
AIs were substantially greater than those of Tam in healthy women, since long- term 
estrogen deprivation gives rise to adverse effects on the brain, pelvic floor, 
cardiovascular system, the bones and other tissues (Baum et al., 2002). 
This fact led to the development of selective ER degraders (SERDs), which are 
antiestrogens that destabilize helix H12 of the LBD of ER, inducing ER degradation 
(McDonnell et al., 2010). Fulvestrant is a very well-known SERD used in patients with 
advanced ER-positive BC and as second-line therapy, which binds to ER preventing 
dimerization and signaling by inducing ER degradation through the ubiquitin-
proteasome pathway (Osborne et al., 2004). Fulvestrant shows a synergistic action with 
docetaxel and many other inhibitors, rendering sensitivity to ER-negative BC to 
chemotherapy (Patel and Bihani, 2018). 
Nevertheless, ER-positive BC tumors develop resistance to endocrine therapy 
after years of treatment that enhanced the development of molecularly targeted 
therapies against advanced ER-positive BC which do not respond to endocrine therapy. 
Due to the fact that various signaling pathways are also affected in BC, several drugs 
have been studied including cyclin-dependent kinase (CDK) 4/6 inhibitors such as 
palbociclib, epigenetic modulators that inhibit histone deacetylase (HDAC), and other 
signaling pathway inhibitors (Pernas et al., 2018). However, advanced BC is still an 
incurable disease that causes death in almost all patients. 
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 3.6 Resistance to endocrine therapy  
Despite the benefits that endocrine therapy shows in ER-positive BC tumors, 20-
30% of the patients develop resistance and tumor recurrence after 5 years of adjuvant 
treatment, representing the major challenge in BC management (Lumachi, 2015). 
Resistance to endocrine therapy is generally divided into two categories; de novo 
resistance, which are ER-positive breast tumors nonresponsive to therapy from the 
beginning of the treatment, and acquired resistance, developed after long exposure to 
antiestrogen therapy in ER-positive tumors initially responding to the treatment 
(Jordan, 2004). De novo resistance is defined as relapse during the first 2 years or 
progressive disease within the first 6 months of endocrine therapy. On the other hand, 
acquired resistance is defined as relapse after the first 2 years of treatment, relapse 
within 12 months of completing endocrine therapy or progressive disease for 
metastatic BC six or more months after starting endocrine therapy (Cardoso et al., 
2018).  
In 2017, a 20-year follow-up study was published reporting BC recurrence data 
after stopping the exposure to endocrine therapy at 5 years (Pan et al., 2017). This 
meta-analysis of the results of 62.923 women with ER-positive BC who were disease-
free after 5 years assessed the associations of tumor diameter and nodal status (TN), 
tumor grade, and other factors with patients’ outcomes during the period from 5 to 20 
years. The risk of distant recurrence was strongly correlated with the original TN status. 
The results revealed that in patients with stage T1 disease, the risk of distant recurrence 
was 13% with no nodal involvement, 20% with one to three nodes involved and 34% 
with four to nine nodes involved. The risk of patients with tumors in stage T2 was 19%, 
26% and 41%, respectively. The risk of death from breast cancer was similarly 
dependent on TN status. In conclusion, even after 20 years of the original diagnosis, ER-
positive BC patients treated with endocrine therapy for 5 years present a persistent risk 
of recurrence and death from BC. This finding highlights the need for new approaches 
to reduce the late recurrence of endocrine-resistant BC (Pan et al., 2017).  
Molecularly, several mechanisms have been proposed to contribute to the 
development of resistance to endocrine therapy. Loss of ER expression is one possible 
cause since 10-20% of initially ER-positive patients become negative on relapse (Souza 
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 et al., 2018). However, around 50% of total ER-positive tumors are resistant to 
tamoxifen despite the expression of ER, which might, therefore, still respond to AIs. 
(Harbeck et al., 2019).  
Activation of growth factor receptors signaling pathways, such as EGFR,  HER2, 
MAPK or PI3K/AKT/mTOR plays a major role in the development of resistance to 
tamoxifen (Augereau et al., 2017). It has been described that EGFR and HER2 are able 
to activate estrogen-independent ER signaling in tamoxifen-resistant BC cells by the 
phosphorylation of ER residue Ser118 (Joel et al., 1998). PI3K-AKT pathway has been 
also reported as an estrogen-independent ER signaling activator. PI3K increased the 
activity of both estrogen-independent activation function 1 (AF-1) and estrogen-
dependent activation function 2 (AF-2) of ER by AKT regulation of ER phosphorylation 
on Ser167 residue. Increased AKT activity protects BC cells from tamoxifen-induced 
apoptosis (Campbell et al., 2001). In addition, the amplification of transcriptional co-
activator proteins and constitutive activation of other inflammation-associated 
transcription factors, such as nuclear factor κB (NF-κB) have been also identified as 
potential mechanisms driving tamoxifen resistance (Fan et al., 2019). 
Nowadays, it is well established that ESR1 mutations occur in metastatic BC and 
influence response to endocrine therapy (Jordan et al., 2015). Next-generation 
sequencing (NGS) techniques have reported that ESR1 mutations occur at a frequency 
of 20-40%, depending on the method. Several groups have identified hot spot mutation 
clusters mainly focused on the ligand-binding domain (LBD) sequence of the ESR1 gene. 
Tyr537 and Asp538 are the most frequently mutated residues, which interact with an 
anchor amino acid, Asp351, to close the LBD creating a ligand-free constitutively 
activated ER (Toy et al., 2013). These mutations have been identified mostly in tumors 
resistant to AIs, anastrozole and letrozole, rather than tamoxifen (Jeselsohn et al., 
2014). More recently, Lisanti Lab has elucidated the molecular mechanism by which 
ESR1 mutation on Tyr537 also confers tamoxifen resistance by enhancing 
mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling (Fiorillo et al., 2018). 
Furthermore, it has been reported that during tumor progression, ESR1 mutations 
emerge and become enriched in the metastatic BC. Recent studies indicate that tumors 
presenting ESR1 mutations may be less responsive to specific SERMs or SERDs, and 
suggest that aromatase inhibitors (AI) may select for the emergence of ESR1 mutations 
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 (Pejerrey et al., 2018). Nevertheless, there are also clinical trials evaluating the role of 
the ESR1 mutations in acquired endocrine-resistant BC, indeed, an ongoing phase II 
study is evaluating the efficacy of fulvestrant in patients with ESR1-mutated BC 
(NCT03202862).  
Consistent with this, NGS analysis of primary and recurrent tumors from ER-
positive BC patients revealed multiple mechanisms in acquired resistant tumors to 
tamoxifen treatment. Importantly, NGS data showed that 55% of patients presented 
phosphatidylinositol 3-kinase CA (PIK3CA) mutations in the tamoxifen-resistant group, 
while 33% of patients displayed PIK3CA mutations in the sensitive group (Li et al., 2018). 
It has been reported that hyperactivation of this pathway induces tumor adaptation to 
anti-estrogenic therapy by mutations on PIK3CA, AKT mutation or loss of PTEN function 
in endocrine-resistant BC (Augereau et al., 2017). In this regard, PIK3 and mTOR 
inhibitors such as everolimus, have been developed to treat tamoxifen-resistant 
tumors with these alterations (Souza et al., 2018). There are several clinical trials 
evaluating the combination of several of these inhibitors as well as CDK4/6 inhibitors 
with endocrine therapy in order to find the best therapeutic approach for different BC 
tumors. However, BC tumors also develop resistance to these new inhibitors (Pandey 
et al., 2019). In the future, monitoring ESR1 mutational status during tumor progression 
could help in the selection of better-personalized therapeutic approaches. 
Our laboratory has demonstrated that tamoxifen-resistant is driven by Sox2-
mediated activation of CSCs (Piva et al., 2014). Here, it is demonstrated that tamoxifen-
resistant cells show increased expression of the Sox2 transcription factor, traditionally 
associated with stemness, which maintains breast cancer cells in a more 
undifferentiated state with stem cell features. In this study, high Sox2 levels are 
correlated with endocrine therapy failure in a cohort of ER-positive breast cancer 
patients treated with tamoxifen. Importantly, shows that CSCs lack or express very low 
levels of ER, thus providing a mechanism for evading the therapeutic effects of 
tamoxifen, leading to the development of resistance. Moreover, a second work of our 
lab demonstrated that another SOX family member, Sox9, is involved in stem cell 
maintenance together with Sox2 (Domenici et al., 2019). These findings support a 
model in which Sox2 expression is required for the maintenance of cancer stem cells in 
tamoxifen-resistant breast cancer. Thus, these findings justify further research into 
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 drugs effective at targeting the Sox2 pathway. 
 
4. Stem cells  
Stem cells are defined as cells that have the ability to perpetuate themselves 
through self-renewal and to generate mature cells of a particular tissue through 
differentiation. According to their plasticity or developmental versatility, stem cells are 
classified as totipotent, pluripotent or multipotent stem cells (Reya et al., 2001). 
Totipotent stem cells have the potential to differentiate into all the different cell types 
of the organism. Pluripotent stem cells can give rise to cells from the three germ layers, 
ectoderm, mesoderm and endoderm. Multipotent stem cells are the most 
differentiated ones since they can only give rise to all the cells within a specific tissue 
or organ (Reya et al., 2001). 
4.1 Breast stem cells 
The human breast epithelium is a highly dynamic tissue that undergoes 
dramatic regenerative changes during puberty, pregnancy lactation and involution. 
Due to this striking regenerative capacity, it was hypothesized that the mammary gland 
contained stem cells that retain the ability of self-renew and differentiate in order to 
keep tissue homeostasis (Fillmore and Kuperwasser, 2008). 
The breast epithelium is hierarchically organized and composed of luminal and 
myoepithelial cells. Following this structure, the multipotent mammary stem cells 
(MaSCs) are at the top of the hierarchy, giving rise to progenitor cells and differentiated 
cells of both lineages. The first evidence of adult MaSCs was obtained by DeOme and 
colleagues after transplantation experiments of fragments of mammary epithelium in 
the cleared fat pad of mice, showing entire regeneration of the mammary gland 
(Deome et al., 1959). Luminal and myoepithelial populations express specific surface 
proteins and several cytoskeletal proteins that can be used to distinguish the two cell 
lineages. Luminal lineage is characterized by the expression of epithelial membrane 
antigen (EMA or MUC1) (Burchell et al., 1983), the epithelial-specific antigen (ESA or 
EpCAM) (Gudjonsson et al., 2002) and, in addition, keratin (K) 8, K18 and K19 (Anstine 
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 and Keri, 2019). Myoepithelial cells, on the contrary, express the common acute 
lymphoblastic leukemia antigen (CALLA or CD10) (Gusterson et al., 1986), α6 integrin 
(or CD49f) (Koukoulis et al., 1991) and K5 and K14, as well as α-smooth muscle actin (α-
SMA) (Anstine and Keri, 2019). 
Since stem cells are present in the mammary gland, many strategies have been 
developed to isolate and purify them. Thus, Fluorescence-activated cell sorting (FACS) 
studies reported ESA+CALLA+/lowEMA-/low cells as candidate bipotent progenitors based 
on the fact that they were able to generate mixed colonies of luminal and myoepithelial 
cells when seeded at low clonal density in two-dimensional (2D) and three-dimensional 
(3D) cultures (Stingl et al., 1998). Stingl and colleagues also demonstrated that 
ESA+CD49f+EMA- sorted cells formed branching structures in collagen gels and 
generated colonies composed of myoepithelial K14-positive cells surrounding a core of 
luminal K18-positive cells (Stingl et al., 2001). Clayton and colleagues showed that 
double-positive cells (EMA+CALLA+) were capable of self-renew and differentiate at 
single-cell level (Clayton et al., 2004). Another FACS sorting approach was used to 
identify a different MaSC population based on the expression of CD49f and ESA. Human 
breast cells expressing ESA and high levels of CD49f (CD49f+ESAhigh) were isolated and 
capable of generating branched TDLU-like structures in vitro (Villadsen et al., 2007). In 
contrast, two years later, the group of Visvader reported that CD49hiEpCAM- cells 
showed mammary regenerating capacity into cleared mammary fat pads of mice and 
thus considered as MaSC-enriched population. Clonogenic assays revealed that 
CD49fhiEpCAM- cells were able to generate complex structures, such as ductal-like 
structures and more dense colonies capable of undergoing alveolar differentiation 
demonstrating the presence of stem/progenitor cells in this population (Lim et al., 
2009).  
In addition, studies in the human hematopoietic system suggested that stem 
cells had the ability to efflux the dye Hoechst 33342, a phenotype known as the side 
population (SP) (Goodell et al., 1997). The same approach was used to identify stem 
cells in the murine (Alvi et al., 2002) and the human mammary gland (Clayton et al., 
2004). Dontu and colleagues cultured mammary epithelial cells in suspension as 
floating colonies called mammospheres, which are enriched for cells with stem cell 
potential. It was demonstrated that mammosphere-derived cells present self-renewal 
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 and differentiation capacity into both luminal and myoepithelial cells (Dontu et al., 
2003). 
Another property used to identify stem cells is the high aldehyde 
dehydrogenase (ALDH) 1 activity. ALDH1 is an enzyme responsible for the oxidation of 
intracellular aldehydes, for example, oxidizing retinol to retinoic acid can induce 
differentiation of stem cells (Tomita et al., 2016). The hematopoietic system was 
reported to present the first association between stem cells and ALDH1 activity (Hess 
et al., 2004). In the human mammary gland, Ginestier and collaborators showed that 
FACS sorted epithelial stem cells with an increased ALDH1 activity had the ability to 
regenerate complex mammary gland structures in vivo (Ginestier et al., 2007). In 
addition, CSCs identified in several cancer types with high ALDH activity associated with 
ALDH1A1 isoform overexpression are highly tumorigenic in xenograft models (Tomita 
et al., 2016). However, in patient breast tumor studies, where CSCs are identified by 
expression of ALDH1A1 isoform, CSC prevalence is not correlative with metastasis, 
because ALDH activity of patient breast tumor CSCs correlates best with ALDH1A3 
isoform expression (Marcato et al., 2011), which we showed to be regulated by Sox9 in 
BC cells (Domenici et al., 2019).  
4.2 Cancer stem cells 
As well as the normal mammary gland, breast tumors present heterogeneous 
cell populations with varying self-renewal capacities, degrees of differentiation and 
tumorigenic potentials (Tharmapalan et al., 2019). Furthermore, alterations in tissue 
homeostasis that impair cell signaling regulation, microenvironment interactions and 
normal stem cell behavior have been reported to be implicated in abnormal 
development, leading to the initiation and tumor progression. These observations led 
to the development of the Cancer Stem Cells (CSCs) hypothesis (Figure I 6A). This 
hypothesis claims that CSCs, which are also named tumor-initiating cells (TICs), 
represent a small subset of stem-like cancer cells that are located at the apex of the 
cellular hierarchy of the tumor, being responsible for tumor initiation and propagation. 
CSCs are characterized by their ability to self-renew, the capacity to initiate tumors and 
the potential to differentiate into non-stem cancer cells generating tumor 
heterogeneity (Reya et al., 2001). TICs were isolated for the first time in acute myeloid 
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 leukemia, demonstrating that CD34+CD38- cells were able to recapitulate the original 
tumor in transplantation experiments in vivo (Bonnet and Dick, 1997). Using similar 
experimental approaches, CSCs have been isolated in several solid tumors (Visvader 
and Lindeman, 2012). The CSC hypothesis was presented as an alternative to the clonal 
evolution hypothesis (Figure I 6B). However, it is now accepted that a combination of 
both the clonal evolution model and the CSC model is needed during tumor progression 
(Bombonati and Sgroi, 2011).  
 
4.3 Breast cancer stem cells   
In breast tumors, CSCs can arise from: newly transformed MaSCs through the 
Figure I 6. Clonal evolution and Cancer stem cell models. (A) The cancer stem cell model 
representation: in the example shown, a mutation(s) in a progenitor cell (brown cell) has endowed 
the tumor cell with stem cell-like properties. These cells have self-renewing capacity and give rise to 
a range of tumor cells, accounting for tumor. (B) The clonal evolution model: red cell represents a cell 
that has acquired a series of mutations that produced a dominant clone. Orange tumor cells arising 
from this clone have similar tumorigenic capacity. Other derivatives (grey) may lack tumorigenicity 
due to stochastic events. Taken from Visvader and Lindeman 2012. 
A
B Clonal evolution model







 acquisition of genetic mutations or epigenetic changes; normal non-stem epithelial 
cells in which the self-renewal capacity is acquired by oncogenic events; or mature 
cancer cells that dedifferentiate into a stem cell-like phenotype demonstrating the 
ability to take on stem cell features, by a process named cellular plasticity (Lee et al., 
2019). 
Importantly, breast cancer stem cells (BCSCs) were first isolated from human 
tumors and identified as Lin-CD24-CD44+ cells (Al-Hajj et al., 2003). Fillmore and 
Kuperwaser showed that CD44+CD24-/low CSCs phenotype could also be isolated from 
breast cancer cell lines (Fillmore and Kuperwasser, 2008). Furthermore, Ponti and 
colleagues demonstrated that primary tumor cells and MCF-7 cells could be maintained 
in culture as mammospheres and these mammospheres were enriched in CD44+CD24-
/low cells, an observation also demonstrated by our laboratory (Ponti et al., 2005 and 
Simões et al., 2011). At the molecular level, gene expression profiles of CD44+CD24-/low 
breast cancer cells compared with normal epithelium revealed an invasiveness gene 
signature that was strongly associated with shorter disease-free interval and overall 
survival (Liu et al., 2007). In addition, cells with this phenotype have been isolated as 
CSCs in other tumors (Li et al., 2007). 
As previously mentioned, high ALDH1 activity has been identified as a marker of 
normal breast stem cells but also as a CSC marker (Ginestier et al., 2007). In fact, ALDH1 
positive cells showed an increased tumor-initiating ability in vivo. Similar to CD44+CD24-
/low phenotype, ALDH1 positive cells with stem cell features were also identified in 
breast cancer cell lines (Charafe-Jauffret et al., 2009). Pece and colleagues described 
the molecular signature of breast CSCs as the combined expression of CD49f, DLL1 and 
DNER markers. This signature marks CSCs with increased mammosphere formation 
capacity and tumor initiation ability upon xenotransplantation (Pece et al., 2010). 
Another important characteristic of CSCs is their role in the development of 
resistance to current therapeutic approaches. They are therefore considered 
responsible for acquired resistance and tumor relapse (Pattabiraman and Weinberg, 
2014). Thus, it has been reported that radiotherapy increased the proportion of 
CD44+CD24-/lowESA+ cells (Phillips et al., 2006) and our laboratory demonstrated that 
tamoxifen treatment also expanded CD44+CD24-/low, EMA+/CALLA+ CSC populations and 
increased mammosphere formation ability (Piva et al., 2014). Moreover, the tumor 
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 microenvironment plays a pivotal role in the regulation of stem cell content. Our 
laboratory showed that hypoxic conditions, often common in the stem cell niche, led 
to the expansion of CSCs (Iriondo et al., 2015). 
However, BCSC populations differ in distinct BC subtypes. For example, ALDH1 
positive BCSCs are more common of luminal and HER2 subtypes, while CD44+CD24-/low 
are enriched in TNBC basal-like tumors, which show the highest BCSC content (Choi et 
al., 2016). Cellular plasticity, considered as the interconversion of cell phenotypes and 
degrees of differentiation, is an important aspect to take into account during therapy. 
Cellular plasticity dynamics were proven in BCSCs during tumor progression in mice 
models (Zomer et al., 2013). Furthermore, targeting BCSCs showed that the stem 
population could dynamically fluctuate from non-CSCs to regenerated CSC pool in order 
to mediate tumor resistance to paclitaxel and 5-fluorouracil drugs (Creighton et al., 
2009).  
A number of dynamic changes within the tumor microenvironment, including 
the phenomenon of epithelial to mesenchymal transition (EMT), influence the response 
to endocrine therapy (Liu et al., 2014). EMT is a conserved process occurring during 
both embryonic development and cancer progression, through which polarized 
epithelial cells become migratory mesenchymal stem cells, in response to growth factor 
signals such as Transforming Growth Factor beta (TGFβ) among others (Nieto et al., 
2016). EMT confers migratory and invasive features to epithelial cancer cells through 
transcriptional repression of cell-cell adhesion molecules as E-cadherin. Conserved 
signaling pathways operating in embryonic development are known to trigger EMT in 
cancer cells. Wnt, TGFβ and Notch signaling pathways induce direct transcriptional 
repression of E-cadherin, including Snail/Slug (SNAI1 and SNAI2), Twist and ZEB1/2 
transcription factors (TFs) (Yifan Wang et al., 2014). ZEBs and Snail TFs repress the 
expression of epithelial markers, such as CDH1, CLDNs and OCCL genes, encoding E-
cadherin, claudin and occludin tight junction proteins, respectively. Twist are potent 
inducers of mesenchymal markers as VIM and CDH2 genes, encoding Vimentin and N-
cadherin proteins (De Francesco et al., 2018). 
Tan and colleagues established an EMT score classifying breast cancer cell lines: 
basal cell lines as intermediate-high EMT phenotype; luminal cell lines, low EMT state 
and an intermediate EMT score for mixed basal-luminal phenotype representing the 
Introduction 
 50 
 wide variety of stages associated with BC heterogeneity (Tan et al., 2014). During the 
development of resistance to therapy, EMT process plays an important role in BC cells, 
since it has been shown to display a gradient of intermediate states of differentiation 
(Nieto et al., 2016). In fact, Wicha lab showed that BCSCs exhibit distinct mesenchymal-
like and epithelial-like stages. The authors demonstrated that mesenchymal-like BCSCs 
are characterized by  CD44+CD24- phenotype mainly quiescent and localized at the 
tumor invasive front, whereas epithelial-like BCSCs present high aldehyde 
dehydrogenase (ALDH) activity with high proliferative status (Liu et al., 2014). Our 
laboratory demonstrated that tamoxifen-resistant cells display an increased invasion 
capacity through Matrigel, due to the increased invasive phenotype of CD44+CD24-/low 
tamoxifen-resistant cells (Piva et al., 2014). In addition, it has been reported that 
continued use of trastuzumab in HER2+ cells increased CSCs frequency by inducing EMT 
leading to HER2+ BC transformation to a TNBC resistant to trastuzumab (Burnett et al., 
2015). More recently, single-cell RNA-sequencing analysis has highlighted the fact that 
metastatic BC cells exhibited gene expression signatures of EMT and stem cells (Chen 
et al., 2019). Intermediate EMT states and distinct epithelial and mesenchymal 
subpopulations of CSCs have been identified and associated with BC metastasis (Chen 
et al., 2019). Furthermore, single-cell sequencing of TNBC cell line SUM149 revealed 
that the heterogeneous population can be divided into three subpopulations that 
express patterns of stemness: EMT-CSCs, MET-CSCs and Dual-EMT-MET CSCs (Wu et 
al., 2020). 
All these observations confirm the heterogeneous landscape of breast CSCs and 
highlight the clinical relevance of targeting both CSCs and non-CSCs to avoid cellular 
plasticity events and the development of resistance. 
 
5. The Sox family of transcription factors  
5.1 Structural basis: groups and domain structures 
SOX genes encode a number of transcriptional regulators that mediate DNA 
binding via the high-mobility group (HMG) domain. Different SOX genes have been 
identified through homology of the HMG domain to the testis-determining factor, sex-
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 determining region Y (SRY). These TFs form the SRY-related HMG box, SOX superfamily 
(Grimm et al., 2019). The HMG domain consists of a 79 amino acid-long DNA-binding 
motif, which facilitates binding in the minor groove of the DNA, through the consensus 
site (A/T)(A/T)CAA(A/T). While most other types of DNA-binding proteins induce minor 
changes in DNA conformation, HMG domain binding significantly bends the DNA helix 
by intercalating amino acid side chains between DNA base pairs. Thus, HMG proteins 
alter the conformation of the DNA to increase protein accessibility and plasticity 
(Lefebvre et al., 2007). 
The human SOX transcription factor family contains more than 20 members 
classified into eight groups (SoxA to SoxH, with two B subgroups, B1 and B2) based on 
gene organization, function and phylogenetic analysis (Bowles et al., 2000). Sox 
proteins within the same group share a high degree of identity (around 70%), while Sox 
members from different groups show very little sequence identity apart from the HMG 
domain (Lefebvre et al., 2007) (Figure I 7): 
- SoxA: SRY gene is the only member of the first subgroup. 
- SoxB1: SOX1, SOX2 and SOX3 genes form this subgroup. They encode for 
transcription activators that share a high degree of sequence similarity, both 
within and outside the HMG box and are implicated in almost equal 
biological activities and display strong functional redundancy.  
- SoxB2 subgroup is formed by SOX14 and SOX21 transcription inhibitors. 
SoxB2 proteins harbor a transrepression domain at C-terminal region.  
- SoxC: this subgroup is characterized by a well-conserved C-terminal region 
with a 33-residue transactivating domain with several transactivation 
proficiencies, shared by SOX4, SOX11 and SOX12 members (Hoser et al., 
2008). 
- SoxD: which includes SOX5, SOX6 and SOX13; share an evolutionarily 
conserved domain at N-terminal region, consisting of various stretches of 
residues, forming two coiled-coil domains, a leucine zipper and a glutamine-
rich motif. This domain allows homo- or heterodimerization. 
- SoxE: SOX8, SOX9 and SOX10 are the members of this subgroup. These 
transcription factors contain distinct dimerization domains close to the HMG 
box and a unique transactivation domain.  
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 - SoxF: members of this subgroup contain a short amino acid motif 
(DXXEFD/EQYL) inside the transactivation domain mediating β-catenin 
interactions regulating gene transcription processes. The members are 
SOX7, SOX17 and SOX18.  
- SoxG: only one member, SOX15 (also known as SOX20), forms this subgroup, 
which exhibits the closest similarity to SoxB1 subgroup. 
- SoxH: this group is formed by the only member that does not show any 
homology to other Sox, apart from the HMG box, SOX30. 
 
This gene family originated through a series of evolutionary processes, including 
duplication and divergence, plays a pivotal role in a number of dynamic processes 
during embryonic development and disease, regulating the molecular basis for the 
genome engagement. In addition to these roles in development, Sox proteins are also 
implicated in tumorigenesis (She and Yang, 2015). 
5.2 Sox transcription factors and tumorigenesis 
In addition to sex differentiation, organogenesis and many other developmental 
processes are controlled by tight regulation of the expression and silencing of SOX 
genes. Many studies identified the role of particular SOX member to a biological 
Figure I 7. Schematic representation of domain structures of the human Sox protein family. Groups 
and representative protein members are indicated to the left. Characteristic HMG box and other 
functional domains are specified alongside. Figure taken from Grimm et al., 2019. 
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 process: SOX9 is implicated in chondrocyte differentiation (Bi et al., 1999), SOX10 in 
neural crest formation (Kuhlbrodt et al., 1998), SOX17 in endoderm specification 
(Hudson et al., 1997) and SOX18 in endothelial cell differentiation (Pennisi et al., 2000). 
Although many Sox members are downregulated in normal adult tissues, 
overexpression and amplification of SOX genes are frequently associated with cancer 
(Dong et al., 2004). For example, SOX1, SOX2, SOX3 and SOX21 were found significantly 
upregulated in lung carcinoma patient samples compared to normal tissue (Güre et al., 
2000).  
Despite the implication of different Sox members in tumorigenesis, Sox2 is the 
most widely studied transcription factor of the family. It is involved in stem cell 
regulation during embryogenesis and adult tissue regeneration in healthy tissues (Liu 
et al., 2013). Sox2 overexpression is frequently detected in tumors, glioma (Garros-
Regulez et al., 2016), ovarian carcinomas (Y. Li et al., 2015) and head and neck 
squamous cell carcinomas (Lee et al., 2014). Another SOX member promoting 
tumorigenesis is SOX9. A recent meta-analysis has associated patient prognosis 
suffering from solid tumors with Sox9 overexpression, pointing out the critical 
tumorigenic role of this Sox TF in pancreatic carcinoma, hepatocarcinoma, esophageal 
squamous cell carcinoma and osteosarcoma (Ruan et al., 2017). 
Many clinical observations have been reported to shed a light on the 
tumorigenicity role of other members of the SOX gene family. SOX4 upregulation is 
observed in the prostate (Bilir et al., 2016), bladder (Gunes et al., 2011) and triple-
negative breast cancer (Zhang et al., 2012). In addition, Sox3 overexpression plays a 
role in hepatocellular carcinomas (Feng et al., 2017). In contrast, dependent on cell and 
cancer type, SOX genes can act as oncogenes or tumor repressors. Here, SOX6 acts as 
a tumor suppressor gene in ovarian cancer (Li et al., 2017), and together with SOX5 and 
SOX21 block the tumorigenic capacity of brain tumor stem cells (Kurtsdotter et al., 
2017). SOX1 also seems to have tumor-suppressive activity by inhibiting tumor cell 
growth and invasion in breast cancer (Song et al., 2016), as well as in cervical carcinoma 
(Lin et al., 2013). 
5.3 Sox proteins in breast cancer 
Multiple studies have demonstrated that human breast tumors show aberrant 
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 SOX gene and protein expression, highlighting the fact that altered activation of this 
gene family may contribute to key aspects of breast cancer pathogenesis and 
progression, among other hallmarks of cancer (Figure I 8). Interestingly, diverse studies 
have suggested both an oncogenic and tumor-suppressive role of specific SOX that 
corresponds with clinical characteristics. For example, SoxC and SoxE overexpression is 
associated with shorter overall survival, suggesting an oncogene function of these Sox 
members. Meanwhile, SOX1 and SoxF members, which frequently are downregulated 
in breast cancer, act as tumor suppressor genes, although SOX18 may act as an 
oncogene in HER2 positive BC tumors  (Mehta et al., 2019).  
SOX4 frequent overexpression in BC has been linked to cell cycle, EMT and 
metastasis regulation. SOX4-directed silencing results in cell cycle arrest, induction of 
apoptosis and altered cell migration (Bilir et al., 2013). SOX4 also triggers the expression 
of EMT inducers and, additionally, activates the TGFβ pathway, which also contributes 
to EMT (Zhang et al., 2012). Several studies have demonstrated that SOX11, SOX12, and 
SOX18 overexpression mediate proliferation, migration, invasion and induction of 
apoptosis in both in vitro and in vivo models of BC (Grimm et al., 2019). In contrast to 
the oncogenic properties demonstrated by the majority of the Sox proteins, SoxF 
members (SOX7 and SOX17) significantly downregulate Wnt/β-catenin activity in BC 
(Stovall et al., 2013; Fu et al., 2010). Also, SOX1 overexpression has been shown to 
prevent Wnt/β-catenin pathway by repressing β-catenin-mediated CCND1 and MYC 
expression, leading to reduced cell proliferation and invasion and induced apoptosis in 
BC cells (Song et al., 2016). 
On the other hand, there is an association between the signaling necessary for 
mammary gland development and the aberrant activation of these networks in breast 
cancer mediated by Sox proteins. Increasing evidence supports the role of Sox factors 
as critical regulators of stem cell fate, such as SOX2 (Novak et al., 2019), SOX4 (Pece et 
al., 2010), SOX9 (Guo et al., 2012), SOX10 (Dravis et al., 2015), and SOX11 (Oliemuller 
et al., 2017) contributing to the regulation of CSC population. Consistent with these 
findings, our group demonstrated that SOX2 promotes tamoxifen resistance in breast 
cancer cells by increasing stem cell features (Simões et al., 2011; Piva et al., 2014). 
Furthermore, we have demonstrated that the SOX2-SOX9 signaling axis regulates the 
breast cancer stem cell content in tamoxifen-resistant cells (Domenici et al., 2019), 
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 becoming an important potential therapeutic target for endocrine-resistant breast 
cancer. 
 
5.3.1 Functional roles of Sox2  
SOX2 overexpression is positively correlated with early-stage breast cancers and 
tumor size, showing increased cell proliferation and metastasis associated with shorter 
overall survival (Mehta et al., 2019). It is well known that SOX2 is expressed early during 
development and is essential in the generation and maintenance of the pluripotent 
stem cell population (Liu et al., 2013). In combination with OCT4 and MYC, SOX2 is 
essential for the formation of induced pluripotent stem cells (iPSCs) (Takahashi and 
Yamanaka, 2006). Consistent with its role in maintaining the stem cell features, several 
studies show that SOX2 expression is induced in tumorspheres and it is sufficient to 
Figure I 8. Schematic overview of Sox proteins regulated functions in breast cancer. The hallmarks 
of cancer, highlighted in blue, that are regulated by Sox proteins in breast cancer. Each hallmark has 




 induce tumor initiation in vivo, indicating that SOX2 plays an important role in 
maintaining the cancer stem cell population (Leis et al., 2012). In addition, SOX2 and 
MYC upregulation by VEGF has been associated with increased breast cancer stem cell 
population (Zhao et al., 2015) as well as the Notch signaling pathway (Simões et al., 
2015), among others. For example, Sox2 has been reported to activate NFκB-CCL1 
signaling for CD4+CD25+ Treg immune cells recruitment which promote breast CSC 
increase (Xu et al., 2017). High Sox2 expression levels also result in the inhibition of 
mTOR signaling pathway (Corominas-Faja et al., 2013). 
However, SOX2 does not only regulate CSCs content in BC disease, it also has a 
role in cell proliferation, EMT and metastasis. SOX2 promotes cell proliferation through 
the activation of Wnt signaling pathway. Sox2 protein interacts with β-catenin 
regulating DNA binding and transcriptional activity in BC cells to induce Cyclin D1 
expression in order to accelerate G1/S cell cycle transition (Chen et al., 2008). A more 
recent study confirmed that β-catenin is an essential Sox2 partner determinant of DNA 
binding and transcriptional activity (Ye et al., 2014). Sox2 promotes metastasis of BC 
cells by activating EMT through Wnt/β-catenin pathway (Li et al., 2013). Indeed, our 
group demonstrated that during the development of resistance to endocrine therapy, 
BC cells acquired an increased invasion capacity led by Sox2 dependent activation of 
Wnt pathway (Piva et al., 2014). Nevertheless, Sox2 does not only induce EMT through 
Wnt signaling, several studies highlight the relationship between SOX2 and a key 
regulator of the EMT process, SNAI2. It has been reported that high Sox2 expression 
rapidly stimulated SNAI2 induction leading to increased invasion and metastasis, 
concluding that Sox2 is a major mediator of CSC self-renewal that also governs the 
metastatic process (Kim et al., 2017). Moreover, several studies have reported a 
significant upregulation of SNAI2 in hormone receptor-positive breast cancer with 
inhibited ER signaling pathway (Liu et al., 2019) and in aggressive endocrine-resistant 
breast cancer (Alves et al., 2018).  
5.3.2 Functional roles of Sox9  
Members of the SoxE group (SOX8, SOX9 and SOX10) are mostly expressed in 
TNBC (Mehta et al., 2019). However, we demonstrated that Sox9 is highly expressed in 
tamoxifen-resistant BC cells (Domenici et al., 2019). SOX9 participates in a wide variety 
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 of cellular processes. A recent bioinformatics study has confirmed that Sox9 is a key 
regulator of mammary gland development and high levels correlate with increased 
stem cell content and poor prognosis. Also, SOX9 regulates the Wnt/β- catenin pathway 
conducting the induction and maintenance of the tumor-initiating capacity (Dong et al., 
2018). Several studies link Sox9 with the regulation of EMT, cell migration and 
metastasis in breast cancer, although the mechanisms by which Sox9 mediates these 
processes remain unclear (Wang et al., 2018). Our group also confirmed that Sox9 is 
required for the maintenance of the mammary stem/progenitor cell pool in the human 
breast epithelium and for commitment to the luminal epithelial lineage (Domenici et 
al., 2019). Previous work reported that overexpression of SNAI2 and SOX9 was 
sufficient to convert differentiated luminal cells into mammary stem cells with long 
term mammary gland reconstituting ability (Guo et al., 2012). In fact, Guo’s Lab recently 
published a new study highlighting the relevance of Sox9 as a key factor in lineage 
plasticity and the progression of basal-like breast cancer cells. The authors have 
demonstrated that SOX9 is required for the activation of the NF-kB pathway in the 
luminal stem/progenitor cells as well as the role of Sox9 in luminal-to-basal 
reprogramming during the progression of DCIS to invasive basal-like BC (Christin et al., 
2020). 
In conclusion, due to the relevant oncogenic function of Sox family proteins in 
development and breast cancer tumorigenesis and particularly Sox2 in tamoxifen-




The pharmacological modulation of transcription factors (TFs) by small 
molecules remains a clear challenge for the development of new therapeutics. 
Traditionally, nuclear receptor TFs are targetable by small molecules through the 
ligand-binding domains. The current challenge is to reach beyond nuclear receptors to 
a broader range of TFs that lack binding domains and target the protein-DNA 
interaction domains. In addition, the DNA binding domains undergo structural 
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 rearrangements upon DNA binding, making drug design difficult (Berg, 2008). Jauch and 
colleagues performed a high-throughput fluorescence anisotropy screening that 
revealed a polyoxometalate as a direct inhibitor of the Sox2-HMG domain produced in 
bacteria (Narasimhan et al., 2011), suggesting the therapeutic potential of these 
molecules against Sox TFs.  
6.1 Biochemistry 
Chemically, a polyoxometalate (POM) is a polyanion, which consists of three or 
more transition metal oxyanions in their high oxidation states linked together by shared 
oxygen atoms to form closed 3D frameworks. They exhibit a huge diversity in size and 
structure with many different properties and functions (Narasimhan et al., 2014). POMs 
have potential applications in a variety of fields like catalysis (Dolbecq et al., 2010), 
nanoscience (Pérez-Álvarez et al., 2019), medicine (Rhule et al., 1998; Bijelic et al., 
2019) and also in macromolecular crystallography (Bijelic and Rompel, 2018). POMs 
comprise isopolyanions and heteropolyanions exhibiting the general formula [MmOy]n− 
and [XxMmOy]n−, respectively. M is the polyatom (early transition metal ion), mostly 
Mo6+, W6+ or V5+. X is the heteroatom, which is either the main group or also a transition 
metal. The polyatoms are restricted to transition metals because they need to possess 
a favorable charge/radius ratio and empty d-orbitals (dπ) to form M-O bonds with 
oxygen atoms via dπ-pπ overlapping (electrons transfer from filled p-orbitals of the 
oxygen atoms to empty d-orbitals of the metals) (Bijelic et al., 2018). 
Structurally, POMs are composed of {MOy} units (y=4-7), being {MO6} unit the 
most common building block, and packed together (self-assembly) in various ways 
exhibiting different shapes and sizes. The first report describing a POM synthesis was 
published in 1826, (NH4)3[PMo12O40] (Berzelius, 1826). However, it was James F. Keggin 
who defined the structure of this first POM. Keggin studied POM structures and their 
self-assembly based on {MO6} units, defining the formula for Keggin structures 
[XM12O40]n−, which follow tetrahedral symmetry composed of 12 octahedral {MO6} 
units (Keggin, 1933) (Figure I 9A). POMs following the formula [XM6O24]n− exhibit 
Anderson-Evans structures based on trigonal symmetry composed of a central 
octahedrally arranged {XO6} heteroatom that is surrounded by a planar arrangement 
of six edge-sharing {MO6} units (Evans, 1948) (Figure I 9B). Meanwhile, Wells and 
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 Dawson elucidated the 18-heteropolyoxotungstates trigonal anion structure 
[P2W18O62]6−. The structures that follow [X2M18O62]n− formula are from the Wells-
Dawson category, characterized by a trigonal symmetry formed by the fusion of two 
[XM9O34]n− building blocks (Dawson, 1953) (Figure I 8C). Currently, there are many 
POMs or POM derivatives, mostly classified within these three structure models, 
Keggin, Anderson and Wells-Dawson, even though there are some other described 
structures (Bijelic et al., 2018). 
 
6.2 POMs and cancer 
Many researchers have demonstrated over decades that POMs have potential 
applications in medicine as inorganic drugs with antibacterial (Rhule et al., 1998), 
antiviral (Yamase 2013; León et al., 2014), and antitumor (Cao et al., 2017; Sun et al., 
2016) activities. POMs were used firstly in cancer treatment against gastrointestinal 
tumors in 1965 when a combination of different POMs H3[PW12O40] and H3[PMo12O40] 
was used for tumor treatment (Mukherjee 1965). Consistent with this, Yamase and 
colleagues evaluated the antitumor properties of several POMs demonstrating that 
were highly efficient in suppressing the tumor growth in different in vivo mice models 
(Yamase et al., 1988). 
Mechanistically, the antiproliferative activity of an anticancer drug is directly 
associated with its ability to enter the cells. It is well accepted that POMs are able to 
penetrate cancer cells by some form of endocytosis because it has been detected in the 
cytoplasm of murine macrophages (Ni et al., 1996). Besides, POM containing 
Figure I 9. Schematic representation of the most common POM structures. Octahedra (left) and ball 
and stick (right) representation mode of Keggin (A), Anderson-Evans (B) and Wells-Dawson (C) 





 nanoparticles have been internalized by clathrin-mediated endocytosis pathway in 
HeLa cells (Geisberger et al., 2013). Several mechanisms have been proposed as 
potential explanations of the antitumor activity of POMs. One of the most important 
mechanisms was identified by Yamase and confirmed by other groups, in which 
repeated reduction-oxidation cycles between the POM and cell components of the 
electron transport chain interfere with ATP generation, leading to the induction of 
apoptosis (Yamase et al., 1988). POMs have been implicated in cell death pathways, 
DNA interactions and protein interactions. Some Wells-Dawson POMs have been able 
to induce apoptosis by affecting the expression of cell death regulators, increasing the 
amount of the pro-apoptotic proteins (Bax and Bim) and reduce the expression of the 
anti-apoptotic protein Bcl-2 and the transcriptional factor NF-kB (Wang et al., 2013; 
Wang et al., 2017). 
Interestingly, intrinsic apoptosis induction by DNA damage has been associated 
with POMs. POM structures were found to directly interact with DNA in a noncovalent 
manner (Dianat et al., 2013). The exact POM binding mechanism to DNA remains 
unknown. However, due to their negative charge and their tendency to bind to neutral 
or hydrophilic surfaces, POMs are able to interact with a wide variety of proteins. POMs 
are potent inhibitors of protein kinase CK2, highly upregulated in many cancer types 
and associated with increased proliferation rate and ability to suppress apoptosis. 
Crystallographic studies revealed that the POM binding site was located at the ATP 
binding pocket interfering with the catalytic activation of the kinase (Prudent et al., 
2010). POMs are also potent HDAC inhibitors affecting normal cell cycle progression 
and differentiation. Besides, they can also act as inhibitors of ATPases/GTPases, 
phosphatases, ectonucleotidases and many other proteins (Bijelic et al., 2019). 
Pure POMs are inorganic molecules that might be toxic in long-term 
applications. Thus, there are increasing efforts to develop POM-based organic-
inorganic hybrids for the encapsulation of POMs not only to reduce the toxicity but also 
to increase its anticancer activity.  A novel modification has been described for safer 
and more effective POM treatment in colorectal cancer in vivo (Sun et al., 2016). 
More recently, several publications highlight the relevance of POM-based 
treatment in multiple cancer types. A degradable POM has been described to inhibit 
the malignant growth of glioma cells by inducing apoptosis and also the ability to cross 
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 the blood-brain barrier, which is the key point in drug development against 
glioblastoma cells (She et al., 2016). POMs have also been reported to be efficient 
against tumors with acquired resistance to radiotherapy by regulating the homeostasis 
of reactive oxygen species (ROS) and Hypoxia-inducible factor-1α (HIF-1α) (Yong et al., 
2017). In breast cancer, K12[V18O42(H2O)]·6H2O POM derivative has been reported to 
show antiproliferative activity on BC cell lines. The results indicated this POM could 
inhibit the proliferation of BC cell lines in a dose-dependent manner as well as 5-
fluorouracil chemotherapeutic drug (Qi et al., 2017). A more recent study has shown 
that POM activated the expression of the PTEN gene to inhibit the phosphorylation of 
the Akt pathway, ultimately inhibiting the proliferation by inducing apoptosis of lung 
cancer cells (H. B. Sun et al., 2019). 
Given the considerable potential of POMs as new therapeutic drugs in cancer 
treatment, more research is warranted in this field and novel and improved methods 
to elucidate the mechanism behind the anticancer activity of POMs. 
6.3 Sox2 and POMs 
 Narasimhan demonstrated that among the different POM structures, only 
Dawson-POMs showed Sox2-HMG domain interaction. Furthermore, they concluded 
that the presence of Dawson-POM contributed to a stabilization effect of the Sox2-
HMG complex and no other structurally unrelated DNA binding domains. Nuclear 
magnetic resonance (NMR) experiments revealed the preferential binding site of POM 
on the Sox2-HMG surface. The C-terminus of helix-3 and the N-terminal region of the 
minor wing of the Sox2-HMG domain form the binding pocket. The negatively charged 
surface of POM can form many favorable electrostatic interactions when bound to Sox2 
positively charged residues (Figure I 10) (Narasimhan et al., 2011). 
A few years later, in 2014 they published a new paper in which they assessed 
the selectivity of a panel of different POMs and their efficiencies in targeting different 
Sox family members (Narasimhan et al., 2014). The authors studied more deeply the 
specificity of Dawson-POMs on Sox TFs inhibition. However, they detected that some 
Dawson-POMs also showed inhibition profiles of not only the Sox-HMG members but 
also other TF families like FoxA1, REST and AP-2. Overall, among the TFs tested, Pax6 
was the most inert to treatment with POMs. Finally, they compared the two main POM 
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 structures (Keggin and Dawson POMs) and concluded that the inhibitory potential of 
Keggin POMs was lower than the one detected for Dawson-POMs. These findings 
suggest that the size or charge of POMs is an important consideration in the inhibition 
of TFs, making Dawson-POMs more suitable for drug development studies. In 
conclusion, although these assays were carried out in vitro using short DNA molecules 
and isolated HMG DNA binding domains, demonstrated that Dawson-POMs are 
suitable for drug development studies against the Sox TF family. 
 
Figure I 10. Sox2-HMG Dawson-POM interactions at the binding site. (A) Representation of the 
residues implicated in the Sox2-HMG and POM interaction on the binding pocket. (B) Overview of the 
complex formed by Sox2-HMG and POM representing the direct interference with DNA. Figure taken 
















The mechanism of resistance to hormone therapy involves the enrichment of 
the CSC population, with a high expression of Sox2. Elimination of CSCs has been 
proposed as combinatorial therapy to improve breast cancer prognosis by eliminating 
or delaying the appearance of recurrence. The potential use of a polyoxometalate as 
Sox2 small molecule inhibitor provides a platform to investigate the molecular 
mechanisms of regulation of CSCs in order to find new therapeutic approaches for 
tamoxifen resistant breast cancer. Therefore, we defined the following hypothesis: 
 
HYPOTHESIS 
The reduction of the CSCs, by targeting Sox2 through POM treatment, will 
contribute to restore the capacity of breast cancer cells to respond to endocrine 
therapy and to eliminate resistance. 
 
2. Objectives 
Based on this knowledge, the main objective of this thesis is to examine the 
potential of reducing CSCs to revert resistance to therapy. Consistent with this 
premise, the specific aims of this project are: 
 
1. To identify highly efficient full-length Sox2 inhibitors through screening several 
POM derivatives. 
 
2. To evaluate POM treatment effects on tamoxifen-resistant breast cancer cells. 
 
3. To analyze the tamoxifen-resistant CSC content after POM treatments. 
 
4. To elucidate the molecular mechanism underlying the effects of POM 
















Material Company, Catalogue number 
17-ßestradiol (E2) Sigma-Aldrich, E2758 
4-Hydroxytamoxifen (Tam) Sigma-Aldrich, H7904 
4X Laemmli Sample Buffer  Bio-Rad Laboratories, 1610747 
7-Aminoactinomycin D (7-AAD)  BioLegend, 420403 
Acetic Acid glacial technical grade ITW reagents, 211008.1214  
Aldefluor kit reagent  Stemcell Technologies, 1700 
Ampicillin  Sigma-Aldrich, A5354 
Annexin V-FITC kit  BD Pharmingen™, 556419 
B-27™ Supplement (50X), serum free Gibco™, 17504044 
Basic fibroblast growth factor (bFGF) ORF Genetics, 01-A01110 
Blasticidine S hydrochloride Sigma-Aldrich, 15205 
Bovine Serum Albumin (BSA) Sigma-Aldrich, A9647 
Clarity™ Western ECL Substrate Bio-Rad Laboratories, 1705060 
Corning® BioCoat™ Matrigel® Invasion Chambers Corning®, 354480 
Crystal Violet Sigma-Aldrich, C0775 
Culture flasks Corning® Costar® 
Culture plates Corning® Costar® 
DAPI  Sigma-Aldrich, D9542  
DC™ Protein Assay Kit Bio-Rad Laboratories, 5000111 
DH5α Competent Cells for Subcloning Thermo Scientific™, EC0111 
Dimethyl Sulfoxide (DMSO)  Sigma-Aldrich, D2650  
DRAQ7 Biostatus, DR71000  
Dulbecco's Modified Eagle Medium/Nutrient 
Mixture F-12 (DMEM/F-12) 
Gibco™, 31331-028 
Dulbecco's Modified Eagle's Medium (DMEM)  Gibco™, 41965-039 
Dulbecco's Phosphate Buffered Saline (DPBS) Gibco™, 14190-094 
Epidermal Growth Factor (EGF)  Invitrogen™, PHG0311 
Ethanol absolute  Oppac, 045TC0037 
Filter Unit Millex-GP Millipore Express, SLGP033RB 
Fetal Bovine Serum (FBS) Gibco™, 10270-106 
FxCycle™ PI/RNase Staining Solution Thermo Scientific™, F10797 
Galacton-Plus™ Substrate  Invitrogen™, T2118 
GeneJuice® Transfection Reagent Merck-Millipore, 70967 
Luciferase Assay System Promega, E1501 
Lysogeny Broth (LB) medium (LENNOX) Pronadisa, 1231.00 
Matrigel® Basement Membrane Matrix Corning®, 356234 
MicroAmp™ Optical 384-Well Reaction Plate with 
Barcode 
Applied biosystems®, 4309849 
Mini-PROTEAN® Precast Gels Bio-Rad Laboratories, 4561085 
NucleoSpin RNA® Macherey-Nagel, 740955250 
Table M 1. List of materials and reagents.  
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Opti-MEM™ I Reduced Serum Medium, 
GlutaMAX™ Supplement 
Gibco™, 51985-026 
Paraformaldehyde solution 4% (PFA) ChemCruz, sc-281692 
Penicillin/streptomycin Gibco™, 1015140-122 
Poly(2-hydroxyethyl methacrylate) (Poly-HEMA) Sigma-Aldrich, P3932 
PureLink™ HiPure Plasmid Maxiprep Kit Invitrogen™, K210007 
PureLink™ RNA Micro Kit Invitrogen™, 12183-016 
Puromycin dihydrochloride Sigma-Aldrich, P8833 
Resolving Gel Buffer (1.5 M Tris-HCl, pH 8.8) Bio-Rad Laboratories, 1610798 
SimpleChIP® Enzymatic Chromatin IP Kit 
Cell Signaling Technologies, 
9003 
Skim milk powder  Sigma-Aldrich, 70166 
Stacking Gel Buffer (0.5 M Tris-HCl, pH 6.8) Bio-Rad Laboratories, 1610799 
Syringe (2 ml)  Injekt®, 4606027V 
TEMED (TMEDA, 1, 2-Bis(dimethylamino)ethane) BIO BASIC, TB0508 
Tris-base (Trizma)  Sigma-Aldrich, T1503 
TRITON X-100 Supelco, 21123 
Trypan Blue Stain (0.4%) Invitrogen™, T10282 
TrypLE™ Express Enzyme Gibco™, 12604-013 
Trypsin-EDTA 1X (0.25%) Gibco™, 25200-056 
Tween 20 Sigma-Aldrich, P9416 
Ultralow attachment 24-well tissue-culture plates Corning®, 3473 
UltraPure™ SDS Solution, 10% Gibco™, 15553 
VECTASHIELD® Mounting Medium with DAPI Vector Labs, H-1200 
β-mercaptoethanol Sigma-Aldrich, M7522 
 
1.2 Cell culture media 
Culture Medium 
MCF-7, T47D, ZR75-1  
(and all derivatives) 
DMEM/F-12, 8% FBS, 1% p/s 
HEK293T DMEM, 8% FBS, 1% p/s 
Mammosphere culture 
DMEM/F-12, 1% p/s, B27 supplement (0,5X), 10 ng/mL 






Table M 2. Formulation of the media used for cell culture.  




Vector Supplier Cat. No. 
pSin-EF2-EGFP-Pur Simões et al., 2011 - 
pSin-EF2-Sox2-Pur Addgene 16577 
pMD.2 (VSV-G) Addgene  12259 
psPAX2 Addgene 12260 
pLKO.1-empty Open Biosystem TRCN0000208001 
pLKO.1-shSOX2(48) Open Biosystem TRCN0000085748 
pSpCas9(BB)-2A-Puro (PX459) V2.0 Addgene 62988 
pLenti6.2-GW/EmGFP ThermoFisher Scientific V36920 
pGL2 TK-luciferase  Prof. Malcolm Parker, London - 
pGL2-ERE TK-luciferase  Prof. Malcolm Parker, London - 
pΔ6RL (β-galactosidase) Vivanco et al., 1995 - 
 
2. Methods 
2.1 Cell culture 
  2.1.1 Culture of human cell lines 
The breast cancer cell lines MCF-7, T47D and ZR75-1 (Table M 4) and human 
embryonic kidney HEK293T cells were obtained from the American Tissue Culture 
Collection (ATCC). All cell lines were cultured at 37 °C and 5% CO2, with different 
culture media as detailed in Table M 2. DNA profiling (Eurofins Genomics, Germany) 
authenticated cell lines were routinely tested for mycoplasma. The corresponding 
tamoxifen-resistant breast cancer lines MCF-7TR, T47D-TR and ZR75-1TR were 
developed in the laboratory after long-term (over 6 months) exposure to 5·10-7 M 4-
Hydroxytamoxifen, as described in (Piva et al., 2014). Tamoxifen-resistant cells were 
maintained in culture in the presence of 5·10-7 M 4-Hydroxytamoxifen, while control 





Table M 3. List of plasmids used in this project.  
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Cell line ATCC® No Tumor Receptors expression Isolation 
MCF-7 HTB-22™ AC ER+ PR+ HER2- 
Pleural effusion 
(Soule et al., 1973) 
T47D HTB-133™ IDC ER+ PR+ HER2- 
Pleural effusion 
(Keydar et al., 1979) 
ZR75-1 CRL-1500™ IDC ER+ PR+/- HER2- 
Ascitic effusion 
(Engel et al., 1978) 
 
2.2 Transformation of plasmids into competent E. coli cells 
DH5α competent cells and 50 μL of the competent cells were mixed with 8 ng 
of the plasmid DNA of interest (Table M 3) gently tapping the tube to mix, followed 
by 30 min incubation on ice. Then, bacteria cells were heat-shocked at 42 °C for 45 
seconds followed by 2 min incubation on ice. 950 μL of Lysogeny Broth (LB) medium 
was added onto the bacteria cells, which were shaken at 37 °C and 225 rpm for 1 h. 
Around 100 μL of the bacteria solution was spread onto LB plates with 100 μg/mL of 
ampicillin and incubated at 37 °C overnight. One of the colonies was picked using a 
pipette tip, added onto 5 mL of LB media with Ampicillin (100 μg/mL) and incubated 
for 8 h at 37 °C and 225 rpm. Bacteria containing media was then transferred into a 
conical flask with 400 mL of LB media with Ampicillin and incubated overnight at 37 °C 
shaking at 225 rpm. Plasmid DNA was isolated following the manufacturer’s 
instructions of the PureLink™ HiPure Plasmid Maxiprep Kit (Invitrogen). 
2.3 Transient transfection 
  2.3.1 DNA transfections and transcriptional assays 
We used an ERE (Estrogen Responsive Element)-luciferase based reporter 
assay to measure the activation of ERα dependent transcription. Cells were 
transfected with the pGL2-ERE TK-luciferase vector containing the thymidine kinase 
(TK) promoter and three copies of a consensus ERE driving the expression of the 
luciferase gene. As control, the pGL2 TK-luciferase vector lacking the consensus ERE 
sites was used (vectors kindly provided by Prof. Malcolm Parker, London). A vector 
expressing β-galactosidase (pΔ6RL) was used as a control for transfection efficiency 
Table M 4. Description of the breast cancer cell lines. AC: Adenocarcinoma, IDC: Invasice Ductal 
Carcinoma. 
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(Vivanco et al., 1995). 
GeneJuice® Transfection Reagent (Merck-Millipore) was used for cell 
transfection as instructed by the manufacturer. Briefly, cell culture medium containing 
serum and antibiotics was removed and cells were washed twice with PBS, before 
adding 300 µL of OptiMEM to each well. For each well, 1,5 µL of GeneJuice® were 
incubated in OptiMEM (100 µL per well) for 5 min. After that, 500 ng of DNA were 
added to the diluted GeneJuice® and further incubated for 15 min. DNA- GeneJuice® 
mixture was then added to the cells for an incubation period of 6 h at 37 °C in a 5% 
CO2 incubator. Following incubation, the transfection medium was removed and cells 
were culture in phenol red-free DMEM/F-12 medium with GlutaMAX supplemented 
with 8% charcoal-stripped FBS (cFBS) with either 10-8 M 17-β-estradiol (E2) or ethanol 
for 48 h. After 48 h, cells were collected and assayed for luciferase and β-galactosidase 
activities, following the manufacturers’ instructions of the Luciferase Assay System 
(Promega) and Galacton-Plus™ Substrate (Invitrogen), respectively. Relative light units 
of luciferase activity were normalized to β-galactosidase activity. 
2.4 Generation of stable gene silencing/overexpressing cell lines  
  2.4.1 Stable Gene Knockdown using short hairpin RNA (shRNA) 
 The 3-plasmid transfection system was used for the lentiviral stable 
knockdown of SOX2 gene, using pLKO.1 backbone vector. pLKO.1-shSOX2(48) was 
used against SOX2 gene and an empty shRNA vector (pLKO.1-empty) was used as 
negative control (Table M 3). Two cell lines are required for this process: a packaging 
cell line in which lentiviruses will be produced (HEK293T) and the target cell line in 
which the transgene should be knocked down (MCF-7TR). The protocol for lentivirus 
infection was performed in several steps as previously described (Simões et al., 2011) 
(Figure M 1).   
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Firstly, HEK293T packaging cells (2·106 cells/P100) were transfected using the 
calcium-phosphate precipitation method for lentivirus production. Briefly, 5 μg of 
pLKO and shSOX2 constructs together with 2,5 μg of psPAX2 (provides integrase, 
reverse transcriptase and structural proteins) and 2,5 μg of VSV-G (provides the 
envelope proteins) were mixed in a final volume of 500 μL of distilled water with 50 
μL of calcium chloride (CaCl2) per condition. Then, the DNA solution was mixed with 
500 μL of 2X HBS (HEPES-buffered solution: 50 mM HEPES, 280 mM NaCl, 10 mM KCl, 
1,5mM Na2HPO4.2H2O, 12 mM glucose, pH=7.05) and incubated for 20 min in the 
presence of oxygen by making bubbles to favor the formation of calcium phosphate 
crystals. Once the crystals were formed the solution was added dropwise to the 
packaging cells in order to be transfected during overnight incubation. Packaging cells 
media was changed to fresh culture media of the target cells for virus production, as 
well as the target cell line for infection was seeded. 
Secondly, after 24 h of lentivirus production, target cells were first infected 
with the supernatant containing virus from packaging cells. For this, 7 mL of 
supernatant from packaging cells were filtered with 0,45 μm filters and 3 mL of fresh 
media were added to a total of 10 mL. Protamine sulfate was added to the mixture at 
a final concentration of 1 µg/mL to increase infection efficiency, enhancing virus 
binding and internalization into target cells. After infection, fresh media was added to 
packaging cells for further virus production for the second round of infection. The 
following day, a second infection of target cells was performed with the supernatant 
containing virus and the packaging cells were discarded. Finally, 24 h after the second 





























Add antibiotic  
selection 
Friday 
Figure M 1. Schematic protocol of the lentiviral infection strategy for stable knockdown cell 
generation.  
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days and afterwards kept in medium containing 0.5 μg/mL of puromycin. The 
efficiency of stable Sox2 knockdown was evaluated by qPCR and western-blotting. 
  2.4.2 Stable Gene Overexpression using lentiviral infections 
SOX2 overexpression in MCF-7 cells was performed with the same calcium 
phosphate precipitation method described for shRNA, but using pSin-EF2-Sox2-Pur 
vector and pSin-EF2-EGFP-Pur (Table M 3) as control, as previously described in 
(Simões et al., 2011). SOX2 overexpressing cells and control cells were named as MCF-
7SOX2 and MCF-7GFP cells, respectively, and kept in culture in the presence of 
puromycin (0,5 μg/mL) after selection. The efficiency of stable SOX2 overexpression 
was evaluated by qPCR and western-blotting. 
  2.4.3 Stable Gene Knockout using CRISPR-Cas9 genome editing 
technology 
CRISPR-Cas9 targeting of SOX2 locus was performed to generate MCF-7TR cells 
carrying a stable knockout of Sox2 protein. Online resources (CRISPRdesign and 
CRISPR) were used to search for high-scoring sites in the SOX2 gene locus. The highest 
scoring sgRNA target to design the vectors were chosen and cloned into the nickase 
plasmid pSpCas9(BB)-2A-Puro (PX459) V2.0 (Table M 3). sgRNA oligo sequences were: 
sgRNA A, 5’-CACCGCTCCATCATGTTGTACATGC-3’ and B 5’- 
CACCGCGGGCCCGCAGCAAACTTCG-3’. All constructs were confirmed by sequencing 
and cloning. MCF-7TR cells were transiently transfected with the resulting CRISPR-
Cas9 vector together with one (as control) or both sgRNA sequences against SOX2 
gene locus, using GeneJuice® Transfection Reagent. Two days after transfection, 
transfected cells were selected with 2 μg/mL puromycin and followed by single-cell 
cloning and screening. The efficiency of stable Sox2 knockout was confirmed by 
western-blotting, resulting in a depleted Sox2 cell line (MCF-7TR-SOX2KO). 
2.5 Functional assays 
  2.5.1 Cell proliferation assay 
To evaluate drug treatment effects on cell proliferation in different cell lines, 
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5000 cells/well were seeded in complete medium in 24-well tissue-culture plates. 
POM treatments were added from a freshly prepared stock solution of 2 mM in the 
cell culture medium on the day after seeding the cells according to each experiment’s 
requirements. Cell proliferation was determined after 7 days by staining the cells with 
crystal violet solution (Sigma). Briefly, cells were washed twice with PBS and fixed with 
200 μL of 4% PFA for 15 min before staining with 200 μL of crystal violet for 20 min on 
a rocker to ensure all the surface was covered. After crystal violet incubation, cells 
were washed twice with PBS and plates allowed to dry overnight. Once plates were 
dry, stained cells were dissolved in 10% acetic acid solution and then absorbance was 
measured at 595 nm. Results are shown as relative cell proliferation to the control 
using the mean of three independent experiments. 
  2.5.2 Wound healing assay  
High cell density was seeded on 6-well tissue culture plates in complete 
DMEM/F-12 medium and allowed to grow until around 90% confluence was reached. 
Then, cells were starved during 24 h using DMEM/F:12 medium supplemented with 
1% FBS and 1% p/s. After starvation, a scratch (wound) was done using a 20 μL pipette 
tip. Subsequently, the medium was changed to remove detached and dead cells and 
drug treatments added for 72h, according to experiment requirements. Six pictures 
per well were taken and three biological replicates were analyzed for each condition. 
The scratch width representing the migration capacity of the cells was measured using 
ImageJ software. Results are shown as relative cell migration capacity from three 
independent experiments. 
  2.5.3 Invasion assay  
For invasion assays, 50000 cells/well, previously starved in 1% FBS DMEM/F-
12 medium, were seeded in triplicate on Corning® BioCoat™ Matrigel® Invasion 
Chambers of 8 μm pore transwell filters in 1% FBS containing medium. All inserts were 
set in 24-well tissue culture plates with 20% FBS containing medium in the lower 
chamber, both in presence or absence of POM treatment. As a control for cell viability, 
cells were plated in parallel at the same density in 24-well tissue culture plates. After 
72 h of incubation, cells on the upper surface of the membrane were removed 
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mechanically by wiping with a cotton swab, and the remaining cells on the lower side 
of the membrane were fixed and stained with crystal violet solution. To determine the 
number of invading cells at least 9 different fields of each well were counted using 
ImageJ software. To normalize the number of invading cells to the amount of viable 
cells, the control plates were also stained with crystal violet solution and absorbance 
was measured at 595 nm after solubilizing the crystal in acetic acid. Results are shown 
as relative cell invasion of three independent experiments. 
  2.5.4 Mammosphere formation assay  
Cells were detached with TrypLE 1X (Invitrogen) and plated in ultralow 
attachment 24-well tissue-culture plates (Corning) at a density of 500 cells/well. Cells 
were grown in Mammosphere culture medium (Table M 2) at 37 °C in 5% CO2. To 
assess the self-renewal capacity of stem cells, primary mammospheres (I MS) were 
dissociated with TrypLE 1X after 5 days to obtain a single-cell suspension and seeded 
to produce a new generation of mammospheres (II MS). The number of 
mammospheres was calculated as the average of 4 wells for each cell line in at least 
three independent experiments. 
2.6 Flow cytometry assays 
  2.6.1 Cell cycle analysis 
FxCycle™ PI/RNase Staining Solution was used to measure the DNA content of 
the cells that allow the study of cell populations in various phases of the cell cycle after 
treatments. The FxCycle™ PI/RNase Staining Solution is a ready-to-use formula 
containing DNase-free RNase A and a permeabilization reagent in PBS. Propidium 
iodide (PI) binds to DNA by intercalating between the bases of DNA. As PI also binds 
to RNA, RNA nucleases treatment is required to distinguish DNA staining. Thus, cells 
were trypsinized, collected and fixed with 70% ethanol, added to cell pellets drop-wise 
while vortexing gently and fix overnight at -20°C. Subsequently, cells were washed 
with PBS in order to remove all the ethanol from cells before proceeding with cell 
staining. 500 μL of FxCycle™ PI/RNase Staining Solution stain were added to each 
sample and incubated for 20-25 min at RT, protected from light. Finally, cells were 
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analyzed without further washing using a FACSCanto II (BD) cytometer. Data were 
analyzed using the FACSDiva software calculating the percentage of cells in each phase 
of the cell cycle. 
  2.6.2 Fluorescence-Activated Cell Sorting (FACS) 
2.6.2.1 Annexin-V staining 
To evaluate apoptosis, cells were stained with Annexin-V-FITC (BD 
Pharmingen™) following the manufacturer‘s guidelines. During the earliest moments 
of the apoptotic program, loss of plasma membrane is one of the first features 
characterizing the apoptotic cells. The membrane phospholipid phosphatidylserine 
(PS) is translocated to the outer leaflet of the plasma membrane, exposing PS to the 
external cellular environment. Annexin-V is a phospholipid-binding protein that has a 
high affinity for PS and binds to cells exposing it. Therefore, staining with Annexin-V-
FITC is used in conjunction with a vital dye such as DRAQ7 to identify early apoptotic 
cells (DRAQ7-negative, Annexin-V-positive) and late apoptotic cells (DRAQ7-positive, 
Annexin-V-positive) (Figure M 2). Then, cells were trypsinized and collected together 
with dead floating cells from the tissue-culture plates. Cell pellets were washed with 
PBS and resuspended in 300 μL of 1X Binding Buffer containing 2 μL of Annexin-V-FITC 
antibody per sample. Cells were incubated shaking gently for 15 min at RT, protected 
from light. Finally, 200 μL extra of 1X Binding Buffer were added to each sample and 
transferred to FACS tubes. DRAQ7 dye was used to measure the viability of the cells 
and mark dead cells. Samples were run in a FACSAria cytometer and data were 
analyzed using the FACSDiva software. 




2.6.2.2 ALDEFLUOR assay 
The ALDEFLUOR™ Kit (STEMCELL Technologies) is a fluorescent reagent system 
used to identify stem/progenitor cells based on their high aldehyde dehydrogenase 
(ALDH) activity. The assay was carried out following the manufacturer‘s guidelines. 
Briefly, after in vitro treatments, 106 cells/sample were resuspended in ALDEFLUOR 
assay buffer. ALDH substrate, bodipyaminoacetaldehyde (BAAA) was added to the 
cells at a final concentration of 1,5 mM. Immediately, half of the cells were transferred 
to the control tubes containing the ALDH inhibitor, diethylaminobenzaldehyde (DEAB) 
at a concentration of 3 mM. Both tubes were incubated for 45 min at 37 °C in darkness. 
After this incubation, cells were centrifuged at 250 g for 5 min at 4 °C and resuspended 
in cold ALDEFLUOR assay buffer. DRAQ7 dye was used to measure the viability of the 
cells and exclude dead cells. Control tubes were always used to ensure accurate gating 
for ALDH-negative activity, adjusting FCS (Forward Scatter) and SSC (Side Scatter) 
voltages according to cell size and complexity (Figure M 3). Samples were run in a 
FACSAria cytometer and data were analyzed using the FACSDiva software. 
 
Figure M 2. Flow cytometry gating strategy used to select the populations of interest for AnnexinV 
staining. FACS plots representing the negative (left) and positive (right) control profiles. Q2 and Q4 
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2.6.2.3 CD24-CD44 surface markers labelling 
Cells were trypsinized and plated in V-bottom 96-well tissue-culture plates for 
the staining of CD24 and CD44 cell surface antigens. PE-conjugated mouse anti-CD24 
antibody (BD) and APC-conjugated mouse anti-CD44 antibody (BD) were used to label 
CD24 and CD44, respectively. In detail, single cells were blocked in 40% FBS in PBS for 
15 min at RT, washed twice with 1% Bovine Serum Albumin (BSA) in PBS and then 
incubated for 30 minutes on ice with the respective antibodies diluted in 1% BSA in 
PBS. Control cells were stained with isotype-matched control antibodies (Table M 5). 
Antibody Company Clone/Cat. No. Concentration Isotype Cat. No.  












Finally, cells were washed twice with 1% BSA in PBS and resuspended in 
FACSFlow buffer (PBS with 1% BSA). 1,5 μL of the cell viability dye 7AAD (BD), a ready-
to-use nucleic acid dye, were added for dead cell exclusion. This dye shows a minimum 
spectral overlap with PE and FITC fluorescence emissions. Control cells were used to 
define the cell population based on size and granularity (FSC and SSC) (P1). Doublets 
(not P2) and dead cells positive for 7AAD (P3) were also excluded. After a single 
fluorochrome signal compensation process, gates were established for CD24-PE and 
Table M 5. List of antibodies used in flow cytometry.  
Figure M 3. ALDEFLUOR assay flow cytometry gating strategy used to select ALDH positive cells. Cells 
treated with DEAB inhibitor (left) were used to define negative cells for ALDH activity and test sample 
(right) was analyzed maintaining the same gate to identify ALDH
+
 cells. 
Sample + DEAB Sample 
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CD44-APC using MCF-7TR cells from adherent cultures to set the threshold that 
allowed the detection of CD44+CD24-/low population in mammosphere culture cells 
(Figure M 4). Finally, samples were run in a FACSAria cytometer and data were 
analyzed using the FACSDiva software. 
 
2.7 RNA analysis 
  2.7.1 RNA extraction and cDNA synthesis 
Total RNA from breast cancer cells was extracted using the illustra™ RNAspin 
Mini Isolation Kit (GE Healthcare) following the manufacturer’s instructions. Genomic 
DNA was degraded by DNAse treatment on columns, as instructed by the 
manufacturer, to avoid contaminations in further analysis. RNA concentration and 
purity were determined by the spectrophotometric measurement of the absorbance 
at 260nm and 280nm using an ND-1000 spectrophotometer (NanoDrop 
Technologies). RNA samples were stored at -80 °C. In general, 1 μg of total RNA was 
Figure M 4. Flow cytometry gating strategy used to select the populations of interest for CD24/CD44 
staining. FACS plots representing the absence of CD44+CD24-/low population (Q4) in adherent culture 
(left) and presence of CD44+CD24-/low population (Q4) in mammosphere culture (right) of MCF-7TR 
cells. P4 population represented the non-CSCs population. 
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used for cDNA synthesis using the Moloney Murine Leukemia Virus Reverse 
Transcriptase (M-MLV) and RNase OUT Ribonuclease Inhibitor (Invitrogen), according 
to manufacturer’s instructions. The amount of each reagent for cDNA synthesis per 
sample are described in Table M 6. 
Reagent Stock concentration Final concentration Volume (μL) 
5X First Strand Buffer 5X 1X 4 
Oligo(dT) Ambion  50 μM 5 μM 2 
dNTPs 10mM (2,5mM/each) 1 mM (250 μM/each) 2 
DTT 0,1M 5mM 1 
RNAse OUT 40 U/μL 1,2 U/μL 0,6 
M-MLV  
Reverse Transcriptase 
200 U/μL 6 U/μL 0,6 
RNA + H2O Variable Variable 20,2 
 
M-MLV mix was added until a final volume of 20 μL and incubated for 1 h at 
37 °C, followed by 1 min at 95 °C to inactivate the enzyme. When the amount of RNA 
available was lower than 1 μg, SuperScript® VILOTM cDNA synthesis Kit (Invitrogen) 
was used for cDNA synthesis, following the manufacturer’s protocol. Thermocycler 
settings for this enzyme were: 10 min at 25 °C, followed by 1 h at 42 °C and enzyme 
inactivation was carried out for 5 min at 85 °C. The cDNA samples were stored at -20 
°C. 
  2.7.2 Primer design and setup 
Primers were designed using the Primer-BLAST tool 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). Designed parameters included 
primers targeting a unique sequence for each gene of 80-150 bp, when possible, 
primer designs were separated by an intron to avoid genomic DNA amplification and 
an optimal melting temperature of 62 °C. After that, primer amplification efficiency at 
different concentrations was tested by serial dilution of cDNA (1X, 0.5X, 0.2X, 0.1X, 
0.05X) and standard curve analysis using the ΔΔCT method. Amplicons resulted from 
the PCR were run on agarose gels to confirm the size was the same as the product 
length predicted by Primer-BLAST. 
Table M 6. Reagents used for RNA retro-transcription reaction. 
Materials and Methods 
 83 
 
  2.7.3 Quantitative Real-Time polymerase chain reaction (qPCR) 
 qPCR was performed using PerfeCTa SYBR® Green Supermix, Low Rox (Quanta 
Biosciences) in either a Viia7 or QuantStudio 6 Flex Real-Time PCR System (Applied 
Biosystems). Conditions for cDNA amplification were set up as follows: Taq 
polymerase activation 95 °C 3 min, denaturation 95 °C 15 sec, annealing/extension 61 
°C 1 min, melting curve 95 °C 15 sec, 60 ˚C 1 min, 95 ˚C 15 sec, 40 cycles. All reactions 
were run in a final volume of 6 μL (5 μL of mix and 1μL cDNA). To detect potential 
contamination, a “blank” reaction with no cDNA template was carried out in parallel 
with each set of reactions. Relative levels of mRNA were determined according to the 
ΔΔCT quantification method, relative to the housekeeping gene 36B4. The primers 
used are listed in Table M 7. 
Gene Sequence 5'→3' Concentration (nM) 
SOX2 F GCACATGAACGGCTGGAGCAACG 900 
SOX2 R TGCTGCGAGTAGGACATGCTGTAGG 900 
SOX3 F TAGGGACACCCACACAAGCG 600 
SOX3 R GCGTTCGCACTACTCTTGCC 600 
SOX4 F GGTCTCTAGTTCTTGCACGCTC 900 
SOX4 R CGGAATCGGCACTAAGGAG 900 
SOX9 F AGACCTTTGGGCTGCCTTAT 900 
SOX9 R TAGCCTCCCTCACTCCAAGA 900 
SOX11 F GGTGGATAAGGATTTGGATTCG 600 
SOX11 R GCTCCGGCGTGCAGTAGT 600 
SOX12 F CCCCCGAGGTTACCGAGATG 600 
SOX12 R GACGGTGGGCTCAGTAGGTG 600 
SOX13 F CCACCAACCTCTGCCTGTCA 600 
SOX13 R TTGGCTGTGAGGTTCAGGGG 600 
SOX15 F TACTCGACAGCCTACCTGCC 600 
SOX15 R GGGTATAGGTGGGCAGCAGTT 600 
SOX18 F CCTCACCGAGTTCGACCAGT 600 
SOX18 R GCTGTAATAGACCGCGCTGC 600 
SNAI2 F GCCAAACTACAGCGAACTGG 300 
SNAI2 R AGTGATGGGGCTGTATGCTC 300 
ALDH1A3 F TCTCGACAAAGCCCTGAAGT 900 
ALDH1A3 R TATTCGGCCAAAGCGTATTC 900 
PS2 F TCGGGGTCGCCTTTGGAGCAG 300 
PS2 R GAGGGCGTGACACCAGGAAAACCA 300 
AREG F TGGAAGCAGTAACATGCAAATGTC 300 
AREG R GGCTGCTAATGCAATTTTTGATAA 300 
Table M 7. qPCR amplification list of primers used in this project. 
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36B4 F GTGTTCGACAATGGCAGCAT 300 
36B4 R AGACACTGGCAACATTGCGGA 300 
 
2.8 Protein analysis 
  2.8.1 Protein extraction 
Cells were washed with PBS and directly lysed with homemade Laemmli buffer 
(50 mM Tris pH 6,8, 1,25% SDS, 15% glycerol). Total cell extracts were heated at 95 °C 
for 15 min for complete lysis and denaturation. For nuclear and cytoplasmic extracts 
fractionation collected for protein-DNA interaction experiments, cells were firstly 
washed with PBS and collected in buffer A (10 mM HEPES, 1,5 mM MgCl2, 10 mM KCl, 
0,5 mM DTT, 1X protease inhibitor) to 1,5 mL Eppendorf tubes using a scraper. Then, 
the lysates were centrifuged at 5500 rpm for 5 min; the supernatant was collected as 
the cytoplasmic protein fraction. Pellets were dissolved in buffer C (20 mM HEPES, 1,5 
mM MgCl2, 25% glycerol, 420 mM NaCl, 0,2 mM EDTA, 0,5 mM DTT, 1X protease 
inhibitor) and incubated for 20 min on ice. After incubation, samples were centrifuged 
at 13000 rpm for 15 min, collecting the supernatant containing the nuclear protein 
fraction. Protein concentration was calculated using Lowry protein assay (BioRad) in a 
spectrophotometer (BioTek) and protein extracts were stored at -80 °C. 
  2.8.2 Western-blotting (WB) 
Protein concentrations of all samples were adjusted, combined with β-
mercaptoethanol (5% final concentration) and 4X Laemmli sample buffer and heated 
at 95 °C for 5 min. Protein extracts were fractionated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE) using the Mini-PROTEAN® Tetra Cell apparatus (Bio-Rad). 
Depending on the molecular weight of the protein of interest, either 8% or 10% 
acrylamide resolving gels were prepared or 4-20% acrylamide gradient Mini-








8% Acrylamide  
Resolving gel (mL) 
10% Acrylamide  
Resolving gel (mL) 
5% Stacking gel 
(mL) 
H2O 2,3 1,9 0,68 
30% Acrylamide 1,3 1,7 0,17 
1.5M Tris (pH 8,8) 1,3 1,3 - 
1.5M Tris (pH 6,8) - - 0,13 
10% SDS 0,05 0,05 0,01 
APS 0,05 0,05 0,01 
TEMED 0,003 0,003 0,002 
 
Samples were run at 100 V for 1,5-2 h in parallel to PageRulerTM Plus Prestained 
Protein Ladder (Thermo Scientific) as protein size marker with a range of 250-10 kDa. 
After SDS-PAGE, samples were transferred to 0,45 μm pore size nitrocellulose 
membranes (Millipore) using a Semi-Dry Transfer Cell (10 V for 30-40 min) or a Trans-
Blot® Turbo™ Transfer System (Bio-Rad). Membranes were washed with TBST (Tris-
buffered saline 0,05% Tween20) and incubated in blocking buffer containing 5% Skim-
milk in TBST for 1h. Primary antibodies (Table M 9) diluted in 3% BSA in TBST were 
incubated with blots at 4 °C overnight. After 3 TBST washes, Horseradish Peroxidase 
(HRP)-conjugated secondary antibodies, either anti-mouse (1:5000) or anti-rabbit 
(1:10000) from Jackson ImmunoResearch, diluted in blocking buffer were incubated 
for 1 h at RT. Membranes were washed again 3 times with TBST and then developed 
using Clarity™ Western ECL Substrate. 
Antigen Company Catalog number Species Dilution 
Sox2 Cell Signaling 3579S  Rabbit 1:1000 
Sox9 Merk-Millipore AB5535 Rabbit 1:4000 
ER Novocastra NCL-ER-6F11 Mouse 1:2000 
pS2 Novocastra NCL-Ps2 Mouse 1:1000 
Cyclin A Novocastra NCL-CYCLIN A Mouse 1:2000 
Cyclin B1 Santa Cruz sc-752 Rabbit 1:1000 
Cyclin E Santa Cruz SC-481 Rabbit 1:1000 
CDK2 Cell Signaling 2546 Rabbit 1:1000 
CDK1/cdc2 Cell Signaling 9116 Mouse 1:1000 
p21 Santa Cruz SC-756 Rabbit 1:1000 
Parp Cell Signaling 9542 Rabbit 1:2000 
Bcl-2 EMD Millipore OP60-20UG Mouse 1:1000 
Table M 8. Reagents for acrylamide gels preparation. 
Table M 9. List of primary antibodies used for western-blotting. 
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GFP Roche 11814460001 Mouse 1:2000 
β-actin Sigma-Aldrich A5441 Mouse 1:50000 
 
  2.8.3 Immunofluorescence (IF) 
Cells grown on cover slides were fixed in 4% paraformaldehyde (PFA) (Sigma) 
for 20 min at RT. After fixation, cells were washed 3 times with PBS, permeabilized with 
0,2% Triton-X-100 (Supelco) in PBS for 15 min at RT and washed other 3 times with 
PBS. Cells were blocked in PBS supplemented with 0,1% Triton-X-100 and 3% BSA for 1 
h and overnight incubated at 4 ˚C with rabbit anti-Sox2 (Cell Signaling, 1:250) and 
mouse anti-ERα (Novocastra, 1:40) primary antibodies (Table M 9) diluted in blocking 
solution. Then, coverslips were washed three times with PBS and secondary antibodies 
were prepared in blocking solution at 1:500 (anti-Rabbit AlexaFluor488, anti-Mouse 
AlexaFluor594, Life Technologies) and incubated for 1 h at RT, followed by nuclear 
staining with DAPI (10 minutes, 300 ng/ml in PBS). Vectashield mounting medium 
(Vector Laboratories Inc.) was used to mount coverslips and stored at 4 °C in the dark. 
Fluorescence imaging was performed using an upright fluorescent microscope 
(Axioimager D1, Zeiss). 
2.9 Protein-DNA interaction 
In order to evaluate DNA-protein interaction, two different approaches were 
carried out, the in vitro Electrophoresis Mobility Shift Assay (EMSA) and the Chromatin 
ImmunoPrecipitation (ChIP) assay in cells. 
  2.9.1 Electrophoresis mobility shift assay (EMSA) 
Electrophoretic mobility shift assay is used to detect protein complexes with 
nucleic acids. Protein and nucleic acids solutions are combined and the resulting 
mixtures are subjected to electrophoresis under native conditions through 
polyacrylamide gel (Native-PAGE). After electrophoresis, the distribution of species 
containing nucleic acid is determined, usually by autoradiography of labeled nucleic 
acid. In general, protein-nucleic acid complexes migrate more slowly than the 
corresponding free nucleic acid. Prior to the EMSA experiment, 10 µg of pSin-EF2-Sox2-
Materials and Methods 
 87 
 
Pur and pSin-EF2-EGFP-Pur (as control) plasmids were transfected into HEK293T cells 
with the calcium-phosphate precipitation method (described in section 2.4.1), to 
enrich for Sox2 in protein extracts. Protein extract fractionations were collected as 
described in section 2.8.1. Only nuclear protein fractions were used for EMSA 
experiments. 
EMSA was performed using double-stranded DNA (dsDNA) probe synthesized 
to contain the predicted Sox2 binding site in the promoter of the P21 gene and a 
sequence of the PAX6 gene promoter as negative control (Narasimhan et al., 2014). 
dsDNA annealing was performed through heating an equimolar mixture of 
complementary DNA strands to 95°C for 5 min in T4 Ligase buffer followed by gradual 
cooling (2 °C down every minute) to ambient temperature for 40 min for P21 F: 5’- 
GGCCTCAAGATGCTTTGTTGGGGTGTCTAG-3’ and R: 5’- 
CTAGACACCCCAACAAAGCATCTTGAGGCC-3’ and PAX6 F: 5’- 
AAGCATTTTCACGCATGAGTGCACAG-3’ and R: 5’- CTGTGCACTCATGCGTGAAAATGCTT-
3’. Then, 10 µg of protein extracts were incubated in Buffer D (20 mM HEPES, 5 mM 
MgCl2, 10 mM KCl, 5% glycerol, 0,2 mM EDTA, 1 mM DTT, 1X protease inhibitor) for 30 
min in the presence or absence of POM derivatives in order to allow the binding to 
Sox2 protein. After that, target dsDNA oligomers were added to the mixture at 1 mM 
concentration for further 60 min incubation at RT. In the meantime, the pre-run of the 
native gel (4-20 % gradient of acrylamide gels in 1X Tris/Glycin) was performed at 100 
V for 90 min. EMSA gels are typically native gels and the pre-running removes excessive 
ammonia and persulfate ions, which can disturb the integrity of labile protein-DNA 
complexes, as well as unpolymerized acrylic acid from impure acrylamide preparations. 
Once the DNA incubation and pre-running of the gel finished, samples were loaded 
with 4X native loading sample buffer and run at 100 V for 1-2 h. For DNA staining after 
electrophoresis, gels were incubated in 20 mL of 0,5X TAE buffer and 2 µL of GelRed® 
Nucleic Acid Gel Stain (Biotium) for 20 min at RT. Pictures were taken in an ultraviolet 
transilluminator. 
  2.9.2 Chromatin Immunoprecipitation (ChIP) 
SimpleChIP® Enzymatic Chromatin IP Kit commercial kit from Cell Signaling was 
used for ChIP assays. Briefly, 107 cells were cross-linked with 1% formaldehyde and the 
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reaction was quenched by 1M glycine, followed by cell lysis with the provided buffers. 
Subsequently, nuclei were digested by the addition of Micrococcal nuclease for 20 min 
at 37 °C in an orbital shaker. The reaction was quenched by the addition of 0,05 M 
EDTA. Micrococcal nuclease digestion was followed by sonication to shear chromatin. 
The resulting chromatin was stored at -80 °C for subsequent chromatin 
immunoprecipitation, after determining chromatin concentration and checking the 
effectiveness of chromatin digestion by electrophoresis in 1% agarose gel assay. A 
proper chromatin digestion gives rise to genomic DNA fragments between 100-1000 
nucleotides. Chromatin was subjected to RNAse and Proteinase K treatment followed 
by DNA purification. At this point, 2% of the purified chromatin was removed and 
stored at -20 °C as “chromatin input” control. For each immunoprecipitation, 10 µg of 
chromatin were incubated at 4 °C overnight in rotation with 2 µg of control rabbit IgG, 
Sox2 antibodies (Table M 9). The following day, 30 μL of protein G-magnetic beads 
were added to the chromatin-antibody solution and incubated at 4 °C for 2 h in 
rotation. Washes and elution of antibody-bound chromatin were performed using a 
magnetic bead separator, as instructed by the manufacturer.  
Chromatin elution from the antibody/protein G magnetic beads was obtained 
in ChIP elution buffer, incubating antibody-protein-DNA complexes at 65 °C for 30 min. 
Protein-DNA crosslink reversal was performed treating with Proteinase K 2 h at 65 °C. 
Eluted chromatin and the 2% input chromatin were purified by using the spin-column 
kit provided and stored at -20 °C. Purified DNA was subjected to qPCR analysis that 
amplifies the predicted Sox2 binding site in different promoters (Table M 10). All ChIP 
analyses were performed as triplicate technical repeats for each of three independent 
experiments and analyzed following the percent input method. 





ESR1 F CGAGTTGTGCCTGGAGTGAT 600 
ESR1 R ACTGGTCTCCCGAGCTCATA 600 
P21 F CTGTTTCCCTGGAGATCAGGT 600 
P21 R ACTGATCCCTCACTAGGTCAC 600 
CCND1 F TGCCGGGCTTTGATCTTT 600 
CCND1 R CGGTCGTTGAGGAGGTTGG 600 
Table M 10. ChIP-qPCR amplification list of primers for analyzed target genes. 
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2.10 In vivo tumor growth assay on the chorioallantoic membrane 
(CAM) 
 Fertilized chicken eggs were cleaned with water and 70% ethanol to remove 
bacteria. Afterwards, eggs were placed into the egg incubator with the pointed end in 
the bottom (embryonic developmental day 0, EDD0). Incubation was performed at 37 
°C under constant 60% humidity and rotation of 100 degrees every 20 min. Separation 
of the developing CAM was induced on EDD4 by drilling a hole of approximately 2 mm 
of diameter in the pointed end of the eggs. After covering the holes with tape, eggs 
were placed again in the incubator without rotation. On EDD7, egg holes were 
enlarged to a final size of approximately 1 cm of diameter and a plastic ring was set 
above blood vessels of the CAM membrane.  
Prior to cell grafting, we generated GFP overexpressing cells by stable gene 
overexpression of pLenti6.2-GW/EmGFP plasmid (Table M 3) using lentiviral infection 
protocol described in section 2.4.1. Thus, 5·105 GFP expressing cells were resuspended 
in PBS and Matrigel (1:1) in the absence or presence of different treatments at a final 
volume of 25 μL/egg. For extreme limiting dilution assay (ELDA) 5·105, 105 and 2·104 
cells/embryo were resuspended and grafted in the middle of a plastic ring set on the 
CAM. On EDD14, holes were enlarged and tumors were photographed in ovo using a 
GFP stereomicroscope (Leica) and excised for cell dissociation and FACS analysis. 
Tumors were minced and digested in 1,5 mL of collagenase (1 mg/mL in PBS Ca2+, 
Mg2+) at 37 °C for at least 30 min. Then, 5 mL of media were added to each tube and 
resuspended thoroughly by pipetting before filtering each sample using a 70 µm 
strainer to a fresh tube. Dissociated cells were centrifuged at 500 g for 5 min. Finally, 
cell pellets were resuspended in 200 of PBS++ and transferred to FACS tubes. DRAQ7 
dye was used to measure the viability of the cells and mark dead cells. Samples were 
run in a FACSAria cytometer at flow rate 5 for 120 sec, recording every GFP+ event in 
100 µL/sample, representing the size of the tumor by the number of GFP+ cells. Data 
were analyzed using the FACSDiva software. 
2.11 Statistical analysis 
Statistical analysis was performed using GraphPad 6.0 software. Data are 
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presented as the mean ± standard error of the mean (SEM). Statistical evaluations 
were performed using two tailed unpaired Student´s t-test or Mann Whitney-U tests 
for comparing two groups, One-way ANOVA or Kruskall-Wallis and the corresponding 
post-hoc tests for more than two groups and two-way ANOVA for comparing more 
than one variable in more than two groups. p values were represented by asterisks as 
follows: (*) p-value < 0.05; (**) p-value < 0.01; (***) p-value < 0.001. Differences were 











1. Screening of different POM derivatives 
The importance of several Sox proteins in tumorigenesis and progression of 
different BC subtypes, acting both as a tumor suppressor and oncogene transcription 
factors has been reported (Song et al., 2016, Zhang et al., 2012, Shepherd et al., 2016, 
Pula et al., 2013). Members of the Sox family may act as molecular markers with 
prognostic factor as well as drivers of the development of resistance to current 
therapeutic approaches (Dong et al., 2004). Studies from our laboratory have 
demonstrated that during development of resistance to tamoxifen treatment, CSC 
content increase is driven by enhanced levels of Sox2 transcription factor (Piva et al., 
2014). Moreover, genetic profiling of Sox2 overexpressing cells also revealed 
increased expression of Sox9 transcription factor. We demonstrated that Sox9 acts 
downstream of Sox2 to control luminal progenitor cell content, ALDH1A3 cancer stem 
cell marker and Wnt signaling activity in tamoxifen-resistant BC cells (Domenici et al., 
2019). 
 The Sox2 regulatory mechanism is complex and important for CSCs 
maintenance. Deregulation of the Sox2 pathway compromises stem cell homeostasis 
and contributes to the development and progression of many cancer types. Therefore, 
it would be relevant to explore further the potential of Sox proteins as drugable 
targets. Thus, Jauch and colleagues identified POMs as specific Sox2-HMG inhibitors 
(Narasimhan et al., 2011). Moreover, they concluded that POMs are highly potent 
inhibitors of the DNA binding activity of the Sox-HMG domain, but with a relatively 
low selectivity profile against different members of the Sox family (Narasimhan et al., 
2014). 
 Based on our previous studies demonstrating the relevance of Sox2 in 
tamoxifen resistant BC and the potential of POMs to act as Sox2 inhibitors, we first 
aimed to identify which of three different polyoxometalate derivatives shows the 
strongest Sox2 inhibitory potential in tamoxifen-resistant BC cells. 
1.1 Expression levels of Sox proteins 
To determine whether selectivity for Sox2 was going to affect the potential 




high-throughput mRNA-seq data from MCF-7TR cells compared to parental cell line 
MCF-7c was used. 
Out of the 20 members of the Sox transcription factor family, only four (SOX2, 
SOX9, SOX11 and SOX3) were differentially expressed between parental and 
tamoxifen-resistant cells. The number of readings, which represent the expression 
levels of a particular gene, and the differences between parental and tamoxifen-
resistant cells that came out for the majority of the other members were 
undetectable, suggesting that the expression of these TFs is negligible in MCF-7 breast 
cancer cells (Table R 1). 
SOX MCF-7c MCF-7TR padj 
SOX1 0,35 2,35 NA 
SOX2 2,92 105,22 2,067E-24 
SOX3 63,81 0,68 2,979E-17 
SOX4 398,94 369,57 6,887E-01 
SOX5 0,67 0,00 NA 
SOX6 0,00 1,44 NA 
SOX7 5,30 6,15 0,8780 
SOX8 0,69 0,31 NA 
SOX9 83,52 184,91 0,0006 
SOX10 0,00 0,00 NA 
SOX11 12,17 0,00 6,729E-05 
SOX12 637,52 555,99 3,743E-01 
SOX13 1048,27 1053,37 9,775E-01 
SOX14 0,00 0,00 NA 
SOX15 8,72 5,92 0,6041 
SOX17 0,00 0,00 NA 
SOX18 22,27 22,17 0,9915 
SOX21 0,35 0,98 NA 
SOX30 0,40 0,00 NA 
 
As previously reported by our laboratory, we found a significant increase in 
SOX2 and SOX9 transcription factors, while SOX3 and SOX11 members were 
significantly downregulated in MCF-7TR cells (Figure R 1A). The significant 
deregulation of SOX2, SOX3, SOX4, SOX9 and SOX11 in MCF-7TR cells was verified by 
qPCR data, while no differences were detected for the ones showing the highest 
Table R 1. Number of readings of SOX members detected in the RNA-seq. 
padj means adjusted p-value by the algorithm of the sequencing machine in 




number of readings (SOX12, SOX13, SOX15 and SOX18) among the other members 
(Figure R 1B). 
 
 
Furthermore, SOX2 and SOX9 upregulation was also detected by mRNA (Figure 
R 1C-D) and protein (Figure R 1E), in three different models of tamoxifen-resistant 
cells analyzed. These data validate not only the RNA-seq data but also the fact that 
Figure R 1. Expression pattern of SOX members in tamoxifen-resistant cells. (A) RNAseq data 
represented as Log2Foldchange of the significantly deregulated SOX TF members in MCF-7TR cells 
compared to MCF-7c. p-values were calculated by the sequencer algorithm. (B) qPCR validation 
analysis of mRNA expression levels of several SOX TF in MCF-7 cells. (C-D) mRNA expression levels of 
SOX2 (C) and SOX9 (D) TF in three different tamoxifen-resistant cell lines (MCF-7TR, T47DTR and ZR75-
1TR) compared to their corresponding control cell lines. (E) Western blot analysis of control (c) and TR 
cell lines blotted for Sox9, Sox2, and β-actin. Graphs represent mean and SEM of at least three 





SOX2 and SOX9 are the unique Sox TF members significantly upregulated in tamoxifen-
resistant BC cells. 
1.2 Cell toxicity tests 
 Several studies have demonstrated the antitumoral properties of POMs, which 
are the reasons for considering potential therapeutic drugs in this context. The 
screening performed in Jauch Lab revealed K6[P2Mo18O62] POM derivative as a direct 
inhibitor of DNA binding activity of the Sox2-HMG domain in vitro (Narasimhan et al., 
2011).  
 Thus, we examined the toxicity of three different POMs, produced by our 
collaborator Prof. Juan M. Gutierrez-Zorrilla from the University of the Basque Country 
(UPV/EHU), to determine the most efficient IC50 for BC cells. We performed cell 
viability dose-dependent curve assays by crystal violet in MCF-7c, MCF-7TR and MCF-
7SOX2 overexpressing cells for each POM derivative (NH4)6Mo7O24 (NH4-Pom), 
K6[P2Mo18O62] (PMo) and K6[P2W18O62] (PW). NH4-Pom and PMo derivatives exerted 
low cytotoxicity on breast cancer cells, while PW showed a decreased cell viability at 
highest concentrations (Figure R 2A-C). The calculated IC50 of each POM derivative for 
each cell line is shown in Figure R 2D. IC50 values of NH4-Pom and PMo were 
significantly higher than PW IC50, which is 55,6 µM for MCF-7c; 52,2 µM for MCF-7TR 





1.3 In vitro Sox2 binding ability 
To characterize further the inhibitory potential of these POM derivatives on 
Sox2 binding to target DNA, we carried out Electrophoretic Mobility Shift Assay 
(EMSA) for detecting protein-nucleic acid interactions. Binding to a specific promoter 
site by Sox2 in nuclear extracts from transiently transfected HEK293T cells 
overexpressing Sox2 full-length protein or GFP protein (as control) was determined.  
P21, one of the genes controlling cell cycle progression, has been shown to be 
regulated by Sox2 (Yamawaki et al., 2017, Herreros-Villanueva et al., 2013). A 30 bp 
dsDNA sequence containing the Sox2 binding region at -5961 bp of the P21 promoter 
transcription start site (TSS) (http://jaspar.genereg.net/) was used as probe. Titration 
assays showed that Sox2 binding to specific DNA sequences from the P21 promoter 
Figure R 2. Cell toxicity test of three different POM derivatives. (A-C) Cell viability dose-
dependent curves in MCF-7c, MCF-7TR and MCF-7SOX2 overexpressing cells of (NH4)6Mo7O24 
(NH4-Pom), K6[P2Mo18O62] (PMo) and K6[P2W18O62] (PW) POM derivatives, respectively. Graphs 
represent mean and SEM of three independent experiments. (D) IC50 calculation of each POM in 




was completely inhibited by 10 µM PW, while 25-50 µM PMo was required to obtain 
the same effect. On the contrary, NH4-Pom failed to block Sox2 binding to target DNA 
(Figure R 3A). 
 
 
 In contrast, incubation with extracts overexpressing the control protein GFP 
did not result in protein-DNA complex formation, independently of the presence of 10 
µM PW. Furthermore, incubation with non-specific DNA sequences from the PAX6 
gene promoter did not lead to Sox2 binding, reflecting the specificity of these binding 
reactions (Figure R 3B). These data suggest that full-length Sox2 expressed in cells can 
bind in vitro to target Sox2 response elements and PMo and PW disrupt these 
interactions in a specific manner. Therefore, PMo and PW are identified as specific 
Figure R 3. POMs in vitro inhibition of Sox2 binding activity. (A) Titration of (NH4)6Mo7O24 (NH4-Pom), 
K6[P2Mo18O62] (PMo) and K6[P2W18O62] (PW) POM derivatives to test the inhibitory potential of Sox2 
transcription factor binding activity by EMSA. (B) Complete EMSA native gel of in vitro Sox2-DNA 
binding activity in the P21 promoter region, as well as in nonspecific target DNA region of PAX6 gene 




inhibitors of Sox2 transcriptional activity with the potential to have an impact on Sox2-
positive cells, such as tamoxifen-resistant BC cells. 
 
2. POMs effects on tamoxifen-resistant breast cancer cells 
 Over the last years, POMs have been proposed as promising candidates for the 
development of different types of drugs with antiviral and antibacterial properties 
(Bijelic et al., 2018; Yamase 2013). In addition, the number of studies reporting 
antitumor activity of different POMs in many cancer types has also been increasing 
(Rhule et al., 1998; Dolbecq et al., 2010; Cao et al., 2017). 
 Due to our previous results showing the inhibitory potential of PMo and PW 
on in vitro Sox2 binding activity and the role of Sox2 in tamoxifen resistance, we 
hypothesized that these POM derivatives could the growth of tamoxifen-resistant BC 
cells. We therefore decided to explore further this hypothesis using different 
strategies combining in vitro and in vivo assays. 
2.1 Evaluation of POM effects on tamoxifen-resistant breast 
cancer cells: in vitro assays 
To determine the therapeutic potential of these POM derivatives in tamoxifen-
resistant BC tumors, we wished to evaluate whether POM treatment may differently 
affect cell proliferation by altering cell cycle progression. In addition, migration and 
invasion capacities of tamoxifen-resistant cells were analyzed. 
  2.1.1 Cell proliferation 
As first approach, we performed cell proliferation assays using conventional 2D 
cell culture. Three different tamoxifen-resistant cell lines, MCF-7TR, T47DTR and ZR75-
1TR, were treated for 7 days with the minimum concentration of POM capable of 
disrupting Sox2-DNA complex in vitro, 50 µM of PMo and 10 µM of PW, according to 
EMSA experiments. In parallel, their corresponding parental cells MCF-7c, T47Dc and 
ZR75-1c were used as control and equally treated with POM derivatives. The modest 




(Figure R 4A). In contrast, PW treatment significantly reduced cell proliferation of the 
three tamoxifen-resistant cell lines compared to their control cells (Figure R 4B). 
  
 
Furthermore, comparison of either single tamoxifen or POM treatment or both 
together with the control condition in the three models, showed inhibition by 
tamoxifen in parental cells, but not major effects due to PMo (Figure R 5A). However, 
PW was able to compromise cell viability of tamoxifen-resistant cells (Figure R 5B). 
These findings suggest that treatment of tamoxifen-resistant cells with PW renders 
them more sensitive to tamoxifen by inhibiting Sox2 transcriptional activity, as 
previously demonstrated by stable downregulation of Sox2 (Piva et al., 2014). 
Figure R 4. POM effects on tamoxifen-resistant breast cancer cell proliferation (I) . (A-B) Viability 
analysis by crystal violet of three different tamoxifen-resistant cell lines (MCF-7TR, T47DTR and ZR75-
1TR) lines, growing in presence of tamoxifen or tamoxifen plus 50 µM PMo (A); and tamoxifen or 
tamoxifen plus 10 µM PW (B) for 7 days. Their corresponding control cells lines were grown in 
presence of ethanol (vehicle) or POM derivatives. Graphs represent mean and SEM of at least three 






  2.1.3 Cell cycle analysis after POM treatment 
To determine whether PW affects cell cycle progression, we performed DNA 
content analysis by flow cytometry using FxCycle™ PI/RNase Staining Solution in MCF-
7TR cells treated with PW for 7 days in presence of tamoxifen. MCF-7c cells were also 
treated with PW in presence of the vehicle. PW treatment increased the percentage 
of MCF-7TR cells in G2/M phase, while decreasing it in G0/G1 phase, suggesting cell 
cycle arrest. No effects were detected in parental MCF-7c cells (Figure R 6A). Western 
blot analysis revealed an increased level of expression of cyclin B1 and reduced levels 
of cyclin A and CDK1 after PW treatment, disrupting the proper regulation of G2/M 
transition (Figure R 6B). Cyclin E and p21 expression levels were also reduced, 
suggesting an abnormal cell cycle progression. 
Figure R 5. POM effects on tamoxifen-resistant breast cancer cell proliferation (II). (A-B) Viability 
analysis by crystal violet of three different tamoxifen-resistant cell lines (MCF-7TR, T47DTR and ZR75-
1TR) and their corresponding control cell lines, growing in presence of vehicles (ethanol and medium), 
tamoxifen, 50 µM PMo and both (A) or vehicles, tamoxifen, 10 µM PW and both (B) for 7 days. Graphs 
represent mean and SEM of at least three independent experiments. p-values were calculated using 




In normal conditions, cyclin B accumulation and degradation occurs slightly later 
than cyclin A degradation (Schmidt et al., 2017). After initiation of the G2/M transition 
CDK1 becomes part of the M-phase promoting factor (MPF), which is composed of 
CDK1 and cyclin B. CDK1 phosphorylation activates the cyclin B1-CDK1 complex and 
triggers the cells to enter into M phase. Similarly, inactivation of both cyclin B1-CDK1 
and cyclin A-CDK2 is required for the completion of mitosis (Schmidt et al., 2017). One 
of the several mechanism of regulation of G2/M transitionwas described by Dash and 
El-Deiry demonstrating that p21 expression and phosphorylation is needed during 
G2/M transition in order to activate cyclin B1-CDK1 complex. Cyclin B1-CDK1 kinase 
activity and G2/M progression were inhibited in p21 null cells (Dash and El-Deiry, 
2005). 
Moreover, it is known that Sox2 transcriptional activity depends on interactions 
with other proteins such as Oct4 or β-catenin to regulate cell proliferation and 
differentiation by targeting cyclin D1 (Chen et al., 2008). Our group and others have 
demonstrated Sox2 direct binding on the promoter of cyclin D1 gene (CCND1) 
(Domenici et al., 2019; Wu et al., 2012; Jung et al., 2014) and also, to the P21 promoter 
(Yamawaki et al., 2017).  
Consistent with these observations, we wanted to address whether PW 
treatment blocked Sox2 binding to CCND1 and P21 gene promoters. We treated MCF-
7TR and MCF-7SOX2 overexpressing cells with 10 µM PW for 72 h. Finally, the effect 
of inhibiting Sox2 binding to the P21 promoter site analyzed using the JASPAR 
database (http://jaspar.genereg.net/) was detected by ChIP. ChIP-qPCR data showed 
that specific Sox2 recruitment at the -5961 bp site of the P21 promoter TSS was 
impaired by PW treatment in MCF-7TR and MCF-7SOX2 cells (Figure R 6C). Also, Sox2 
recruitment at previously reported TSS on CCND1 promoter (Domenici et al., 2019 and 
Chen et al., 2008) was blocked by PW treatment in MCF-7TR and MCF-7SOX2 cells 
(Figure R 6D). However, although Sox2 recruitment on the promoter of these genes in 
MCF-7SOX2 cells is not statistically significant, still there was a slight increase in the 
fold change when compared to the IgG control. These effects could be because MCF-
7SOX2 cells express higher levels of Sox2 than MCF-7TR cells, which may be too high 






Figure R 6. PW induces cell cycle arrest in tamoxifen-resistant cells. (A) Graphical representation of 
the percentage of MCF-7c (top) and MCF-7TR (bottom) cells in G0/G1, S or G2/M phases in presence 
of 10 µM PW for 7 days. (B) Western blot analysis of MCF-7c and MCF-7TR cell extracts treated with 
PW and blotted for cyclin B1, cyclin A, CDK1, p21, cyclin E, CDK2 and β-actin. (C-D) ChIP-qPCR assay 
showing Sox2 recruitment and PW inhibition on P21 (C) and CCND1 (D) TSS in MCF-7TR (left) and MCF-
7SOX2 cells (right). Graphs represent mean and SEM of three independent experiments; p-values were 




In addition, treating cells with either single tamoxifen, PW or both together, 
further confirmed these results, including the expected tamoxifen-dependent arrest 
in G0/G1 phase of MCF-7c cells (Figure R 7A). Cell cycle analysis of MCF-7TR cells in 
presence of PMo derivative showed no effect at all, except for the inhibition by 
tamoxifen in MCF-7c cells (Figure R 7B). Together, these data confirmed that PW has 
an effect on cell cycle progression by inducing in G2/M phase arrest in tamoxifen-
resistant BC cells. 
 
 
  2.1.4 Effects of POM treatments on apoptosis 
To address whether POM derivatives induced cell death through apoptosis we 
analyzed the Annexin-V and DRAQ7 staining profiles of MCF-7c and MCF-7TR cells 
after POM treatment by fluorescence-activated cell sorting (FACS). FACS data 
demonstrated that PW treatment did not affect MCF-7c cells, while it caused a 
Figure R 7. Effects of POM derivatives on cell cycle progression. (A-B) Graphical representation of the 
percentage of MCF-7c (top) and MCF-7TR (bottom) cells in G0/G1, S or G2/M phases, growing in 
presence of vehicles, tamoxifen, 10 µM PW and both (A) or vehicles, tamoxifen, 50 µM PMo and both 
(B) for 7 days. Graphs represent mean and SEM of three independent experiments; p-values were 




significant increase in the percentage of both early and late apoptosis in MCF-7TR cells 
(Figure R 8A-B) consequently increasing the percentage of apoptotic cells (Figure R 
8C). Moreover, western blot analysis of Parp and Bcl-2 pro- and anti-apoptotic 
proteins showed the reduced expression of total Parp leading to an increase of cleaved 
Parp and the reduction of Bcl-2 levels by PW treatment in MCF-7TR cells, confirming 
the induction of apoptosis (Figure R 8D). Further treatment with either single 
tamoxifen, PW or both together also confirmed these results in MCF-7TR cells (Figure 
R 8E). A small increase in the percentage of apoptotic MCF-7c cells in presence of these 
treatments was detected, but it was not significant. In contrast, the weak effects on 
apoptosis provoked by PMo were no statistically significant (Figure R 8F). 
Together, these findings suggest that PW is a more effective inhibitor than PMo, 





Figure R 8. PW treatment increases apoptosis in tamoxifen-resistant cells. (A) Representative profiles 
of FACS analysis of Annexin-V apoptosis staining in MCF-7 cells treated 10 µM PW for 7 days. Q2 and 
Q4 point at late and early apoptotic cells (blue and purple dots, respectively). (B) Graphical 
representation of the percentage of early and late apoptotic MCF-7c (top) and MCF-7TR (down) cells 
treated with PW. (C) Graphical representation of the percentage of total apoptotic MCF-7c and MCF-
7TR cells upon PW treatment. (D) Western blot analysis of extracts from MCF-7c and MCF-7TR cells 
treated with PW, were blotted against cleaved Parp, Bcl-2 and β-actin. (E-F) Graphical representation 
of the total apoptotic MCF-7c and MCF-7TR cells treated with vehicles, tamoxifen, 10 µM PW and both 
(E) or vehicles, tamoxifen, 50 µM PMo and both (F) for 7 days. Graphs represent mean and SEM of 
three independent experiments; p-values were calculated using two-tailed Student’s t-test and two-




2.1.5 Cell migration and invasion in two-dimensional (2D) cell cultures 
 Previous studies from our laboratory have demonstrated that MCF-7TR cells 
exhibit an increased invasion capacity (Piva et al., 2014). Since migration and invasion 
are key events leading to tumor progression and metastasis in cancer, we 
hypothesized that PW treatment might contribute to repress these functions in 
tamoxifen-resistant cells. 
 As first approach, we performed wound healing assay for cell migration by 
treating cells for 72 h with 10 µM PW, in presence of tamoxifen for MCF-7TR or vehicle 
for MCF-7c cells. The results showed a limited migratory capacity of control cells, 
which was not affected by PW, while MCF-7TR cells increased cell migration was 
significantly impaired by PW treatment (Figure R 9A-B). Next, we performed cell 
invasion assays through Matrigel in presence of PW. Increased invasion capacity of 
MCF-7TR cells was significantly prevented by PW treatment. Nevertheless, even 
though MCF-7c cells showed minimum invasion capacity through Matrigel, PW 
treatment also prevented cell invasion (Figure R 9C-D). Cell treatments with either 
single tamoxifen, PW treatment or both together confirmed the observation that 
whenever PW was present, MCF-7TR cells were not able to neither migrate (Figure R 





Epithelial to mesenchymal transition (EMT) has been reported to drive the 
dissociation and dissemination of cancer cells through regulation of cell migration and 
Figure R 9. Effects of PW on cell migration and invasion ability of tamoxifen-resistant cells. (A) 
Representative images of the wound healing assay for cell migration of MCF-7c and MCF-7TR cells in 
presence of 10 µM PW. Drawn area to be covered by migrating cells was calculated just after wound 
was made (0h) and 72 hours later (72h), respectively. (B) Quantification of the relative cell migration 
was calculated as occupied area by the cells at 72h respect to that area at 0h. Values are relative to 
MCF-7TR control condition. (C) Representative images of invaded MCF-7c and MCF-7TR cells after 72h 
in presence of 10 µM PW. (D) Quantification of relative Matrigel cell invasion of MCF-7c and MCF-7TR 
cells upon treatment. Values are relative to MCF-7TR control condition and normalized to viable cell 
number. (E) Quantification of the relative cell migration capacity of MCF-7c and MCF-7TR cells in 
presence of vehicles, tamoxifen, 10 µM PW and both. Values are relative to MCF-7TR control 
condition. (F) Quantification of relative Matrigel cell invasion of MCF-7c and MCF-7TR cells in presence 
of vehicle, tamoxifen, 10 µM PW and both. Values are relative to MCF-7TR control condition and 
normalized to viable cell number. Graphs represent mean and SEM of three independent experiments; 




invasion capacity in different cancer types (Nieto et al., 2016). It is well established 
that the SNAI transcription factor family plays a pivotal role in the regulation of EMT 
in breast cancer (Liu et al., 2016). The overexpression of SNAI1 gene in MCF-7 breast 
cancer cells induced EMT, cell migration and increased tumorigenicity (Smith et al., 
2014). Besides, SNAI2 plays a major role during EMT conducting metastatic spread of 
triple-negative breast cancer (Ferrari-Amorotti et al., 2014). In addition, it has been 
reported a significant upregulation of SNAI2 in aggressive endocrine-resistant breast 
cancer (Alves et al., 2018). Several groups link increased SNAI2-mediated EMT in 
hormone receptor-positive breast cancer with inhibited estrogen receptor signaling 
pathway (Liu et al., 2019), increased Sox2-driven self-renewal capacity (Kim et al., 
2017) and paracrine Met signaling in mammary luminal progenitors (Di-Cicco et al., 
2015), among many other mechanisms. Therefore, we hypothesized that SNAI2 could 
also be involved in the regulation of EMT in tamoxifen-resistant breast cancer cells. 
Therefore, we analyzed the expression levels of SNAI2 gene by qPCR in three 
tamoxifen-resistant cell lines in presence of 10 µM PW treatment for 72 h. Results 
showed a significant increase in SNAI2 expression in all tamoxifen-resistant cells 
(Figure R 10A-C). Furthermore, PW treatment significantly reduced SNAI2 expression 
in MCF-7TR and ZR75-1TR cells (Figure R 10A and Figure R 10B). However, this 





Since Sox2 and SNAI2 have been linked in previous studies and the analysis by 
qPCR data showed that PW reduced SNAI2 expression, we decided to analyze whether 
this effect was a consequence of PW-mediated Sox2 inhibition. To this end, we 
generated MCF-7TR cells lacking Sox2 expression by either stable silencing with shRNA 
(TR-shSOX2) or endogenous deletion of SOX2 using CRISPR-Cas9 technology (TR-
SOX2KO) (Figure R 10D). Interestingly, tamoxifen-resistant cells lacking Sox2 
expression showed significantly reduced SNAI2 expression levels compared to MCF-
7TR cells (Figure R 10E). Moreover, PW treatment did not further reduce SNAI2 levels 
in these cells (Figure R 10E). Together, these data suggest that PW specifically blocks 
Sox2 regulation of SNAI2 EMT marker leading to the inhibition of migration and 
invasion capacities of tamoxifen-resistant BC cells. 
Figure R 10. PW treatment significantly reduces Sox2 mediated SNAI2 expression levels in 
tamoxifen-resistant cells. (A-C) mRNA expression levels of SNAI2 EMT marker upon PW treatment, in 
three different tamoxifen-resistant cell lines: MCF-7TR (A), ZR75-1TR (B) and T47DTR (C) cells 
compared to their corresponding control cell lines. (D) Sox2 control of expression western blot analysis 
of extracts from MCF-7TR cells (TR) compared to TR cells lacking Sox2 expression, TR-shSOX2 and TR-
SOX2KO, treated with PW. β-actin blot was used as loading control. (E) mRNA expression levels of 
SNAI2 EMT marker upon PW treatment in MCF-7TR cells (TR) compared to TR-shSOX2 and TR-SOX2KO. 
Graphs represent mean and SEM of three independent experiments; p-values were calculated using 




2.2 Evaluation of POM effects on tamoxifen-resistant breast 
cancer cells: in vivo assay 
  2.2.1 In vivo chicken chorioallantoic membrane (CAM) model 
 Considering our observations about the effects of PW as a therapeutic drug 
against tamoxifen-resistant breast cancer cells, we decided to explore whether Sox2 
inhibition by PW affects tumor progression by assessing the functional role of this 
POM derivative in vivo using the chorioallantoic membrane (CAM) model. CAM is a 
highly vascular membrane found in chicken eggs that is easily accessible and enables 
efficient cancer cell grafting and growth due to the immunodeficient state of the chick 
embryo during the development (Deryugina and Quigley, 2008). This model allows 
tumor cell growth on the CAM, mimicking the tumorigenic process, including growth, 
invasion, angiogenesis and colonization of distant tissues (Lokman et al., 2012). To 
enable quantification of tumor growth we generated GFP overexpressing cell lines, in 
order to visualize the tumor on the CAM and perform FACS analysis as a read-out of 
tumor growth. 
 We first investigated whether PW treatment has an effect on parental MCF-
7 cells in vivo. Thus, we took advantage of MCF-7GFP cells previously generated in the 
lab (Simões et al., 2011). MCF-7GFP cells were grafted onto the exposed CAM of 
chicken embryos at developmental day 7 (EDD7) in presence of either tamoxifen or 
two different concentrations of PW, 10 and 20 µM, and allowed to grow for 7 days. At 
EDD14, tumors were excised, photographed and processed for FACS analysis (Figure 
R 11A), displaying the expected significant reduction in tumor size only in tamoxifen-
treated tumors compared to control, which was reflected in the number of GFP+ cells 
detected (Figure R 11C). 
 To determine PW effect on MCF-7TR derived tumors, we generated a stable 
cell line overexpressing GFP protein by lentiviral infection and thus produced MCF-
7TR-GFP cells. MCF-7TR-GFP cells were also grafted onto the exposed CAM of chicken 
embryos at developmental day 7 (EDD7) in presence of tamoxifen and two different 
concentrations of PW, 10 and 20 µM, and allowed to grow until EDD14 (Figure R 11B). 




in tumor size reflected in the number of GFP+ cells in PW-treated tumors compared 
to controls (Figure R 11D). These results also confirm that MCF-7TR-GFP tumors show 
resistance to tamoxifen treatment in vivo. To determine whether PW by itself was 
affecting tumor growth, we grafted MCF-7TR-GFP cells onto the exposed CAM in 
presence of single treatments, either tamoxifen or two different concentrations of PW 
(Figure R 11E). FACS analysis confirmed the same result, a significant reduction in 
tumor size in PW-treated tumors (Figure R 11F). We conclude from these experiments 





To confirm that tumor growth reduction is due to PW-mediated inhibition of 
Sox2 transcription factor in tamoxifen-resistant cells in vivo, we generated MCF-7TR-
GFP cells lacking Sox2 expression by stable silencing with shRNA (TR-GFP-shSOX2) and 
Figure R 11. PW treatment impairs in vivo tumorigenicity of tamoxifen-resistant cells in the CAM 
model. (A-B) Representative images of MCF-7GFP (A) and MCF-7TR-GFP (B) derived tumors implanted 
on the CAM for 7 days in presence of vehicles, tamoxifen and PW or both. (C-D) Graphical 
representation of the number of GFP positive cells per tumor detected by FACS analysis in MCF-7GFP 
(C) and MCF-7TR-GFP (D) derived tumors. (E) Representative images of MCF-7TR-GFP derived tumors 
implanted on the CAM for 7 days in presence of vehicle and single treatments of tamoxifen and PW. 
(F) Graphical representation of the number of GFP positive cells per tumor detected in MCF-7TR-GFP 
derived tumors. GFP channel (top) and bright-field (down) pictures of the same tumor are shown 




developed GFP overexpressing cells from previously created SOX2 CRISPR-Cas9 
knockout cells (TR-SOX2KO-GFP) (Figure R 12A). Cells were grafted onto the exposed 
CAM of chicken embryos at developmental day 7 (EDD7) in presence of 10 µM PW, 
and allowed to grow for 7 days (Figure R 12B). Quantification of GFP positive cells 
indicated a significant reduction in the size of MCF-7TR-GFP-derived tumors treated 
with PW. In addition, Sox2 silenced cells (TR-GFP-shSOX2) formed significantly smaller 
tumors than control cells, but similar to PW-treated tamoxifen-resistant tumors. 
Importantly, PW treatment did not further reduce the size of TR-GFP-shSOX2 derived 
tumors (Figure R 12C). Tamoxifen-resistant cells with endogenous depletion of SOX2 
(TR-SOX2KO-GFP) were hardly able to develop tumors, indicating that Sox2 
transcription factor is required for tamoxifen-resistant breast cancer tumorigenesis. 
Together, these findings indicate that PW-mediated Sox2 inhibition leads to reduced 





3. Analysis of the tamoxifen-resistant CSC content after POM treatment 
 It is well established that tumors contain a subpopulation of cancer cells that 
share properties with stem cells (Reya et al., 2001) and that tumors are initiated and 
maintained by stem cell population (Pece et al., 2010; (Tharmapalan et al., 2019).  
Our laboratory has demonstrated that the development of resistance to 
tamoxifen in breast cancer cells is driven by Sox2-dependent activation of CSCs (Piva 
et al., 2014). Therefore, we hypothesized that the inhibition of Sox2 through POM 
treatment will reduce the CSC populations, contributing to restore the capacity of 
response to endocrine therapy. 
Figure R 12. PW-mediated inhibition of Sox2 transcription factor impairs in vivo tumorigenicity of 
tamoxifen-resistant cells. (A) Western blot analysis of extracts from MCF-7TR-GFP, MCF-7TR-GFP-
shSOX2 and TR-SOX2KO-GFP stable cells generated for CAM experiments, blotted for Sox2, GFP and 
β-actin. (B) Representative images of MCF-7TR-GFP, TR-GFP-shSOX2 and TR-SOX2KO-GFP derived 
tumors implanted on the CAM for 7 days in presence of 10 µM PW. (C) Graphical representation of 
the number of GFP positive cells per tumor detected in MCF-7TR-GFP, TR-GFP-shSOX2 and TR-




3.1 Mammosphere formation ability 
 Mammosphere formation assay is a widely used assay to enrich for CSCs 
(Dontu et al., 2003). As previously reported from our group, MCF-7TR cells formed a 
higher number of primary mammospheres (I MS) than control cells, which was 
dramatically reduced by PW treatment (Figure R 13A). To monitor the self-renewal 
capacity of breast CSCs, secondary (II MS) mammosphere formation ability was 
determined and found to be significantly diminished after treating MCF-7TR cells with 
PW (Figure R 13B). Cell treatments with either single tamoxifen or PW treatments or 
both together confirmed the observation that MCF-7TR cells were not able to form 
neither I MS nor II MS in the presence of PW (Figure R 13C). 
 
 
 To determine whether the observed effect on mammosphere formation was 
owing to PW-mediated inhibition of Sox2, we used a panel of parental and tamoxifen-
resistant MCF-7 cells whose Sox2 expression levels were modulated. We used MCF-
7TR cells lacking Sox2 expression, by either stable silencing with shRNA (TR-shSOX2) 
or endogenous deletion of SOX2 using CRISPR-Cas9 technology (TR-SOX2KO), and 
MCF-7 parental cells overexpressing Sox2 previously generated in the lab (Simões et 
al., 2011) (Figure R 14A).  
 According to our hypothesis, PW should not affect the mammosphere 
formation ability of MCF-7TR cells depleted for Sox2, while it should compromise the 
Figure R 13. PW treatment reduces mammosphere formation ability in tamoxifen-resistant cells. (A) 
Primary mammosphere (I MS) formation assay of MCF-7c and MCF-7TR cells in presence of 10 µM 
PW. Values are relative to MCF-7c control condition. (B) Primary (I MS) and Secondary mammosphere 
(II MS) formation assay of MCF-7TR cells upon 10 µM PW treatment in tamoxifen-resistant cells. (C) I 
MS and II MS formation assay of MCF-7TR cells in presence of vehicles, tamoxifen, 10 µM PW and 
both. Graphs represent mean and SEM of three independent experiments; p-values were calculated 




increased efficiency of MCF-7SOX2 overexpressing cells. Indeed, PW treatment 
reduced I MS formation capacity of both MCF-7TR and Sox2 overexpressing cells 
(Figure R 14 B-C). In contrast, Sox2 depletion significantly reduced I MS formation 
ability until similar levels to those of PW-treated tamoxifen-resistant cells. 
Importantly, PW treatment did not further reduce this effect (Figure R 14B). 
Additionally, to verify that the reduction in self-renewal capacity of tamoxifen-
resistant cells induced by PW was due to Sox2 inhibition, we also performed II MS 
mammosphere formation assay with these cell lines. The results demonstrated that 
the ability to form II MS was significantly diminished by PW treatment, not only in 
MCF-7TR cells, but also in MCF-7SOX2 overexpressing cells (Figure R 14D-E). 
Furthermore, MCF-7TR cells lacking Sox2 expression formed significantly less II MS 
without any further effect due to PW treatment (Figure R 14D). These data suggest 
that PW specifically blocks Sox2-mediated mammosphere formation ability of 






3.2 Analysis of CD44+CD24-/low cell population  
 Since our observations demonstrate that PW treatment affects the self-
renewal capacity of CSC of tamoxifen-resistant cells, we wished to determine whether 
CD44+CD24-/low CSC population was also affected. Our group and others have 
demonstrated that cells with CD44+CD24-/low CSC phenotype can be isolated from BC 
Figure R 14. PW-mediated inhibition of Sox2 transcription factor reduces mammosphere formation 
ability in tamoxifen-resistant cells. (A) Western blot analysis of extracts from MCF-7c, MCF-7TR, MCF-
7TR-SOX2KO, MCF-7TR-shSOX2 and MCF-7SOX2 overexpressing cells blotted for Sox2 and β-actin. (B-
C) I MS formation assay in presence of 10 µM PW of MCF-7TR cells compared to TR cells lacking Sox2 
expression, TR-shSOX2 and TR-SOX2KO (B) and MCF-7c cells compared to MCF-7SOX2 overexpressing 
cells (C). (D-E) II MS formation assay, in presence of 10 µM PW, of MCF-7TR cells compared to TR-
shSOX2 and TR-SOX2KO (D) and MCF-7c cells versus MCF-7SOX2 overexpressing cells (E). Graphs 





cells (Fillmore and Kuperwasser, 2008) and maintained in culture as mammospheres 
to enrich in CD44+CD24-/low population (Simões et al., 2011). Furthermore, our group 
also demonstrated that tamoxifen-resistant cells display a significant increase in the 
proportion of CD44+CD24-/low cells, which correlates with increased SOX2 mRNA and 
protein levels (Piva et al., 2014). 
Therefore, we evaluated the ability of CD44+CD24-/low MCF-7TR cells to grow in 
mammosphere culture conditions in presence of PW. As expected, MCF-7TR cells were 
enriched in CD44+CD24-/low cell population in I MS cultures (Figure R 15A), compared 
to adherent cell culture. CD44+CD24-/low cells sorted from primary mammospheres 
formed a dramatically reduced number of secondary mammospheres in the presence 
of either PW alone or in combination with tamoxifen, suggesting a significant 
reduction in their self-renewal ability (Figure R 15B-C). 
 
 
3.3 POM effects on ALDEFLUOR activity 
In order to further investigate the effect of pharmacological inhibition of Sox2 
through PW treatment on CSC content, we evaluated the aldehyde dehydrogenase 
(ALDH) activity of tamoxifen-resistant cells. Elevated ALDH activity, measured by 
increased ALDEFLUOR activity by FACS, has been reported as another feature of stem 









 stem cell population in MCF-7TR cells cultured as adherent cells (Adh) or I 










cell population sorted from I MS of MCF-7TR cells in presence of vehicles, tamoxifen, 10 µM PW and 
both. Graphs represent mean and SEM of three independent experiments; p-values were calculated 




cells, as a consequence of the increased activity of aldehyde dehydrogenase 1 (ALDH1) 
enzyme in the human mammary gland (Ginestier et al., 2007). We have also 
demonstrated that ALDEFLUOR activity was enhanced by increased levels of ALDH1A3 
isoform in tamoxifen-resistant cells (Domenici et al., 2019). 
 Interestingly, the elevated ALDEFLUOR activity of MCF-7TR cells was 
significantly reduced by PW treatment. Moreover, MCF-7TR cells lacking Sox2 
expression showed significantly lower endogenous ALDH activity than tamoxifen-
resistant cells but similar to MCF-7c cells. Further treatment of these cells with PW 
showed no effect, suggesting that reduced ALDH activity by PW treatment is due to 
the inhibition of Sox2 transcription factor (Figure R 16A). 
ALDH1A3 has been reported to be the most important ALDH isoform 
responsible for ALDH activity in breast cancer cells, representing a marker of poor 
prognosis in breast cancer patients (Kong et al., 2011) and correlating with increased 
ALDH activity in tamoxifen-resistant cells (Domenici et al., 2019). Indeed, MCF-7TR 
cells showed significantly higher levels of ALDH1A3 than control cells, which were 
repressed by PW treatment. In addition, the reduction of endogenous Sox2 levels 
inhibited ALDH1A3 expression compromising PW effect in both TR-shSOX2 and TR-
SOX2KO cells (Figure R 16B). These results indicate that reduced ALDH activity by PW 






3.4 Analysis of stem cell frequency 
 Since our findings have revealed that PW treatment reduces the stem cell 
populations in tamoxifen-resistant cells, we decided to validate the pharmacological 
potential of PW targeting CSCs in vivo, using the CAM model. Therefore, we performed 
an extreme limiting dilution assay (ELDA) in vivo. Limiting dilution assays are widely 
established for quantifying the proportion of biologically active particles in a large 
population (Taswell, 1987). The term limiting dilution analysis (LDA) refers to the 
statistical analysis of data from limiting dilution assays, whose classical aim is to 
estimate the active cell frequency. We used ELDA software application for LDA, with 
Figure R 16. PW-mediated inhibition of Sox2 transcription factor inhibits ALDH activity in tamoxifen-
resistant cells. (A) FACS analysis of ALDEFLUOR positive cells in MCF-7c, MCF-7TR, TR-shSOX2 and TR-
SOX2KO cells treated with 10 µM PW for 72h, represented as fold change relative to MCF-7c cells. (B) 
mRNA expression levels of ALDH1A3 gene upon 72h, 10 µM PW treatment in MCF-7c, MCF-7TR, TR-
shSOX2 and TR-SOX2KO cells. Graphs represent mean and SEM of three independent experiments; p-




particular attention to the needs of stem cell assays defined by Hu and Smyth, 2009, 
available at http://bioinf.wehi.edu.au/software/elda/. 
 Different MCF-7TR-GFP cell densities (5·105, 105 and 2·104 cells) were grafted 
onto the exposed CAM of chicken embryos at EDD7 and allowed to grow for 7 days in 
presence of 10 µM PW treated with vehicle or 10 µM PW in presence of tamoxifen 
(Figure R 17A). FACS data showed that tumors formed in the presence of PW were 
significantly smaller and displayed less bioluminescence than control tumors (Figure 
R 17B). Most importantly, PW treated cells implanted at low density (2·104 cells) were 
unable to form substantial tumors (2/7 tumors), while control cells developed 6/7 
tumors, although smaller than with other cell densities. ELDA assay demonstrated that 
PW treatment significantly reduced tumor-initiating stem cell frequency by 8,56 fold 
(p= 1,70e-05) in tamoxifen-resistant cells (Figure R 17C). These findings suggest that 
PW reduces breast cancer stem cells, leading to reduced tamoxifen resistance in vivo. 
 
Figure R 17. PW treatment reduces tamoxifen-resistant stem cell population in vivo. (A) 
Representative images of ELDA from MCF-7TR-GFP derived tumors growing in the CAM for 7 days 
treated with 10 µM PW, in presence of tamoxifen. GFP channel (top) and bright-field (down) pictures 
of the same tumor are shown; scale bar, 1mm. (B) Graphical representation of the number of GFP 
positive cells per tumor on the CAM detected by FACS analysis (n=6-7). (C) Calculation of tumor-
initiating stem cell frequency by Extreme Limiting Dilution Assay (ELDA). Tumor-initiating stem cell 
quantitation table: the limiting dilutions implanted and tumor emergence per implantation group, as 




4. Elucidating the mechanism underlying the effects of POM treatment 
4.1 Activation of the ER signaling pathway 
Several reports have shown breast stem cells lack or express low levels of ER 
(Clayton et al., 2004, Liu et al., 2008). Furthermore, previous work from our laboratory 
demonstrated that there is an inverse relationship between Sox2 and ER protein 
expression, leading to a reduced ER transcriptional activity in tamoxifen-resistant cells 
(Piva et al., 2014). Based on this relationship, we hypothesized that PW mediated 
inhibition of Sox2 may lead to enhanced ER activity in tamoxifen-resistant breast 
cancer cells.  
As first approach, we performed immunofluorescence staining of Sox2 and ERα 
proteins in MCF-7TR cells upon PW treatment, to analyze ERα expression on Sox2 
expressing cells (Figure R 18A). Quantification of Sox2 and ERα fluorescence intensity 
in the nuclei of Sox2 positive cells showed that Sox2 intensity remains similar, while 
ERα expression was higher in PW treated cells than in control MCF-7TR cells (Figure R 
18B), leading to a modest, but significant, increase in the ERα/Sox2 intensity ratio 
(Figure R 18C). These results suggest that ER expression levels are increasing within 





One potential explanation for these findings is that Sox2 TF negatively 
regulates ERα expression. The sequence of the promoter of the ESR1 gene was 
analyzed using JASPAR database of transcription factor binding profiles 
(http://jaspar.genereg.net/) for putative Sox2 binding sites, identifying a potential 
response element following the sequence CTTTGTA. Chromatin immunoprecipitation 
(ChIP) analysis was performed in MCF-7TR cells in the presence or absence of 10 µM 
PW for 72 h. ChIP-qPCR data showed that specific Sox2 recruitment at a site -292 bp 
of the ESR1 promoter TSS was impaired by PW treatment in MCF-7TR cells (Figure R 
19A). Similar results were obtained in MCF-7SOX2 overexpressing cells (Figure R 19B), 
suggesting a direct regulation on ERα transcription by Sox2 protein. 
Figure R 18. PW treatment increases ER expression in Sox2 positive tamoxifen-resistant cells. (A) 
Representative images of immunofluorescence analysis of Sox2 and ERα in MCF-7TR cells treated with 
10 µM PW for 72 h. Blue staining shows cell nuclei (DAPI); scale bar 10 µm. (B-C) Graphical 
representation of mean intensity of Sox2 and ERα stainings (B) and the ERα/Sox2 intensity ratio (C) 
within each Sox2 positive cell, upon 10 µM PW treatment. Graphs represent mean and SEM of three 







To explore further whether Sox2 might regulate ER transcriptional activity in 
tamoxifen-resistant cells, we hypothesized that PW mediated pharmacological 
inhibition of Sox2 transcriptional activity would rescue ER activity in tamoxifen-
resistant cells, which we have previously shown was compromised in these cells (Piva 
et al., 2014). Thus, we performed transcriptional assays, using an estrogen activated 
ER-dependent luciferase reporter (ERE-luc) in estrogen deprived tamoxifen-resistant 
cells previously treated with vehicle or 10 µM PW for 72 h. Parental cells were used as 
control for basal ERE-luc activity. PW treatment was sufficient to restore ER 
transcriptional activity levels of MCF-7TR cells to those observed in parental cells 
(Figure R 20A). The rescue of ER transcriptional activity was also confirmed in another 
tamoxifen-resistant cell line, ZR75-1TR, showing a significant increase in ER 
transcriptional activity when treated with PW (Figure R 20B). Data from previously 
performed mRNA-seq experiments revealed that tamoxifen-resistant cells present 
significantly reduced levels of well-known ESR1 target genes such as AREG and PS2 
(Figure R 20C), confirming the reduced activation of ER pathway in tamoxifen-resistant 
cells. 
Figure R 19. Sox2 TF binding on ESR1 gene promoter of tamoxifen-resistant cells. ChIP-qPCR assay in 
MCF-7TR (A) and MCF-7SOX2 overexpressing (B) cells showing Sox2 recruitment at a site -292 bp of 
the ESR1 TSS and its inhibition by 72 h 10 µM PW treatment. Graphs represent mean and SEM of three 






To test further the hypothesis that PW treatment rescued ER transcriptional 
activity in tamoxifen-resistant cells, we evaluated the expression levels of those ESR1 
target genes. E2 dependent activation of AREG gene expression did not reach the 
levels showed by parental cells, however, there was a significant increase by PW 
treatment in MCF-7TR cells (Figure R 20D). On the other hand, E2 dependent 
reactivation of PS2 gene expression levels in MCF-7TR cells treated with PW was 
detected at both mRNA (Figure R 21A) and protein (Figure R 21B) levels. Most 
importantly, E2 induced similar PS2 levels in MCF-7TR cells treated with PW and in the 
ones lacking Sox2 expression, when compared to the control condition (Figure R 21C). 
These data demonstrate that Sox2 depletion mimics the effect of PW treatment on 
Figure R 20. PW restores ER transcriptional activity in tamoxifen-resistant cells. (A-B) ERE-luc activity 
in estrogen starved MCF-7 (A) and ZR75-1 (B) cells treated 48 h with vehicle or 10 nM E2 after 
transfection. Cells were also previously treated with vehicle or PW for 72 h and data are normalized 
to ER activity in absence of E2 of parental cells (c). (C) RNAseq data of AREG and, PS2 ER target genes 
in MCF-7TR cells compared to control cells. Data coming from three independent biological replicates. 
(D) mRNA expression levels of AREG gene in estrogen starved MCF-7TR cells treated with 10 µM PW 
for 72 h in presence of vehicle or 10 nM E2. MCF-7c cells cultured in presence of vehicle or 10 nM E2 
were used as control. Graphs represent mean and SEM of three independent experiments. p-values 




the expression of this ER target gene in tamoxifen-resistant cells, suggesting the 




Together these findings suggest that compromised ER transcriptional activity 
during the development of resistance to tamoxifen is relieved by PW mediated 
inhibition of Sox2, thus leading to partially restored ER signaling activation. 
 
 
Figure R 21. PW partially restores ER pathway activation in tamoxifen-resistant cells. (A-B) 
Expression of ER target gene PS2 mRNA (A) and protein (B) levels in estrogen starved MCF-7TR cells 
treated with 10 µM PW for 72 h in presence of vehicle or 10 nM E2. MCF-7c cells cultured in presence 
of vehicle or 10 nM E2 were used as control. (C) mRNA expression levels of PS2 gene in estrogen 
starved MCF-7TR cells, treated with 10 µM PW for 72 h, compared to TR cells lacking Sox2 expression 
(TR-shSOX2 and TR-SOX2KO), in presence of vehicle or 10 nM E2. Graphs represent mean and SEM of 













Breast cancer (BC) is the most common cancer and the first leading cause of 
cancer death in women worldwide (Bray et al., 2018). Over 70% of breast cancers are 
ER-positive (Harbeck et al., 2019) and, therefore, hormone therapy is the main 
treatment option for BC patients. Tamoxifen, an estrogen antagonist, has been the 
standard endocrine therapy for women with early-stage and metastatic ER-positive 
BC for decades (Jordan, 2004). However, most patient tumors evolve to a resistant 
state in which tumor cells do not respond to hormone therapy, which remains a 
serious clinical problem. A better understanding of the underlying mechanisms 
governing the development of resistance will lead to the identification of better 
treatments. 
 Current therapeutic approaches do not eliminate a subset of cells called cancer 
stem cells (CSCs) or tumor-initiating cells, which reinitiate tumor growth leading the 
recurrence in many patients (Visvader and Lindeman 2012; Celià and Id 2018). 
Increased stem/progenitor cell population has been associated with the development 
of resistance to radiation therapy (Phillips et al., 2006) by promoting epithelial to 
mesenchymal transition (EMT) via the upregulation of adhesion molecules and EMT-
associated proteins, among other mechanisms (Ko et al., 2018). An analysis of BC core 
biopsies revealed that increased CD44+CD24-/low stem cell population of breast CSCs 
mediate chemotherapy resistance (Li et al., 2008). More recently, several studies have 
demonstrated the implication of tumor microenvironment (Plava et al., 2019) and 
lipid metabolism affecting the self-renewal capacity of CSCs as key aspects in the 
development of chemoresistance (Wang et al., 2018). 
Breast stem cells have been reported to lack ER or express very low levels 
(Clayton et al., 2004), which may facilitate the resistance of CSCs to the anti-
proliferative effects of endocrine drugs such as tamoxifen. Studies in our laboratory 
have shown that enhanced levels of Sox2 and the absence or very low expression of 
ER drive the increase of CSC content and the activation of Wnt signaling, leading to 
the development of resistance to tamoxifen (Piva et al., 2014). Considering that the 
enrichment of the CSC population in tamoxifen resistance implies the loss or reduction 
of ER transcriptional activity and elevated Sox2 expression and activity, targeting Sox2 
transcription factor (TF) may favor stem cell differentiation, rendering tumor cells 




potential inhibitor of Sox2 transcriptional activity in order to use it as a therapeutic 
drug to avoid resistance and prevent tumor recurrence. 
Here, we have found that Sox2 is the most highly expressed Sox TF within the 
family in tamoxifen-resistant cells when compared to parental cells. In addition, we 
have identified the polyoxometalate derivative K6[P2W18O62] (PW), as an efficient Sox2 
inhibitor both in vitro and in vivo. PW-mediated pharmacological inhibition of Sox2 
renders tamoxifen-resistant cells more sensitive to tamoxifen by inducing cell cycle 
arrest and apoptosis. We have also observed that the tumor-promoting role of Sox2, 
which enhances invasion and migration of tamoxifen-resistant cells, is impaired by PW 
treatment. In addition, we have demonstrated that PW blocks the self-renewal 
capacity of breast CSCs by Sox2 specific inhibition, leading to reduced tumor growth 
in vivo. Mechanistically, we have found that Sox2 inhibition of ER expression 
compromises its transcriptional activity during development of resistance to 
tamoxifen. This effect is relieved by PW-mediated inhibition of Sox2 DNA binding 
activity in tamoxifen-resistant cells, leading to restored ER signaling pathway and 
tamoxifen sensitivity. 
 
1. Screening of different POM derivatives 
 An initial screening to test POM derivatives as potential Sox2 inhibitors 
identified the Dawson-polyoxometalate K6[P2Mo18O62] (PMo) as a direct inhibitor of 
the Sox2-HMG domain (Narasimhan et al., 2011). These authors also studied the 
specificity of a panel of different POMs targeting Sox TF members and concluded that 
some Dawson-POMs can inhibit the Sox-HMG domains of several members of the 
family (Narasimhan et al., 2014), might be explained by the fact that the HMG domain 
sequence used for these in vitro assays is highly conserved among all Sox members 
(Lefebvre et al., 2007). 
 Characterization of the expression pattern of Sox TF members in tamoxifen-
resistant cells revealed that Sox2 is the most highly expressed Sox member in 
tamoxifen-resistant cells when compared to parental cancer cells. SOX3, SOX4, SOX9 




tamoxifen-resistant cells, except for SOX9, which is upregulated, as we have shown 
(Domenici et al., 2019). 
Many studies reported on the involvement of Sox2 in resistance to BC therapy 
and demonstrated that it affects a wide range of molecular mechanisms (Novak et al., 
2019). Breast CSC sensitivity to paclitaxel depends on the expression of Sox2, since 
knockdown of Sox2 increases chemosensitivity and reduces CSC invasion capacity 
(Mukherjee et al., 2017). Others have reported that tumor-associated macrophages 
promote chemoresistance by upregulating the expression of Sox2 via EGFR and STAT3 
activation in CSCs (Yang et al., 2013). Sox2 expression also correlates with breast 
tumor grade and basal-like subtype leading to increased tumorigenic capacity (Chen 
et al., 2008). Sox2 levels are similar in breast DCIS and early stages of invasive disease, 
suggesting that Sox2 expression is an early event during the transformation towards 
a more aggressive, invasive and undifferentiated phenotype of the disease (Lengerke 
et al., 2011). Additionally, Sox2 has been also implicated in tamoxifen resistance by 
different mechanisms. For example, tamoxifen treatment downregulates Merlin, thus 
avoiding proteasomal degradation of TARBP2 protein (TAR (HIV-1) RNA binding 
protein 2), which stabilizes Sox2 enabling tamoxifen resistance of BC cells (Wang et 
al., 2019). Our group demonstrated that Sox2 overexpressing cells show increased 
invasion capacity (Simões et al., 2011) and CD44+CD24-/low stem cell population 
presents higher Sox2 expression levels in tamoxifen-resistant cells (Piva et al., 2014), 
as it was corroborated by other group years later (Leung et al., 2017). Integrative 
analysis of gene expression and DNA methylation profiles reveal significant 
differences between parental and tamoxifen-resistant models of BC (Lin et al., 2013). 
The authors detected high Sox2 expression and alterations of E2F gene family 
members as well as RB-related pocket protein genes. The methylation status of the 
promoters of other SOX genes such as SOX3, SOX4, SOX9, and SOX13 led to lower 
expression levels in tamoxifen-resistant cells. These findings highlighted stem cell-
associated pathways as being central in the resistant phenotype (Lin et al., 2013). 
Despite the known involvement of Sox members in cancer biology, a gene 
expression profiling analysis of SOX genes from publicly available RNA sequencing data 
for 11 cancer types (The Cancer Genome Atlas TCGA, http://cancergenome.nih.gov) 




al., 2014). Sox3 reported very low expression on invasive BC samples as well as in the 
majority of cancer types analyzed. On the other hand, immunohistochemistry analysis 
of more than fifty pairs of tumor and healthy samples have revealed that Sox3 
overexpression is detected in 75,9% of hepatocellular carcinoma (HCC) tissues. 
Statistical analysis demonstrated that high expression of Sox3 correlates with 
advanced tumor stage and poor tumor differentiation leading to worse recurrence-
free survival and overall survival in HCC patients (Feng et al., 2017). Sox3 expression is 
also elevated in primary glioblastoma accompanied by an increase in proliferation, 
migration and invasion capabilities through enhanced Hedgehog (Hh) signaling. The 
authors suggest that Sox3 is able to promote malignant behavior in glioblastoma cells 
by maintaining glioblastoma stem cells in their undifferentiated state (Marjanovic 
Vicentic et al., 2019). 
Sox4 overexpression has been reported in several human cancers (Thu et al., 
2014), including prostate (Bilir et al., 2016), bladder (Gunes et al., 2011) and triple-
negative breast cancer (TNBC) (Zhang et al., 2012). In fact, Sox4 is found to regulate 
EMT and contribute to the metastatic spread of BC progression in TNBC (Zhang et al., 
2012). In addition, it has been described that Sox4 transfers TGF-β mediated signaling 
to promote Sox2 expression in gastric cancer and gliomas (Grimm et al., 2019). In 
contrast, we have shown that Sox4 mRNA expression levels are lower in tamoxifen-
resistant than parental cells, showing an inverse correlation with Sox2 expression. 
Sox9 is also one of the most investigated members of the Sox TF family, 
together with Sox2. Mouse linage tracing experiments have shown the relevance of 
Sox9 in the regulation and maintenance of stem/progenitor cells in the mouse 
mammary gland (Guo et al., 2012). In the human breast, we demonstrated that Sox9 
marks luminal progenitor cells with stem cell-like properties identified as both 
CD49f+EpCAM+ and  ALDH+ populations (Domenici et al., 2019). In cancer, the role of 
Sox9 is controversial. In vitro studies have reported SOX9 upregulation as an 
oncogenic driver during tumorigenesis of several types of cancer such as pancreatic 
cancer, hepatocarcinoma or esophageal squamous cell carcinoma, linked to worse 
prognosis, while high levels of Sox9 in melanoma have been reported as a tumor 
suppressor (Ruan et al., 2017). These mixed observations highlight a tissue-dependent 




the regulation of CSC population in breast tumors (Chakravarty et al., 2011). Sox9 
expression is enriched in TNBC tumors compared to ER-positive and HER2-positive 
tumors (Pomp et al., 2015). Indeed, increased Sox9 expression is associated with 
CD44+CD24-/low CSC phenotype as well as poor prognosis (Lei et al., 2016). More 
recently, Sox9 has been reported to regulate FXYD3 gene expression, an estrogen-
inducible gene significantly upregulated in ER-positive breast CSCs mediated 
tamoxifen resistance (Xue et al., 2019). The authors described a direct Sox9 regulation 
of FXYD3 gene expression, and a positive regulatory feedback loop for FXYD3 
amplification and function; since it is indispensable for Sox9 nucleus localization. 
Mechanistically, FXYD3 interacts with SRC and ER triggering SRC signaling transduction 
and Sox9 entry in the nucleus, required for breast CSCs maintenance and tamoxifen 
resistance. These findings are in agreement with our previous work revealing that 
Sox9 participates in a regulatory loop with Sox2 promoting oncogenic signaling 
implicated in the maintenance of breast CSCs in tamoxifen-resistant cells (Domenici et 
al., 2019). Interestingly, Garros-Regulez and colleagues identified the same regulatory 
feedback loop of Sox2-Sox9 signaling which induces resistance to the 
chemotherapeutic drug temozolomide. These authors demonstrated that Sox2 and 
Sox9 overexpression in glioma cells regulates the activity of glioma stem cells and 
conclude that rapamycin abrogated Sox2-Sox9 expression in combination with 
temozolomide inhibit glioma tumor growth (Garros-Regulez et al., 2016). 
Sox11 expression in BC has been directly correlated with poor clinical outcome. 
Sox11 is associated with the most aggressive form of BC, because it has been reported 
to be a critical regulator of cell proliferation, migration, invasion and survival in basal-
like BC (Zvelebil et al., 2013). Furthermore, Sox11 has been reported as the unique 
transcription factor required for the growth of basal-like BC cells, but not for the 
growth of non-basal-like BC cells (Shepherd et al., 2016). More recently, it has been 
published that Sox11 promotes an epithelial/mesenchymal hybrid state and alters 
metastatic properties of invasive BC cells (Oliemuller et al., 2020). High Sox11 levels 
are associated with poor outcomes in patients and with a mesenchymal state of ER-
negative BC cells. The authors have demonstrated that Sox11 expressing cells in ER-
negative BC cells display invasive features, leading cells to metastasize preferentially 




EMT has also been reported in the context of endocrine therapy. Researchers have 
shown that Sox11 overexpression enhances tamoxifen resistance by activating EMT 
through SNAI2 upregulation (Xiao et al., 2020). In contrast, we have found that Sox11 
is significantly downregulated in tamoxifen-resistant BC cells, reflecting the variety of 
mechanisms to develop resistance. 
Nevertheless, since our laboratory has demonstrated the Sox2 oncogenic 
signaling axis through Sox9 as a crucial network in the regulation of breast CSCs, the 
potential inhibitory effect of POMs on Sox2 TF activity (Narasimhan et al., 2011) makes 
POM-based therapy suitable to target Sox2-mediated tamoxifen resistance. 
Furthermore, the low expression levels of the other Sox proteins in tamoxifen-
resistant cells prevent cross-reactivity of POM derivatives with other Sox members. In 
this regard, our analysis of three POM derivatives, (NH4)6Mo7O24 (NH4-Pom), 
K6[P2Mo18O62] (PMo) and K6[P2W18O62] (PW), has shown that full-length Sox2 protein 
expressed in cells binds to defined Sox2 response elements in vitro and only PMo and 
PW disrupt these interactions in a specific manner. Narasimhan and colleagues 
described direct binding of PMo to Sox2-HMG DNA binding domain (Narasimhan et 
al., 2011), we have demonstrated not only that both PMo and PW block Sox2 binding 
to target genes but inhibit full-length Sox2 protein transcriptional activity. 
 
2. POMs effects on tamoxifen-resistant breast cancer 
 The ability of cells to progress through the cell cycle, avoid apoptosis and 
invade surrounding tissues are key events in BC tumor progression (De Angelis et al., 
2019; Xu and Yang 2017). 
In this thesis work, we have shown a significant reduction in cell proliferation 
of three different tamoxifen-resistant cell lines rendering them more sensitive to 
tamoxifen by PW-mediated inhibition of Sox2. This data are in agreement with 
previously demonstrated restored tamoxifen sensitivity by stable downregulation of 
Sox2 (Piva et al., 2014). Moreover, we have detected cell cycle arrest in G2/M phase 
of tamoxifen-resistant cells after PW treatment. We have also demonstrated 




p21 after PW treatment, suggesting a deregulated G2/M transition. One of the 
mechanisms governing G2/M transition is mediated by cyclin B1-CDK1 complex, which 
has to be phosphorylated to enter into mitosis (Schmidt et al., 2017). Here, Dash and 
El-Deiry demonstrated that p21 phosphorylation on T57 residue by CDK2 binds to 
S126-phosphorylated cyclin B1 allowing cell cycle progression. CDK1 phosphorylation 
on T161 promotes its binding to the p21-cyclin B1 complex, which becomes activated 
as a functional kinase driving G2/M transition. Cyclin B1-CDK1 kinase activity and 
G2/M progression in cells lacking p21 expression are restored after reexpression of 
p21 but not T57A mutant p21, confirming the phosphorylated status of p21 as a key 
aspect in the regulation of G2/M transition (Dash and El-Deiry, 2005). Similarly, 
inactivation of both cyclin B1-CDK1 and cyclin A-CDK2 is required for the completion 
of mitosis. 
p21 is also a well-known inhibitor of the G1/S phase progression by targeting 
cyclin D1-CDK complexes (Bertoli et al., 2013). At this point, cell cycle progression is 
triggered by partial phosphorylation of Rb by cyclin D-CDK complexes, while p21 can 
disrupt these interactions and inhibit cell cycle progression (Wang et al., 2011). p21 
transcription is mainly regulated by p53 protein and cell cycle arrest in G1/S transition 
is a p53-dependent process (Holland et al., 2001). Sox2 has also been shown to 
specifically bind to p21 promoter in endometrial cancer cells controlling its expression 
levels (Yamawaki et al., 2017). In this regard, we have shown that PW treatment 
prevents Sox2 binding to the P21 promoter in tamoxifen-resistant cells, suggesting a 
potential mechanism for p21 repression after PW treatment. Nevertheless, despite 
p21 ability in inhibiting the cell cycle, it can also protect cells against apoptosis (further 
discussed below). 
Additionally, CCND1 is another Sox2 target gene (Chen et al., 2008) and an 
important cell cycle regulator forming CDK complexes with CDK4 and CDK6 during G1 
phase (Bertoli et al., 2013). Our group has demonstrated Sox2 direct binding on the 
promoter of CCND1 gene (Domenici et al., 2019) and in this thesis work we have 
shown that Sox2 recruitment on the promoter of this gene is blocked by PW 
treatment. However, we could not detect either a reduction in cyclin D1 levels or any 




compensatory effects that ensure cyclin D1 levels during the progression of the cell 
cycle.  
Many groups have reported Sox2 mediated regulation of cell cycle progression 
in many systems by different molecular mechanisms. In gastric cancer, which 
frequently shows Sox2 downregulation, Sox2 overexpression has been demonstrated 
to lead cell cycle arrest and apoptosis of gastric cancer cells by decreasing cyclin D1 
levels, phosphorylated Rb protein and increasing p27 levels (Otsubo et al., 2008). This 
observation was also reported by Luo and colleagues concluding that Sox2-mediated 
cell cycle arrest ends up with the induction of apoptosis through the downregulation 
of the DNA repair protein poly ADP ribose polymerase (Parp) (Luo et al., 2018).  
In a subgroup of medulloblastoma tumors, Sox2 expressing cells responsible 
for radiation-resistant phenotype have been shown to express Olig2 inhibitor protein 
that suppresses p53 and p21 expression allowing cell cycle progression and tumor 
recurrence (Treisman et al., 2019). Sox2 is also a target gene of the formed fusion 
protein EWS/FLI1, resulting in Sox2 upregulation in most cases of Ewing's sarcoma 
(Ren et al., 2016). Ewing's sarcoma cells survive and proliferate by Sox2 mediated 
downregulation of p21, p27 and cyclin E to facilitate G1/S phase transition and cell 
apoptosis avoidance, thus highlighting Sox2 inhibition as a potential therapeutic 
approach (Ren et al., 2016). In prostate cancer, Sox2 expression has been detected in 
several human prostate tumors and patient-derived xenografts (Li et al., 2020). DU145 
prostate cancer cell line expressing reduced levels of Sox2 reveals reduced cell 
proliferation and induced apoptosis by downregulating cyclin E and inducing p27 
expression (Lin et al., 2012). 
 In contrast, depletion of Sox2 in pancreatic cancer cells caused a decrease of 
cells in the S phase of the cell cycle. Mechanistically, Sox2 was found to bind to the 
promoters of P21 and P27 genes acting as a transcription suppressor, thus, p21 and 
p27 protein expression levels increase with Sox2 suppression. Here, the authors 
demonstrated that Sox2 controls cell cycle progression through the repression of P21 
and P27 gene expression in pancreatic cancer cells (Herreros-Villanueva et al., 2013). 
High Sox2 expression is correlated with histological grade and poor prognosis in 
endometrial tumors (Yamawaki et al., 2017). Sox2 dependent regulation of P21 gene 




leading cell cycle progression. Low p21 together with high Sox2 expression in 
advanced endometrial cancer patients has been associated with the worst outcome 
(Yamawaki et al., 2017). Together, these observations highlight the differential 
functions of Sox2 in cell cycle progression. Different mechanisms of action have been 
described on multiple cell cycle regulators in several systems, suggesting a tissue-
specific role of Sox2. 
 Several studies have implicated CSCs and Sox2 expression in tumor recurrence 
and cell resistance to apoptosis. In this thesis work, we have shown a subsequent 
induction of apoptosis by PW treatment in tamoxifen-resistant cells after cell cycle 
arrest. In breast cancer,  cells resistant to chemotherapy treatment with carboplatin 
showed an increase in Bcl-2, Oct-4 and Sox2 expression, suggesting protection from 
apoptosis and an increase in stem cell-like phenotype (Guiro et al., 2015). Diverse 
mechanisms have been described to explain Sox2 regulation on apoptosis in BC. For 
example, miR-101 can inhibit Sox2-mediated cell growth in BC cells. Overexpression 
of miR-101 resulted in significantly reduced Bcl-2 expression, while increasing Bax and 
cleaved caspase3 levels confirming the induction of apoptosis after miR-101-mediated 
Sox2 downregulation (Wang et al., 2017). In agreement with these findings, we have 
shown that PW treatment increases the percentage of the apoptotic cells by inducing 
cleaved Parp and repressing Bcl-2 expression levels. ChIP studies and human genome-
wide promoter microarrays have determined the promoter occupancies of Sox2 TF in 
BC cells (Jung et al., 2014). The results revealed that Sox2 binds to BCL2 gene 
promoter, among many other genes associated with stemness and cancer, suggesting 
a direct control of this key regulator of apoptosis in BC cells (Jung et al., 2014). These 
findings support our observation that Bcl-2 expression is reduced in tamoxifen-
resistant cells after PW inhibition of Sox2 activity. Additionally, several studies have 
shown that p21 expression protects from apoptosis. The overexpression of p21 in BC 
cell lines has been reported to decrease cell sensitivity to radiation-induced apoptosis 
by inhibition of CDK proteins which are essential for the activation of caspase cascade 
(Karimian et al., 2016). Moreover, p21 regulates the expression of genes involved in 
cell cycle progression, DNA repair and regulation of apoptosis such as E2F family, 
NFκB, c-Myc and STAT (Wu et al., 2009). For example, c-Myc has been shown to 




inhibit its transcription leading to the induction of apoptosis (Soria and Gottifredi, 
2010). Furthermore, p21 expression protects glioblastoma tumor cells against 
irradiation-induced apoptosis mediated by TNF-related apoptosis-inducing ligand 
(TRAIL) death receptor (Seoane et al., 2004). Mechanistically, p21 blocks the activation 
of caspases 3 and 9, suggesting that p21 depletion would be necessary for the 
complete induction of the apoptotic pathway. Therefore, since we have also detected 
p21 reduction after PW treatment, these findings support our observation that PW 
inhibition of Sox2 activity induces apoptosis in tamoxifen-resistant cells.  
In other systems, Sox2 silencing effectively induces apoptosis via the activation 
of death receptor and mitochondrial signaling pathways in human non-small cell lung 
cancer cells (Chen et al., 2014). Lung cancer cells lacking Sox2 expression increase the 
expression of key inducers of apoptosis such as tumor necrosis factor-α (TNF-α) or p53 
and repress Survivin protein, clinically associated with Sox2 expression and bad 
prognosis (Chen et al., 2014). Sox2 also induces resistance to radiotherapy in cervical 
cancer by enhancing cell proliferation and avoiding apoptosis. Interaction between 
Sox2 and Hedgehog (Hh) signaling pathway has been demonstrated by direct 
regulation of the Hedgehog Acyltransferase (HHAT) gene promoter (Huang et al., 
2018). Sox2 inhibition induces apoptosis in Ewing’s sarcoma cells by the induction of 
cleaved Parp followed by the activation of the caspase-3 pathway. In addition, the 
apoptotic pathway activated by mitochondrial dysfunction is also affected due to the 
downregulation of Bcl-2 anti-apoptotic protein after Sox2 silencing (Ren et al., 2016). 
The acquisition of invasive phenotypes during the development of resistance 
to therapy has been usually associated with aberrant activation of the EMT program 
(Mehta et al., 2019). In the last few years, many studies have demonstrated the 
appearance of EMT-like stages in BC progression, classifying BC cell lines as 
intermediate-high EMT, low EMT an intermediate EMT scored phenotypes (Tan et al., 
2014). Several studies have found a relationship between SOX2 and SNAI2/Slug. Sox2 
expression rapidly stimulates SNAI2 induction leading to increased invasion and 
metastasis in BC by stabilizing CSC content (Kim et al., 2017). Moreover, a significant 
upregulation of SNAI2 has been detected in hormone receptor-positive BC with 
inhibited ER signaling pathway (Liu et al., 2019) and in aggressive endocrine-resistant 




inhibited cell migration and invasion capacities of non-small cell lung cancer cells 
mediated by increased expression of E-cadherin and decreased expression of 
vimentin, SNAI1/Snail and SNAI2/Slug (Chang, 2019). In HCC patients and in vivo 
xenografts, SNAI2/Slug overexpression has been associated with Sox2 induction. 
Notably, knockdown of SNAI2 reduces Sox2 expression and inhibits HCC cell migration 
(Zhao et al., 2015). Also, Sox2 has been related to tumor aggressiveness and EMT in 
tongue squamous cell carcinoma by inducing not only the expression of EMT markers 
such as SNAI2 but also the activation of Wnt/β-catenin pathway, enhancing cell 
migration and invasion (Liu et al., 2018). Our lab has also previously described 
activation of Wnt signaling by Sox2 in tamoxifen-resistant breast cancer cells (Piva et 
al., 2014). 
Consistent with these studies, we have detected limited migratory and invasive 
capacities of tamoxifen-resistant cells when treated with PW. Furthermore, our results 
show a significant increase in SNAI2 expression in three tamoxifen-resistant cell lines 
expressing high levels of Sox2. Although PW treatment significantly reduces SNAI2 
expression in MCF-7TR and ZR75-1TR cells, it does not in T47DTR cell line. These 
variations might be attributed to the intrinsic differences between these cell lines. 
More importantly, we have shown not only that stable Sox2 downregulation 
significantly reduced SNAI2 expression levels in tamoxifen-resistant cells and that PW 
treatment does not further repress SNAI2 levels in these cells. These results suggest 
that PW specifically blocks Sox2 regulation of SNAI2 EMT marker leading to the 
inhibition of migration and invasion capacities. 
Together, these findings suggest that PW-mediated inhibition of Sox2 could be 
driving changes in the EMT program through SNAI2, which could be responsible for 
the observed effects in cell migration and invasion. Therefore, we proposed that PW 
treatment could repress the aggressive phenotype and therefore inhibit in vivo tumor 
growth of tamoxifen-resistant BC cells and tested this possibility using the 
chorioallantoic membrane (CAM) model. 
The immunodeficient state of the chick embryo during development enables 
the grafting and growth of tumor cells without species-specific limitations, 
representing a significant advantage of the CAM model over the murine model (Marga 




for gas and waste exchange during embryo development, provides an excellent 
environment for primary tumor formation and a basis for angiogenesis studies 
(Deryugina and Quigley, 2008). Moreover, the European Parliament certified that this 
system represents an intermediate stage between isolated cultured cells and animals, 
which does not raise any ethical or legal problem (Directive 2010/63/EU of the 
European Parliament and of the Council of 22 September 2010 on the Protection of 
Animals used for Scientific Purposes). 
Considering the obvious advantages, the CAM model is widely used to study 
tissue grafts (Ebert 1954; Haag et al., 2012), tumor growth and metastasis (Fergelot et 
al., 2013), wound healing (Kilarski et al., 2009), drug delivery and toxicologic analysis 
(Kishore et al., 2008), and angiogenic and anti-angiogenic molecules (Leong et al., 
2010). The first CAM assay analyzing the tumor growth of cancer cells was reported in 
1911 when Rous and Murphy demonstrated the growth of the Rous sarcoma 
transplanted onto the CAM (Ribatti, 2016). The CAM assay has been successfully 
developed into a tumor xenograft model for several cancer types such as 
glioblastoma, pancreatic cancer, hepatocellular carcinoma, osteosarcoma and breast 
cancer (Li et al., 2015). In this regard, our in vivo experiments using the CAM model 
highlight the importance of PW as a potential therapeutic drug for treating tamoxifen-
resistant BC patients. We have demonstrated that PW treatment inhibits in vivo tumor 
growth by specific inhibition of Sox2-mediated tamoxifen resistance in BC cells. 
 
3. Analysis of the tamoxifen-resistant CSC content after POM treatment 
 The Cancer Stem Cell (CSC) hypothesis claims that a subset of tumor cells with 
stem-cell-like properties is responsible for tumor growth, progression and resistance 
to conventional therapies. Breast CSCs have been shown to induce resistance to 
chemo- (Tanei et al., 2009; De Angelis et al., 2019) and radiotherapy (Phillips et al., 
2006; Huang et al., 2018). Recently, Wang and colleagues have shown that leptin-
JAK/STAT3 pathway regulates lipid metabolism through fatty acid β-oxidation (FAO), 
promoting breast cancer stemness and chemoresistance. The authors demonstrate 




chemotherapy while reducing cancer stemness in vivo (Wang et al., 2018). In addition, 
Sox2 has also been implicated in the CSC phenotype and development of 
chemoresistance in glioblastoma (Jeon et al., 2011) and prostate cancer (Jia et al., 
2011), as well as in paclitaxel-resistant ovarian cancer (Li et al., 2015). 
 Our group found that tamoxifen-resistant cells present increased 
mammosphere formation capacity, indicating an elevated self-renewal capacity of 
CSCs. Mammosphere suspension cultures of MCF-7 cells increase the CD44+CD24-/low 
population (Simões et al., 2011) and this increase is stronger in MCF-7TR derived 
mammospheres, which is influenced by Sox2 and Wnt signaling (Piva et al., 2014). 
Although several mechanism of resistance to hormone therapy have already 
been introduced in the Introduction section 3.6; other reports have also shown that 
short-term treatments with tamoxifen or fulvestrant anti-estrogens increase breast 
CSCs in patient-derived samples through Jag1-Notch4 receptor activation, which 
suggests that targeting Jag1-Notch4 receptor could overcome resistance in certain 
subtypes of breast cancers (Simões et al., 2015). More recently, it has been described 
a novel signaling interaction between tumor microenvironment (TME) and breast CSCs 
through Notch signaling. Thus, the authors have demonstrated that direct cell-cell 
contact of TME-derived endothelial cells provide the Notch ligand Jagged1 (Jag1) to 
surrounding breast CSCs, leading to Notch1-dependent upregulation of Zeb1. 
Increased Zeb1 levels favors BC plasticity, stemness and colonization, highlighting that 
Jag1-Notch1-Zeb1 axis depletion would decrease BC aggressiveness (Jiang et al., 
2020).  
CSCs with high aldehyde dehydrogenase activity (ALDH+) have been detected 
following endocrine therapy resistance. We demonstrated that ALDH1A3 isoform 
regulates enhanced ALDH activity in tamoxifen-resistant cells (Domenici et al., 2019). 
Additionally, interleukin-1β (IL-1β) signaling pathway activation has been reported as 
a new mechanism acquired by ALDH+ cells after developing resistance to endocrine 
treatments (Sarmiento-Castro et al., 2020). 
In this thesis work, we have shown that PW specifically blocks Sox2 mediated 
mammosphere formation ability of tamoxifen-resistant BC cells, by compromising the 
self-renewal capacity of CSCs. Furthermore, we have demonstrated that CD44+CD24-




In addition, we have found that PW specific inhibition of Sox2 reduces ALDH+ cells in 
tamoxifen-resistant cells by regulating ALDH1A3 expression. Finally, our extreme 
limiting dilution assays reveal that PW reduces breast CSCs, leading to reduced 
tamoxifen resistance in vivo, thus confirming the relevance of CSCs in hormone 
resistance and the ability of PW to target CSCs. 
Several studies have reported Sox2 overexpression in sphere cultures enriched 
for CSCs in different systems. For example, Sox2 is stabilized by paired-related 
homeobox 1, isoform A (PRRX1A), promoting malignant behavior by inducing sphere 
formation and proliferation in non-small cell lung cancer (NSCLC) cells (Sun et al., 
2020). In head and neck squamous carcinomas (HNSCC) resistant to conventional 
therapy showed PI3K/mTOR pathway activation leading to an increase in CSC content 
mediated by Sox2 and ALDH1A1. Sox2 protein levels decreased following PI3K/mTOR 
inhibition in HNSCC cancer cells, but the mechanism was not defined (Keysar et al., 
2017). Santini and colleagues have found that Sox2 overexpression in melanoma stem 
cells governs the self-renewal capacity of ALDH+ cells since knockdown of Sox2 
significantly decreases melanoma sphere formation (Santini et al., 2014). Pancreatic 
ductal adenocarcinomas (PDAC) often develop resistance to chemotherapy. 
Gemcitabine-resistant cells show increased tumorsphere formation regulated by GLI-
Sox2 signaling axis. The authors have demonstrated that the downregulation of GLI TF 
decreases Sox2 expression, sensitizing pancreatic cancer cells to gemcitabine 
treatment (Jia et al., 2019). 
In breast cancer, recent studies have been reporting relevant results 
supporting that targeting breast CSC inhibits drug resistance. Napabucasin, a small 
STAT3 inhibitor, has been shown to suppress BC relapses and metastasis by inhibiting 
stem cell-like properties (mammosphere formation, ALDH activity and the expression 
of stemness markers Sox2, Oct4 and Nanog) (Liu et al., 2019). Different drugs have 
been reported to show antitumor activity by affecting Sox2 expression levels in BC 
cells, despite not targeting Sox2 transcriptional activity.  
Firstly, Pevonedistat, a small-molecule inhibitor of neddylation currently in 
phase II clinical trial in patients with advanced non-small-cell lung cancer (NSCLC) 
(NCT03965689), downregulates SOX2 expression leading to the sensitization of BC 




MSX2-SOX2 axis that regulates stem cell content and drug resistance of BC cells. Since 
Sox2 repressor, MSX2 is the substrate of FBXW2 E3 ligase and due to the fact that 
Pevonedistat inactivates this ligase; Pevonedistat treatment caused MSX2 mediated 
Sox2 repression, leading to inhibition of mammosphere formation and sensitization of 
BC to tamoxifen (Yin et al., 2019). 
Secondly, Iadademstat, a clinically proven inhibitor of the lysine-specific 
demethylase 1 (LSD1) in acute leukemia patients (Maes et al., 2018), also targets Sox2-
driven breast CSCs (Cuyàs et al. 2020). Mechanistically, Iadademstat blocks Sox2 
dependent mammosphere formation ability of BC cell lines repressing the CSC 
phenotype. This drug prevents the activation of a lysine-specific demethylase 1 (LSD1) 
targeted specific Sox2 enhancer leading to a reduction in Sox2 expression and CSC 
content in BC tumors (Cuyàs et al., 2020). More recently, it has been reported that 
Pranlukast, a drug used to treat asthma, binds to CD49f inducing conformational 
changes in CD49f that affect its interaction with β1-integrin and alters CD49f-
dependent signaling in triple-negative breast cancer (TNBC) cells. Altered CD49f-
dependent signaling decreases CD44 and Sox2 expression, SOX2 promoter 
transactivation leading to reduced CSC frequency and in vivo tumorigenicity 
(Velázquez-Quesada et al., 2020). 
To our knowledge, there are no reports demonstrating the inhibitory potential 
of any drug on Sox2 transcriptional activity and, as a consequence, reducing stem cell 
content and tamoxifen resistance, as we have shown here. Our results clearly show 
that PW inhibits Sox2 transcriptional activity in tamoxifen-resistant cells affecting CSC 
content and tamoxifen resistance in vivo. Despite the significant body of literature 
about the potential of POMs to reduce tumorigenesis, there are some concerns in the 
field about POM cytotoxic effects and delivery properties. To address these problems, 
several strategies have been identified in order to increase bioactivity and reduce the 
side effects of POM based therapy (Bijelic et al., 2019). 
An effective approach to solve POM toxicity effects has been developed in 
glioblastoma cancer cells by designing a degradable organically-derived POM, which 
is composed of a cleavable organic group that leads to its degradation (She et al., 
2016). This surface modification of POMs with organic molecules could guide POMs to 




functionalization. A strategy to in vivo deliver anticancer drugs to colorectal cancer 
cells in a more effective and safer way has been designed (Sun et al., 2016). POM-
based drugs were encapsulated in hydrophilic nanoparticles that need to undergo 
reductive elimination to release the pharmacologically effective anticancer POM. As a 
result, this POM derivative shows remarkable inhibitory action on a human colorectal 
cancer cell line higher than conventional cisplatin treatment (Sun et al., 2016). Our 
collaborators have designed chitosan nanogels to use as nanocarriers for POM based 
therapy, thus demonstrating that K6[P2Mo18O62] POM is physically loaded into 
covalently cross-linked nanogels for local delivery (Pérez-Álvarez et al., 2019). 
Nevertheless, developing drugs that target TFs for antitumor therapy remains 
a challenge due to their lack of hydrophobic and deep ligand-binding pockets; studies 
still focus on POM inhibitory potential rather than delivery properties. In this regard, 
K6[P2Mo18O62] (PMo) has been reported to inhibit the DNA binding activity of AP-2γ TF 
in MCF-7 BC cells leading to a significant induction of apoptosis when treated with 400 
µg/ml for 48 h (Hu et al., 2018). However, the authors reported that the in vitro AP-2γ 
DNA binding activity was impaired by 2 µM K6[P2Mo18O62] treatment, suggesting that 
the effects on apoptosis could be more due to POM toxicity, rather than inhibition of 
AP-2γ transcriptional activity (Hu et al., 2018). Moreover, although we have not 
analyzed AP-2γ activity in our cells, we have not detected apoptosis induction in BC 
cell lines when treated with 50 μM K6[P2Mo18O62] derivative. 
 Together, these findings highlight the therapeutic relevance of targeting Sox2 
TF and the potential clinical use of POMs for targeting CSCs in a defined group of 
tamoxifen-resistant BC patients. 
 
4. Activation of the ER signaling pathway 
 Patients with endocrine-resistant tumors due to prolonged tamoxifen 
treatment, usually maintain wild-type ER expression (Notas et al., 2015). Endocrine 
therapy resistance has been closely related to loss of ER transcriptional activity, 
deregulation of ER co-activators, activation of ER related pathways or deregulation of 




1994 that the expression of estrogen-activated ER target genes, such as PS2 and PGR 
is decreased in MCF-7 tamoxifen-resistant cells (Lykkesfeldt et al., 1994). Although 
transcriptome profiling studies confirmed the inhibition of estrogen-mediated ER 
transcriptional activation of its target genes (Sun et al., 2019), the key mechanisms by 
which ER transcriptional reprogramming is implicated in the resistance to endocrine 
therapy remain poorly understood. 
Previous work in our lab detected an inverse correlation between Sox2 and ER 
expression. The lack of co-expression between these two proteins is very clear in CSC 
populations since most Sox2-positive are ER-negative within mammospheres, 
similarly to the CD44+CD24-/low CSC population (Piva et al., 2014). Moreover, the lack 
of ER expression has also been reported in normal breast stem cells (Clayton et al., 
2004). Other groups have also shown the correlation between CSCs and the absence 
of ER expression. Ginestier and colleagues showed that ALDH+ BC cells present an 
inverse association with ER expression (Ginestier et al., 2007), while gene expression 
analysis of CD44+CD24-/low cells demonstrates that this CSC population expresses low 
levels of ER (Shipitsin et al., 2007). Transcriptome profiling data have shown that 
tamoxifen treatment induces a number of stem-like characteristics that are related to 
a more aggressive cellular phenotype. Indeed, a study developed with 160 patients 
from which 13 cases did not respond to tamoxifen therapy and relapsed, showed that 
Sox2-related pathway is the most significantly enhanced in relapsing patients, 
confirming that tamoxifen non-responders express a set of gene signatures related to 
a more stem-like phenotype (Notas et al., 2015). These observations indicate that 
during tamoxifen treatment the tumor mass undergoes an enrichment process in ER-
negative CSC population responsible for the resistant phenotype. 
The inverse correlation between Sox2 and ER has been also evaluated in Sox2 
overexpressing cells, highlighting the fact that Sox2 overexpressing cells show 
significantly reduced ER transcriptional activity as well as increased CSC content 
(Simões et al., 2011). Indeed, our group reported reduced levels of ER target genes 
PGR and PS2 genes, as well as reduced sensitivity to tamoxifen in Sox2 overexpressing 
cells, indicating that Sox2 not only maintains breast CSCs but also regulates ER activity 
and mediates tamoxifen resistance (Piva et al., 2014). PGR gene was identified as an 




this sense, PR-positive tumors dependent on estrogen for growth would respond to 
endocrine therapies. However, clinical data have demonstrated that Luminal B type 
BC tumors, which are ER-positive but PR-negative, are less dependent on estrogen and 
therefore less responsive to tamoxifen treatment (Osborne et al., 2005). These ER-
positive and PR-negative tumors are characterized by a more aggressive phenotype 
with lower patient survival after the loss of PR, suggesting that additional changes in 
other tumor cell regulatory mechanisms might happen. In agreement with our data, 
this PR-negative status has been also reported in tamoxifen-resistant cells and in the 
transcriptome of patient-derived tamoxifen-resistant tumors (Fu et al., 2016), which 
our group correlated with an increase in Sox2 expression levels in a cohort of 
tamoxifen-resistant tumor samples (Piva et al., 2014). 
 Therefore, according to the well-reported inverse correlation of Sox2 and ER 
and its role in CSCs, we found that immunofluorescence analysis of Sox2 and ER 
staining revealed an increase in the ER/Sox2 staining ratio upon PW treatment. 
Tamoxifen-resistant cells show higher ER expression levels within each Sox2-positive 
cell when treated with PW. Furthermore, ChIP-qPCR data confirm that Sox2 
recruitment on ESR1 promoter is impaired by PW treatment in tamoxifen-resistant 
cells, suggesting a negative regulation. Reduced ER transcriptional activity is recovered 
by PW treatment in tamoxifen-resistant cells leading to an increase in the estrogen-
activated ER target gene PS2, mimicking the effects of Sox2 downregulation. The wide 
variety of mechanisms controlling ER transcriptional activity in tamoxifen-resistant 
cells might explain the activation of determined ER target genes as PS2, but no others 
such as PGR (Fu et al., 2016). On top of that, epigenetic reprogramming of specific 
transcriptomes mediated by EZH2-ER-GREB1 regulatory axis might also drive 
resistance to tamoxifen resistance in BC cells (Wu et al., 2018). Here, the authors 
showed that ER induced transcriptome changes after the development of resistance 
to tamoxifen, confirming that epigenetic changes induce ER transcriptional 
alterations. Nevertheless, another mechanism by which tamoxifen-resistant cells 
restore ER transcriptional activity reported as PS2 gene re-expression and tamoxifen 
sensitivity was also described. Cui and colleagues demonstrated that miR-873 
regulates ER transcriptional activity and tamoxifen resistance by targeting CDK3 in BC 




CDK3 overexpression provoked by miR-873 low levels. ChIP assays on the recruitments 
of ER co-repressors N-CoR and SMRT, important in the anti-proliferative action of 
tamoxifen, revealed that tamoxifen-resistant cells failed to recruit these co-repressors 
to the promoter of the PS2 gene. On the contrary, miR-873 expressing cells effectively 
recruited N-CoR and SMRT, confirming the restoration of the ER transcriptional 
activity not only in vitro but also in vivo (Cui et al., 2015).  
Altogether, although these findings highlight that the regulation of ER 
transcriptional activity is very complex, it is moderately recovered by PW-mediated 
inhibition of Sox2 TF in tamoxifen-resistant cells, leading to partially restored ER 
signaling and tamoxifen sensitivity. In conclusion, we propose a potential 
pharmacological therapeutic approach in which PW-based inhibition of Sox2 
transcriptional activity impairs Sox2-mediated key biological processes rendering BC 
cells more sensitive to tamoxifen. Hence, K6[P2W18O62] Dawson-Polyoxometalate 
could be the basis for the development of new therapeutic drugs to treat a defined 








Figure D 1. Model of K6[P2W18O62] POM derivative mechanism of action in tamoxifen resistant cells. 
Sox2 increases CSC content and reduces ER levels and transcriptional activity through direct regulation 
on its promoter, leading to the development of resistance to tamoxifen. PW-mediated 
pharmacological inhibition of Sox2 impairs tamoxifen-resistant cell survival by restoring tamoxifen 
sensitivity through ER pathway reactivation and inhibiting Sox2 dependent cellular processes.  
























































In summary, the data presented confirm our hypothesis and demonstrate that 
targeting Sox2 in tamoxifen-resistant cells leads to the reduction of the CSC 
populations. These findings highlight the importance of developing new therapeutic 
approaches against CSCs to improve the treatment of tamoxifen-resistant tumors in 
breast cancer patients. 
 
The results obtained lead to the following conclusions: 
 
1. Full-length Sox2 protein expressed in cancer cells can bind to defined Sox2 
response elements in vitro and PMo and PW derivatives disrupt these 
interactions in a specific manner. 
2. PW induces cell cycle arrest in the G2/M phase, leading to induction of 
apoptosis and rendering tamoxifen-resistant cells more sensitive to tamoxifen. 
3. PW specifically blocks Sox2 regulation of the SNAI2 EMT marker leading to 
inhibition of migration and invasion capacities of tamoxifen-resistant breast 
cancer cells. 
4. PW-mediated pharmacological inhibition of Sox2 impairs tamoxifen-resistant 
tumor growth in vivo. 
5. PW reduces self-renewal capacity of breast CSCs. Limited ALDH activity of 
tamoxifen-resistant cells after PW treatment is driven by the inhibition of 
Sox2-mediated regulation of ALDH1A3 isoform. 
6. Sox2 repression of ESR1 gene may lead to compromised ER transcriptional 
activity in tamoxifen-resistant cells. This negative regulation is relieved by PW-
mediated inhibition of Sox2 DNA binding activity leading to partially activated 
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Abstract 
SOX11 is an embryonic mammary epithelial marker that is normally silenced prior to 
birth. High SOX11 levels in breast tumours are significantly associated with distant 
metastasis and poor outcome in breast cancer patients. Here, we show that SOX11 
confers distinct features to ER-negative DCIS.com breast cancer cells, leading to 
populations enriched with highly plastic hybrid epithelial/mesenchymal cells, which 
display invasive features and alterations in metastatic tropism when xenografted into 
mice. We found that SOX11+DCIS tumour cells metastasize to brain and bone at 
greater frequency and to lungs at lower frequency compared to cells with lower SOX11 
levels. High levels of SOX11 leads to the expression of markers associated with 
mesenchymal state and embryonic cellular phenotypes. Our results suggest that 
SOX11 may be a potential biomarker for breast tumours with elevated risk of 
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Abstract 
Many inflammation-associated diseases, including cancers, increase in women after 
menopause and with obesity. In contrast to anti-inflammatory actions of 17β-
estradiol, we find estrone, which dominates after menopause, is pro-inflammatory. In 
human mammary adipocytes, cytokine expression increases with obesity, 
menopause, and cancer. Adipocyte:cancer cell interaction stimulates estrone- and 
NFκB-dependent pro-inflammatory cytokine upregulation. Estrone- and 17β-estradiol 
-driven transcriptomes differ. Estrone:ERα stimulates NFκB-mediated cytokine gene 
induction; 17β-estradiol opposes this. In obese mice, estrone increases and 17β-
estradiol relieves inflammation. Estrone drives more rapid ER+ breast cancer growth 
in vivo. HSD17B14, which converts 17β-estradiol to estrone, associates with poor ER+ 
breast can- cer outcome. Estrone and HSD17B14 upregulate inflammation, ALDH1 
activity, and tumorspheres, while 17β-estradiol and HSD17B14 knockdown oppose 
these. Finally, a high intratumor estrone: 17β-estradiol ratio increases tumor-initiating 
stem cells and ER+ cancer growth in vivo. These findings help explain why 
postmenopausal ER+ breast cancer increases with obesity, and offer new strategies 
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R. M. and Vivanco, MdM. A Sox2-Sox9 signalling axis maintains human breast luminal 
progenitor and breast cancer stem cells. Oncogene. 2019 Jan 8; 38(17): 3151-3169. 
 
Abstract 
Increased cancer stem cell content during development of resistance to tamoxifen in 
breast cancer is driven by multiple signals, including Sox2-dependent activation of 
Wnt signalling. Here, we show that Sox2 increases and estrogen reduces the 
expression of the transcription factor Sox9. Gain and loss of function assays indicate 
that Sox9 is implicated in the maintenance of human breast luminal progenitor cells. 
CRISPR/Cas knockout of Sox9 reduces growth of tamoxifen-resistant breast tumours 
in vivo. Mechanistically, Sox9 acts downstream of Sox2 to control luminal progenitor 
cell content and is required for expression of the cancer stem cell marker ALDH1A3 
and Wnt signalling activity. Sox9 is elevated in breast cancer patients after endocrine 
therapy failure. This new regulatory axis highlights the relevance of SOX family 
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of LYN Kinase Dysregulation Drive Aggressive Behavior in Breast Cancer Cells. Cell 
Reports. 2018 Dec 26; 25(13):3674-3692. 
 
Abstract 
The SRC-family kinase LYN is highly expressed in triple-negative/basal-like breast 
cancer (TNBC) and in the cell of origin of these tumors, c-KIT-positive luminal 
progenitors. Here, we demonstrate LYN is a downstream effector of c-KIT in normal 
mammary cells and protective of apoptosis upon genotoxic stress. LYN activity is 
modulated by PIN1, a prolyl isomerase, and in BRCA1 mutant TNBC 
PIN1 upregulation activates LYN independently of c-KIT. Furthermore, the full-length 
LYN splice isoform (as opposed to the Δaa25-45 variant) drives migration and invasion 
of aggressive TNBC cells, while the ratio of splice variants is informative for 
breast cancer-specific survival across all breast cancers. Thus, dual mechanisms-
uncoupling from upstream signals and splice isoform ratios-drive the activity of LYN in 
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Abstract 
New strategies in regenerative medicine include the implantation of stem cells 
cultured in bio-resorbable polymeric scaffolds to restore the tissue function and be 
absorbed by the body after wound healing. This requires the development of 
appropriate micro-technologies for manufacturing of functional scaffolds with 
controlled surface properties to induce a specific cell behavior. The present report 
focuses on the effect of substrate topography on the behavior of human mesenchymal 
stem cells (MSCs) before and after co-differentiation into adipocytes and osteoblasts. 
Picosecond laser micromachining technology (PLM) was applied on poly (L-lactide) 
(PLLA), to generate different microstructures (microgrooves and microcavities) for 
investigating cell shape, orientation, and MSCs co-differentiation. Under certain 
surface topographical conditions, MSCs modify their shape to anchor at specific 
groove locations. Upon MSCs differentiation, adipocytes respond to changes in 
substrate height and depth by adapting the intracellular distribution of their lipid 
vacuoles to the imposed physical constraints. In addition, topography alone seems to 
produce a modest, but significant, increase of stem cell differentiation to osteoblasts. 
These findings show that PLM can be applied as a high-efficient technology to directly 
and precisely manufacture 3D microstructures that guide cell shape, control adipocyte 
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Abstract 
In this work we explore the effect of surface nanoarchitecture of polystyrene (PS) and 
polystyrene-b-poly(acrylic acid) (PS-b-PAA) diblock copolymer films on cell viability. PS 
and PS-b-PAA have been nanopatterned at temperatures of 110, 120 and 140°C using 
nanoporous aluminium oxide membranes (AAO) as a template. Surface architecture 
strongly depends on the infiltration temperature and the nature of the infiltrated 
polymer. High patterning temperatures yield hollow fibre shape architecture at the 
nanoscale level, which substantially modifies the surface hydrophobicity of the 
resulting materials. Up to date very scarce reports could be found in the literature 
dealing with the interaction of microstructured/nanostructured polymeric surfaces 
with cancer cells. Therefore, MCF-7 breast cancer cells have been selected as a model 
to conduct cell viability assays. The findings reveal that the fine-tuning of the surface 
nanoarchitecture contributes to the modification of its biocompatibility. Overall, this 
study highlights the potential of AAO membranes to obtain well-defined tailored 
morphologies at nanoscale level and its importance to develop novel soft functional 
surfaces to be used in the biomedical field. 
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Introducción 
 En la actualidad, el cáncer de mama es la neoplasia maligna diagnosticada con 
más frecuencia y la primera causa de muerte por cáncer en mujeres en todo el mundo. 
Entorno al 70% de los tumores de mama expresan el receptor de estrógeno (ER) es 
decir, son ER-positivos. Los pacientes con tumores ER-positivos suelen recibir terapia 
endocrina, como el tamoxifeno (antagonista de ER), sin embargo, el 30% de los casos 
desarrollan resistencia a la terapia, dando lugar a las recidivas. 
Numerosos estudios han demostrado que las células madre cancerígenas 
(CSCs, de Cancer Stem Cells en inglés) son responsables del inicio y el mantenimiento 
del tumor y están implicadas en el desarrollo de resistencia a los tratamientos. 
Estudios de nuestro laboratorio han permitido concluir que las células resistentes al 
tamoxifeno contienen una proporción más elevada de CSCs, presentan una mayor 
capacidad de invasión y un fenotipo más agresivo que las células parentales. Todo ello 
es  mediado por el incremento de la expresión del factor de transcripción Sox2, una 
de las principales señales implicadas en el desarrollo de resistencia al tamoxifeno.  
En el año 2011 se publicó un estudio en el que se identificó a los 
polioxometalatos (POMs) como inhibidores directos de la actividad transcripcional de 
Sox2. Químicamente, los POMs son polianiones, que constan de tres o más oxianiones 
de metales de transición en sus más altos estados de oxidación, unidos entre sí por 
átomos de oxígeno para formar estructuras 3D cerradas. Diferentes investigadores 
han demostrado que los POMs tienen potenciales aplicaciones en medicina como 
posibles fármacos antibióticos, antivirales e incluso antitumorales.  
En base a estas observaciones, en esta tesis se propone la hipótesis de que la 
reducción en el contenido de CSCs, mediante la inhibición farmacológica con POM de 
la actividad de Sox2, contribuirá a restaurar la capacidad de las células del cáncer de 
mama para responder a la terapia endocrina y evitar las recidivas. Así, los objetivos 
principales de este trabajo consisten en identificar POMs eficientes en la inhibición de 
Sox2 y evaluar sus efectos en las células resistentes al tamoxifeno, así como analizar 
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el contenido de CSCs resistentes al tamoxifeno tras el tratamiento con POM y dilucidar 
el mecanismo molecular subyacente a los efectos de este tratamiento.  
Materiales y métodos 
El trabajo aquí presentado se llevó a cabo en células en cultivo, tanto de líneas 
celulares como de células resistentes al tamoxifeno generadas en el laboratorio. 
Además, se generaron líneas celulares modelo mediante el uso de la tecnología 
CRISPR-Cas9. Por otro lado, se emplearon técnicas de biología molecular tales como 
la extracción de RNA, qPCR, western blot y ChIP. También se llevaron a cabo ensayos 
funcionales de actividad reportera, análisis de citometría de flujo, proliferación, 
migración e invasión, así como microscopía de inmunofluorescencia. Para los ensayos 
de crecimiento tumoral in vivo se utilizó el modelo de crecimiento en la membrana 
corioalantoidea (CAM) de embriones de pollo. 
Resultados 
1.-Cribado de diferentes derivados de POM 
Estudios previos demostraron la importancia de varias proteínas de la familia 
de factores de transcripción Sox en la tumorigénesis y progresión de diferentes 
subtipos de cáncer de mama. A su vez, el laboratorio de Ralf Jauch, que identificó los 
POMs como inhibidores de la actividad de Sox2, concluyó en un segundo estudio que 
los POMs son inhibidores muy potentes de la actividad de unión al ADN del dominio 
Sox-HMG, pero que presentan una baja especificidad entre los diferentes miembros 
de la familia Sox. 
Por ello, inicialmente, analizamos la expresión de todos los miembros de la 
familia Sox a fin de detectar niveles de expresión diferenciales entre las células 
resistentes al tamoxifeno (MCF-7TR) y las parentales (MCF-7c). Los datos de expresión 
génica revelaron que únicamente SOX2 y SOX9 presentan un aumento significativo en 
sus niveles, siendo Sox2 el factor de transcripción más diferencialmente expresado en 
tres modelos celulares diferentes de resistencia al tamoxifeno. El resto de los 20 
miembros de la familia Sox o no presentan diferencias significativas o están menos 
expresados en las células resistentes en comparación a las parentales.  
Basándonos en nuestros estudios anteriores que muestran la relevancia de 
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Sox2 en la resistencia al tamoxifeno y el potencial de los POMs para actuar como 
inhibidores, decidimos examinar la eficacia de tres POMs diferentes, (NH4)6Mo7O24 
(NH4-Pom), K6[P2Mo18O62] (PMo) and K6[P2W18O62] (PW), en la inhibición de la 
actividad de unión al ADN de Sox2 in vitro. Los resultados sugieren que la proteína 
Sox2 completa expresada en las células HEK293T se une a elementos de respuesta de 
Sox2 definidos en los promotores de genes diana y que los derivados PMo y PW son 
capaces de impedir estas interacciones de manera específica. 
2.-Efectos de los POMs en el cáncer de mama resistente al tamoxifeno 
Para estudiar el potencial terapéutico de estos derivados de POM en células 
resistentes al tamoxifeno, quisimos evaluar si el tratamiento con POM afecta 
diferentes procesos celulares.  
Primeramente, realizamos ensayos de proliferación celular en los diferentes 
modelos de resistencia al tamoxifeno. Los datos muestran que únicamente PW reduce 
significativamente la proliferación celular de las tres líneas celulares resistentes al 
tamoxifeno. Esto se ve reflejado también en un incremento de la parada de ciclo 
celular y la inducción del fenómeno de muerte celular programa (apoptosis) tras el 
tratamiento con PW. Molecularmente, se detectaron alteraciones en los niveles de 
expresión de proteínas importantes implicadas en estos procesos y reguladas por Sox2 
como p21 y Bcl-2 entre otras. 
En segundo lugar, se llevaron a cabo ensayos de migración e invasión celular. 
Los datos revelaron que las células resistentes presentan unas capacidades de 
migración e invasión mayores que se ven significativamente reducidas tras el 
tratamiento con PW. Estas observaciones se ven reforzadas con el análisis de la 
expresión de SNAI2, un regulador clave del proceso de transición epitelio-
mesénquima (EMT), dependiente de la actividad de Sox2, el cual se ve reducido en las 
células resistentes a tamoxifeno tras el tratamiento con PW.  
Por último, se evaluó el efecto de PW en ensayos in vivo utilizando modelo de 
crecimiento en la membrana corioalantoidea (CAM) de embriones de pollo que 
permite implantar células tumorales y analizar el crecimiento tumoral. Así, tras 
generar células estables que sobreexpresaran la proteína verde fluorescente (GFP en 
inglés) en MCF-7c, MCF-7TR y reducir la expresión de Sox2 en estas células por 
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diferentes técnicas de biología molecular, se implantaron en embriones de pollo 
durante una semana para analizar el crecimiento tumoral. La cuantificación de células 
positivas para GFP de cada tumor analizada por citometría indicó una reducción 
significativa en el tamaño del tumor, reflejada en el número de células GFP+ derivadas 
de tumores resistentes al tamoxifeno tratados con PW. El tratamiento de PW no tuvo 
efecto sobre el crecimiento tumoral de las células parentales en la CAM, así como 
tampoco lo tuvo en las células que carecían de la expresión de Sox2, cuyas capacidades 
tumorigénicas ya se vieron mermadas por la falta de este factor de transcripción. Estos 
resultados confirman que la inhibición de Sox2 mediada por PW conduce a una 
reducción del crecimiento de los tumores resistentes al tamoxifeno in vivo. 
3.-Análisis del contenido de CSC resistentes al tamoxifeno tras el tratamiento con POM 
Estudios previos de nuestro laboratorio demostraron la importancia de las 
CSCs durante el desarrollo de resistencia al tamoxifeno regulado por el incremento de 
Sox2. Por tanto, analizamos el contenido de CSCs en las células resistentes al 
tamoxifeno tras el tratamiento con PW. Ensayos de formación de mamoesferas 
primarias y secundarias confirmaron que PW bloquea específicamente la formación 
de mamoesferas mediada por Sox2, afectando a la capacidad de autorrenovación de 
las CSCs.  
 Asimismo, el análisis de la actividad aldehído deshidrogenasa (ALDH), que 
identifica a la población de las CSCs, revela una reducción de la actividad únicamente 
en las células resistentes al tamoxifeno tras el tratamiento con PW, que a su vez es 
dependiente de la actividad de Sox2. Consistentemente, la expresión de ALDH1A3, la 
isoforma más importante en la regulación de la actividad ALDH en las células de cáncer 
de mama, también se ve reprimida por el tratamiento con PW, únicamente en las 
células resistentes al tamoxifeno.  
 Dado que nuestros resultados apoyaban la hipótesis de que el tratamiento con 
PW reduce la población de CSCs en las células resistentes al tamoxifeno, decidimos 
validar el potencial farmacológico de PW en ensayos in vivo, utilizando el modelo 
CAM. Para ello realizamos un ensayo de dilución limitante extrema (ELDA en inglés) in 
vivo. El ensayo ELDA confirma que el tratamiento con PW reduce significativamente la 
frecuencia de células madre iniciadoras de tumores en 8,56 veces (p = 1,70e-05) en 
tumores derivados de células resistentes al tamoxifeno. Estos hallazgos confirman que 
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PW reduce las CSCs, lo que lleva a una menor resistencia al tratamiento con 
tamoxifeno in vivo. 
4.-Activación de vía de señalización de ER 
 Se ha demostrado que las células madre mamarias carecen o expresan niveles 
bajos del ER, así como una relación inversa entre la expresión de las proteínas Sox2 y 
ER y la reducción de la actividad transcripcional de ER en células resistentes al 
tamoxifeno. Teniendo en cuenta estas observaciones previas, nos planteamos la 
hipótesis de que la inhibición de Sox2 mediada por PW puede conducir a una mayor 
actividad de ER en células de cáncer de mama resistentes al tamoxifeno y recuperar 
la sensibilidad al tratamiento. De esta manera, el análisis de la expresión de ambas 
proteínas en células resistentes al tamoxifeno en presencia de PW mostró que los 
niveles de expresión de ER aumentan en cada célula resistente positiva para Sox2 tras 
el tratamiento con PW. Así, comprobamos si Sox2 regula negativamente la expresión 
de ER en las células resistentes al tamoxifeno. Para ello, realizamos ensayos de ChIP, 
donde evaluamos la interacción de Sox2 con el promotor del gen de ER (ESR1). Los 
datos de ChIP muestran que el reclutamiento de Sox2 en el sitio específico de unión 
del promotor de ESR1 está afectado por el tratamiento con PW.  
Con el fin de verificar la idea de que Sox2 puede ser un regulador clave de la 
actividad transcripcional de ER en células resistentes al tamoxifeno, planteamos la 
hipótesis de que la inhibición farmacológica de la actividad transcripcional Sox2 
mediada por PW rescataría la actividad de ER en células resistentes al tamoxifeno. 
Ensayos reporteros de la actividad transcripcional confirmaron que el tratamiento con 
PW es suficiente para restaurar los niveles de actividad de ER de las células resistentes 
a los observados en las células parentales. Curiosamente, la activación dependiente 
de estrógeno de los niveles de expresión génica de PS2 (gen diana de ER) en células 
resistentes tratadas con PW se detecta tanto a niveles de ARNm como de proteína, de 
manera dependiente de la expresión de Sox2. 
En conclusión, estos hallazgos demuestran que la actividad transcripcional de 
ER, comprometida durante el desarrollo de resistencia al tamoxifeno, es recuperada 
mediante la inhibición de la actividad de Sox2 mediada por PW en células resistentes 
al tamoxifeno, lo que lleva a la activación parcial de la vía de señalización de ER 
restaurando la sensibilidad al tamoxifeno. 
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Conclusiones 
Los resultados obtenidos conducen a las siguientes conclusiones: 
1. La proteína Sox2 completa expresada en células cancerosas puede unirse a 
elementos de respuesta definidos de Sox2 in vitro y los derivados de POM, 
PMo y PW, interrumpen estas interacciones de manera específica. 
2. PW induce la detención del ciclo celular en la fase G2/M que conlleva la 
inducción de la apoptosis y hace que las células resistentes al tamoxifeno sean 
más sensibles al tamoxifeno. 
3. PW bloquea específicamente la regulación del marcador de EMT SNAI2 
mediada por Sox2, que conduce a una inhibición de las capacidades de 
migración e invasión de las células resistentes al tamoxifeno. 
4. El factor de transcripción Sox2 es necesario para la tumorigénesis de células de 
cáncer de mama resistentes al tamoxifeno. La inhibición farmacológica de Sox2 
mediada por PW perjudica en el crecimiento de tumores resistentes al 
tamoxifeno in vivo. 
5. PW reduce la capacidad de autorrenovación de las células madre cancerosas 
mamarias, lo que lleva a una reducción de la resistencia al tamoxifeno in vivo. 
La reducción en la actividad de ALDH de las células resistentes al tamoxifeno 
tras el tratamiento con PW es impulsada por la inhibición de la regulación de 
la isoforma ALDH1A3 mediada por Sox2. 
6. La actividad transcripcional de ER comprometida en células resistentes al 
tamoxifeno puede ser reprimida mediante la regulación directa de Sox2 sobre 
el promotor del gen ESR1. Esta posible regulación negativa se ve aliviada 
mediante la inhibición mediada por PW de la actividad de unión al ADN de Sox2 
en células resistentes al tamoxifeno, provocando la reactivación de la ruta de 
señalización de ER y restaurando la sensibilidad al tamoxifeno. 
 
 
 
